table content shareholder outlook consolidated financial statement summary fiscal year general midterm consolidated statement income fresenius share outlook consolidated statement business segment future market comprehensive income fresenius medical care health care sector consolidated statement fresenius kabi market financial position fresenius helios group sale earnings consolidated statement cash flow fresenius vamed sale earnings consolidated statement business segment change equity financing consolidated segment reporting management report investment note see detailed register page procurement see detailed register page fundamental information research development general note group planned change note consolidated annual report group business model human resource statement income goal strategy social area note consolidated corporate performance dividend statement financial position criterion opportunity risk report note fresenius cease voluntary opportunity management note accordance u gaap reporting risk management german commercial code research development risk area hgb employee assessment overall risk change supervisory board management board auditor report procurement corporate governance declaration quality management report responsibility environmental report supervisory board management sustainability economic report board health care industry supervisory board overall business development fresenius se co kgaa result operation financial management board position asset liability fresenius management se overall assessment supervisory board business situation fresenius management se glossary table content shareholder outlook consolidated financial statement summary fiscal year general midterm consolidated statement income fresenius share outlook consolidated statement business segment future market comprehensive income fresenius medical care health care sector consolidated statement fresenius kabi market financial position fresenius helios group sale earnings consolidated statement cash flow fresenius vamed sale earnings consolidated statement business segment change equity financing consolidated segment reporting management report investment note see detailed register page procurement see detailed register page fundamental information research development general note group planned change note consolidated group business model human resource statement income goal strategy social area note consolidated corporate performance dividend statement financial position criterion opportunity risk report note fresenius cease voluntary opportunity management note accordance u gaap reporting risk management german commercial code research development risk area hgb employee assessment overall risk change supervisory board management board auditor report procurement corporate governance declaration quality management report responsibility environmental report supervisory board management sustainability economic report board health care industry supervisory board overall business development fresenius se co kgaa result operation financial management board position asset liability fresenius management se overall assessment supervisory board business situation fresenius management se glossary financial calendar report st quarter conference call live webcast may annual general meeting frankfurt main germany may fresenius medical care fresenius kabi payment dividend may report nd quarter conference call live webcast august dialysis product iv drug clinical nutrition report rd quarter health care service infusion therapy medical device conference call live webcast november dialysis service transfusion technology subject prior approval annual general meeting care coordination schedule update information live webcasts event wwwfreseniuscomeventsandpresentations fresenius group figure u gaap million u million u million change million million change sale earnings sale sale ebit fresenius share adr ebitda net income ebit operating cash flow net income capital expenditure depreciation amortization acquisition ordinary share adr earnings per share r expense security identification cusip cash flow balance sheet employee december ticker symbol fre ticker symbol fsnuy operating cash flow isin de isin usm operating cash flow sale bloomberg symbol fre gr structure sponsored level adr total asset reuters symbol fregde ratio adr share noncurrent asset fresenius helios fresenius vamed main trading location frankfurt xetra trading platform otcqx equity equity ratio net debt hospital operation project service net debt ebitda hospital investment health care facility key figure business segment profitability ebit margin contact return equity tax roe million million change million million change return operating asset rooa sale return invested capital roic ebit dividend per share net income employee december corporate headquarters postal address contact shareholder contact journalist operating cash flow elsekrönerstraße fresenius se co kgaa investor relation corporate communication special item capital expenditure net income attributable shareholder fresenius se co kgaa special item acquisition bad homburg v h bad homburg v h telephone telephone including noncontrolling interest germany germany telefax telefax pro forma acquisition special item pro forma acquisition order intake na na email irfrefreseniuscom email prfrefreseniuscom pro forma excluding advance made amount billion fiduciary employee december agreement acquisition hospital rhönklinikum ag pro forma acquisition ltm average exchange rate net debt ebitda investment property plant equipment intangible asset acquisition proposal net income attributable parent company respective business segment special item interactive tool year overview additional key figure available wwwfreseniuscominteractivetool detailed overview special item please see reconciliation table page financial calendar report st quarter conference call live webcast may annual general meeting frankfurt main germany may fresenius medical care fresenius kabi payment dividend may report nd quarter conference call live webcast august dialysis product iv drug clinical nutrition report rd quarter health care service infusion therapy medical device conference call live webcast november dialysis service transfusion technology subject prior approval annual general meeting care coordination schedule update information live webcasts event wwwfreseniuscomeventsandpresentations u million u million change million million change sale ebit fresenius share adr net income operating cash flow capital expenditure acquisition ordinary share adr r expense security identification cusip employee december ticker symbol fre ticker symbol fsnuy isin de isin usm bloomberg symbol fre gr structure sponsored level adr reuters symbol fregde ratio adr share fresenius helios fresenius vamed main trading location frankfurt xetra trading platform otcqx hospital operation project service hospital health care facility key figure business segment sale million million change million million change contact ebit net income corporate headquarters postal address contact shareholder contact journalist operating cash flow elsekrönerstraße fresenius se co kgaa investor relation corporate communication capital expenditure acquisition bad homburg v h bad homburg v h telephone telephone germany germany telefax telefax order intake na na email irfrefreseniuscom email prfrefreseniuscom employee december net income attributable parent company respective business segment special item detailed overview special item please see reconciliation table page fresenius global health care group providing product service dialysis hospital outpatient medical care addition fresenius focus hospital operation also manage project provide service hospital health care facility employee dedicated service health country worldwide shareholder shareholder stephan sturm chairman management board great pleasure write today first quirónsalud spain leading private hospital operator time position fresenius chief executive officer network comprises hospital outpatient center excited honored leading great unique occupational risk prevention center located company know new fresenius chief every metropolitan region spain quirónsalud financial officer since worked closely germanybased fresenius helios combine two leader predecessor ceo ulf mark schneider helped term quality size acquisition offering advance company always put patient first whose growth synergy potential opportunity product service stand quality reliability com exchange knowledge experience lead improved pany whose employee never get complacent medical care patient country already achieved instead work hard find even better solution path continue pursue acquisition quirónsalud turn fresenius helios inter consistency commitment national fresenius medical care fresenius kabi fresenius vamed decade creates addi eventful year fresenius four tional opportunity cooperation among four business business segment continued make progress milestone segment initially spain prospectively coun acquisition spanish hospital operator quirón try well salud fresenius helios based purchase price largest acquisition fresenius history shareholder shareholder fresenius helios also remains highly successful home market last summer acquired niederberg hospital north rhinewestphalia company th hospital across germany increased number patient treated invested almost million upgrading modernizing facility something continue wiesbaden example spend well million completely new hospital building bed operating room large invest ment completed highly modern facility functional design concept minimizes dis tances patient staff one improve medical quality provide fresenius medical care introduced completely new generation hemodialysis machine caresystem successfully developed among many step improve dialysis therapy activity fresenius medical care last year introduced completely four business segment new generation hemodialysis machine care system simplifies workflow clinical staff reduces waste make overall treatment even safer effi cient increased number dialysis clinic reached another milestone last autumn fresenius part acquiring india secondlargest dialysis chain sandor medical care celebrated th anniversary fresenius nephro service expanded care coordina active renal replacement therapy since back tion initiative service dialysisrelated area late fresenius medical care founding acquiring xenios ag germany extended range evolve pure product supplier verti service area cardiac lung therapy cally integrated dialysis company offering dialysis treatment well dialysis product next year fresenius fresenius kabi also continued grow region medical care increased number patient fivefold dia product area particular highlight resumption lyzer production fold sale fold expanding strong growth china latin america broadened position world leading dialysis company product offering worldwide intravenous generic alone launched new product united state acquired production facility prefilled syrinx continued invest high quality efficiency shareholder shareholder manufacturing process plant melrose park near chicago significantly expanded modernized around u million addition started expansion medical disposable plant mihla eastern germany order intake surpassing billion mark first time sale growth project service business fresenius vamed also developed well last year europe remains fresenius vameds important region term sale continuously expanding activity africa asia latin america middle east fresenius vamed thereby important pioneering milestone acquisition spanish hospital operator work make highquality medical care accessible steadily quirónsalud fresenius helios increasing number patient around world way opening healthcare market future every reason believe continue success combined make fresenius th successful development year expect increase consecutive record year sale net income rose sale percent net income even strongly subject shareholder approval annual percent also see outstanding medium long general meeting increase dividend th term growth potential fresenius accordingly consecutive time shown even set ambitious new target business year time political economic uncertainty company aiming sale billion net post stable growth said share price income billion mean goal fresenius share gained percent germany increase sale net income percent dax index rose percent since last year three next four year leading rating agency award fresenius investment grade corporate credit rating additional proof financial mar growth size end however kets trust company stability efficiency potential greatest value serving important goal patient health wellbeing successful business develop new therapy invest better yet affordable medicine similarly size important factor consider fresenius helios draw comparative data hospital germany qual ity management system established based data industryleading term structure trans parency addition doctor nurse specialist shareholder shareholder area exchange information colleague thanks international production network encompass fresenius helios hospital knowledge transfer ing facility every continent react quickly taken even higher level following acquisition increase demand ensure patient supplied quirónsalud reliably often lifesaving drug fresenius medical care patient benefit fresenius vamed meanwhile implemented almost experience gained dialysis clinic health care project country company almost country use knowledge refine clearly market leader field size give u procedure clinic improve treatment continu access uniquely wide range experience help u ally develop dialysis product least reason turn design customized solution health care facili fresenius medical care long market tech tie around world industrialized country nology leader every intention keep way developing nation effort better coordinate many medical service related dialysis call care coordination fresenius reason want continue growing medical care size economic strength enormous expe growth enable u offer even better product rience huge advantage decisive factor enabling treatment contribute provision highquality u provide even better comprehensive care yet affordable health care bringing continuous improve patient ments care ever people remain challenge well future happy proud ceo opportunity bringing continuous lead company pursue goal valued improvement care ever shareholder also proud commitment dedication fresenius investment people remain trust helping u continue growing want challenge well thank sincerely future size also help u fresenius kabi strengthen capa bility assure steady supply urgently needed highest quality drug patient large economically success ful company afford huge investment production stephan sturm process making melrose park chairman management board take production technology develop inside company introduce plant worldwide summary summary fiscal year sale group sale increased earnings group ebit increased million million million ebit margin organic sale growth acquisi group net income increased summary tions contributed divestiture reduced million growth con sale growth currency translation stant currency negative effect sale region earnings development latin america region asiapacific north america europe billion million ebit net income ebit margin b efore special item net income attributable shareholder fresenius se co kgaa detailed overview special item please see reconciliation table page summary cash flow operating cash flow balance sheet total asset increased creased million million mainly due cash flow margin increased business expansion total shareholder summary cash flow acquisition equity including nonc ontrolling interest dividend increased increased million million december net debt ebitda ratio december operating cash flow asset equity liability million million dec dec dec dec operating cash flow operating cash flow margin noncurrent asset equity noncontrolling interest trade account receivable debt current asset liability ltm average exchange rate net debt ebitda special item pro forma acquisition fresenius share fresenius share fresenius share continued excellent performance reaching record high december increase fresenius significantly performed dax fresenius share stock market development dax rose period fresenius fresenius share share gained following year volatile start surprising result market capitalization fresenius billion brexit referendum financial market recovered december increase compared course year slight recovery global economy previous year average daily trading volume xetra calming effect market decreased fresenius share compared dax increased euro stoxx gained previous year dax trading volume year stoxx europe index ended remained nearly unchanged comparison time year index subsector health care period decreased leading u index performed united state fresenius sponsored level follows p increased dow jones american depositary receipt adr program program industrial average increased four fresenius adr correspond one fresenius share closing price fresenius share december adrs traded otcqx international premier mar represents gain ket segment closing price comparison five year fresenius share capital structure performed benchmark dax percentage point total number issued share end december share increase due exercise option stock fresenius share relative share price performance absolute share price performance fresenius share v dax fresenius share fresenius share dec feb apr jun aug oct dec fresenius share dax fresenius high low fresenius share monthly price range option plan information stock option plan found million equivalent group net income page note annual report based proposed dividend closing price end dividend yield dividend fresenius share attractive investment anyone fresenius delivered excellent financial result invested five year ago reinvested dividend th consecutive year proposing share would increased capital decem holder increase dividend per share ber average annual return total proposed dividend distribution expense tax key data fresenius share number share stock exchange quotation high low yearend quotation market capitalization million total dividend distribution million dividend per share earnings per share x etra closing price frankfurt stock exchange total number ordinary share multiplied respective xetra yearend quotation frankfurt stock exchange proposal net income attributable shareholder fresenius se co kgaa special item fresenius share september award best european divi development dividend dend share hosted society dividendenadel fresenius se co kgaa received special dividendenadel award award jury honored annual dividend increase fresenius share seen two decade shareholder structure chart show shareholder structure end else krönerfresenius foundation largest shareholder fresenius se co kgaa share according notification pursuant german security trading act wphg allianz global investor gmbh held share blackrock inc held information notification please fresenius share visit wwwfreseniuscomshareholderstructure december shareholder survey identified ownership subscribed capital shareholder base fresenius solid total proposal institutional investor held million share subscribed capital million share identi fied retail holding topten investor held analyst recommendation share capital share mostly held investor recommendation published financial analyst germany united state great britain important guide institutional private investor making investment decision according survey february rated buy hold sell recommendation shareholder structure region shareholder structure investor region retail holding identified identified great britain germany else krönerfresenius institutional foundation investor rest europe usa due rounding difference figure add fresenius share list bank provide regular analyst coverage analyst recommendation fresenius latest recommendation found wwwfreseniuscomanalystsandconsensus equalweight hold investor relation neutral investor relation activity accordance accumulate add buy transparency rule german corporate governance code outperform overweight communicate comprehensively promptly openly private institutional investor well financial ana lysts equal treatment market actor impor tant u intensified dialog capital market addition quarterly conference call web particularly well time investor relation team cast fresenius gave presentation major european named best medtech sector europe fresenius share u financial market expanded contact also continued dialog private investor institutional investor analyst international inves especially via internet wwwfreseniuscomeventsand tor conference roadshows numerous oneonone presentation private shareholder follow live web meeting also organized field trip bank giving cast conference call use continuously investor analyst opportunity discus matter increased information offer website management board would like contact u find fresenius investor relation team manage financial calendar please take look last page ment team recognized result extel survey report visit u wwwfreseniuscominvestors broad survey conducted company thomson reuters annually survey investor analyst various aspect good investor relation fresenius business segment fresenius medical care fresenius medical care achieved strong sale earnings growth strengthened leading position global dialysis market especially service area fresenius medical care world leading provider business development dialysis product service individual chronic kid fresenius medical care increased sale u business segment ney failure kidney function patient million u million organic sale disease fails dialysis take vital task cleansing growth acquisition divestiture increased sale blood toxin surplus water vertically integrated currency effect negatively affected sale company fresenius medical care offer service dialysis health care service sale dialysis service care product along entire dialysis value chain coordination increased constant currency country fresenius medical care worldwide network u million u million dialysis production site expanded leading product sale increased constant currency market position treated patient u million u million dialysis clinic worldwide number treatment ebit increased u million increased million us million ebit margin onetime item ebit increased net income increased u million u million onetime item net income increased sale region total currency fresenius translation medical care u million change effect sale north america europe middle east africa asiapacific latin america corporate total acquisition u million tax settlement cost agreement principle granuflo naturalyte case u million tax acquisition us million tax net income attributable shareholder fresenius medical care ag co kgaa acquisition u million tax settlement cost agreement principle granuflo naturalyte case u million tax acquisition u mil lion tax business segment fresenius medical care regional development sale segment north america remained fresenius medical care largest u million change business region sale grew u north america million compared u million health care service ebit increased u million dialysis product u million ebit margin total international health care service average revenue per treatment united state dialysis product u compared u aver total age cost per treatment united state decreased worldwide u u health care service business development outside north amer dialysis product total ica business segment emea europe middle east sale dialysis service care coordination africa asiapacific latin america impacted nternational represents business segment emea europe middle east africa asiapacific latin america currency translation effect sale increased including sale generated corporate function u million constant currency u million u u million million ebit decreased u million u million ebit margin treatment quality physician clinical staff dialysis acquisition divestiture clinic offered patient highestquality treatment illus business segment fresenius medical care expanded clinical trated clinical quality parameter shown table network please see page management report last year acquired stake indian dialysis detail treatment quality group sandor nephro service group investor secondlargest provider dialysis treatment please refer page f management report india operates dialysis center financial outlook fresenius medical care sparsh nephrocare brand acquisition strengthens information please see fresenius medical care annual report fresenius medical care core business one world visit website wwwfreseniusmedicalcarecom fastestgrowing economy fresenius medical care region europe middle east total change north america africa latin america asiapacific dialysis clinic december dialysis patient december treatment quality parameter fresenius medical care patient usa emea latin america asiapacific kt v hemoglobin g dl hemoglobin g dl albumin g dl phosphate mg dl hospitalization day data refer last quarter international standard bcr crm business segment fresenius kabi business grew organi c ally region product segment emerging market china latin america showed particularly strong growth organic sale growth ebit growth exceeded original expectation fresenius kabi specializes therapy care chronic business development ally critically ill people portfolio includes iv drug sale increased million organic business segment ie intravenously administered generic anesthetic anal sale growth divestment australian gesics antiinfectives drug treatment onco german oncology compounding business reduced logical critical disease another product segment sale negative currency translation effect clinical nutrition segment one mainly related devaluation argentine peso company worldwide offer parenteral enteral chinese yuan euro nutrition product infusion therapy portfolio includes europe achieved organic sale growth infusion solution blood volume substitute north america organic sale growth mainly driven medical device transfusion technology segment new product launch fresenius kabi showed strong offer infusion nutrition pump well consum overall growth emerging market achieved organic ables administration pharmaceutical clinical sale growth latin america asiapacific organic nutrition product moreover portfolio includes prod sale growth million china worth special ucts used collection processing blood compo mention nents well transfusion medicine sale region currency total translation fresenius kabi million change effect sale europe north america asiapacific latin america africa total special item constant currency business segment fresenius kabi sale product segment follows product segment generic iv drug segment expanded product organic million sale growth portfolio additional regional market worldwide intro iv drug duced approximately iv drug united state clinical nutrition introduced nine iv drug year review two infusion therapy medical device prefilled syringe product continuously transfusion technology working offering product packaging dosage total form like prefilled syrinx especially userfriendly safe ebit rose million currency translation clinical nutrition expanded global market negative effect presence threechamber bag parenteral nutrition distribute product smoflipid coun million change try last year received regulatory approval sell europe product united state enteral nutrition intro north america duced highprotein tubefeed product early enteral nutri asiapacific latin america africa tion intensive care patient european country administrative fresubin intensive developed patient increased corporate r expense protein requirement low moderate energy require ebit ments ebit margin infusion therapy product segment able business segment net income efore special item b help alleviate shortage supply standard infusion net income attributable shareholder fresenius kabi ag special item product basis temporary prolonged import permit granted u food drug administration fda medical device transfusion technology segment acquisition investment received ce approval new amicore apheresis fresenius kabi acquired production facility device introduced product malaysia thailand portfolio seven iv drug prefilled syrinx vietnam apheresis certain blood component obtained u medical technology company becton dickinson blood donor addition successfully company prefilled syrinx gaining importance due introduced cat mart device country high demand placed application safety hospital united state catsmart device automated auto efficiency transfusion process make possible quickly provide invested manufacturing facility launched patient erythrocyte operation certain investment program year example event heavy blood loss reduces need melrose park near chicago invest total around transfusion donor blood u million order increase modernize production capacity drug another example please refer page f management report germany began expansion location financial outlook fresenius kabi mihla thuringia amount invested million information please see fresenius kabis website mihla plant produce component medical disposable wwwfreseniuskabicom special item detailed overview special item please see reconciliation table page special item reported group corporate segment business segment fresenius helios acquisition quirónsalud important strategic step significantly expands position largest p rivate hospital operator europe f urther improved business germany reached sale earnings target fresenius helios leading hospital operator germany million change end helios group operated hospi sale business segment thereof acute care tals acute care hospital including maximum care ho thereof postacute pitals berlinbuch duisburg erfurt krefeld schwerin care wiesbaden wuppertal well postacute care clin ebit ic addition also operated outpatient clinic ebit margin net income patient postacute care center prevention center special item nursing home group approximately net income attributable helios kliniken gmbh bed treat million patient including special item approximately million inpatient year established sixyear development plan acute business development care postacute care clinic acquired germany fresenius helios increased sale development plan provides ebit margin improve million million organic sale growth two percentage point year target margin acquisition contributed achieved acute care hospital accounted sale postacute care clinic accounted acquisition attributable revenue september fresenius helios announced acquisi tion idc salud holding slu quirónsalud spain largest fresenius helios increased ebit million private hospital operator quirónsaluds network comprises million ebit margin hospital outpatient center around occupational increase attributable broadbased posi risk prevention orp center located economically tive performance across hospital network important area spain company offer full spectrum net income increased million inpatient outpatient care quirónsalud treat approxi million mately inpatient approximately million patient per year operates total approximately bed special item net income attributable helios kliniken gmbh special item business segment fresenius helios quirónsalud sale million ebitda investment million fresenius helios invested total million purchase price billion cash debt million amount million accounted free basis relevant spanish antitrust authority approved acquisition million primarily new building transaction december without imposing con modernization hospital schleswig duisburg ditions acquisition closed january pforzheim wiesbaden investment mil quirónsalud consolidated february lion sale may fresenius helios closed acquisition municipal hospital velbert german state million change north rhinewestphalia hospital bed sale investment investment million property plant addition helios expanded outpatient clinic network equipment subsidy property plant equipment hospital admission treatment acquisition due broad range service high treatment quality total purposerelated public investment subsidy according section hospital funding act khg helios number inpatient outpatient treated increased strategic initiative helios hospital partner wir für gesundheit business segment change inpatient semi network comprising hospital across germany inpatient admission subject strict measurable quality criterion acute care hospital postacute care pluscard wir für gesundheit includes supplemental clinic occupational health insurance provides special service outpatient admission high level comfort partner hospital infor mation hospital network pluscard avail key structural data performance indicator developed able wwwwirfuergesundheitde german follows helios also fostering digitalization health care company new helioshub platform first kind change germany support entrepreneur startup devel acute care hospital oping innovation directly benefit patient well bed family member physician network length stay day postacute care clinic helios hospital across germany offer excellent opportuni bed tie implement pilot project assess improve length stay day working closely doctor patient please visit occupancy wwwhelioshubcom information please refer page f management report financial outlook fresenius helios information please see fresenius helios website wwwheliosklinikende german special item primarily relating transaction business segment fresenius vamed service project business developed well sale earn ings target achieved order intake exceeded billion mark first time form excellent basis future growth fresenius vamed manages project provides service table show sale development activity hospital health care facility worldwide business segment total portfolio range along entire value chain project fresenius million change vamed sale development planning turnkey construction via mainte project business nance technical management total operational man service business agement illustrated diagram page offer ings target different area health care prevention acute care postacute care outpatient care range ebit grew million million competency enables u support complex health care ebit margin increased project facility efficiently successfully stage life business ebit grew million million cycle specialist provider deliver full spec service business million million net trum service worldwide vamed unique position income improved million million thus far successfully completed business low capital intensity reflected project country share property plant equipment bal ance sheet pretax return equity business development fresenius vamed increased sale million million organic growth project business divestiture reduced sale currency translation project business comprises consulting project devel effect major impact sale opment planning turnkey construction financing man agement project vamed responds flexibly local sale region need client providing customtailored solution total one source also carry project cooperation fresenius million change vamed sale partner vamed pioneer publicprivate partnership europe ppp model end model africa implemented asiapacific latin america total net income attributable vamed ag business segment fresenius vamed vamed value chain project business service business project development planning project management service operational management construction technical technical management commercial total operational infrastructural management europe remains vameds strongest sale market ger equipment maintenance medical technology manage many completed construction surgery area ment technical management operational intensive care station main emergency ward well management integrated portfolio service aimed redesigned highrise inpatient building berlin optimal operation health care facility charité hospital first milestone reached largest responsible total operational manage ppp project german health care sector construc ment health care facility continent approxi tion modernization universitätsklinikum schleswig mately bed addition part techni holstein uksh austria vamed received additional cal operation service vamed provides service globally order including ppp order general planning con approximately hospital approximately bed struction financing well technical operation austria continued partnership main radiooncology facility two location vienna decem tained since vienna general hospital akh one business segment ber expansion neurological rehabilitation europe largest hospital germany began providing facility completed vienna vamed also manages technical service uksh mid vamed also led project ia poland switzerland consortium responsible technical infrastructural also expanded operation africa including service berlin charité hospital since addition ghana government commissioned vamed pro vamed signed additional service contract major european vide turnkey construction five regional hospital market germany austria switzerland italy polyclinic tunisia building oncology center facility make u largest private rehabilitation asiapacific region vamed successfully worked provider austria also operate wellknown rehabil realization lifecycle project abu dhabi itation facility switzerland czech republic contract china lao vamed commissioned turnkey construction hospital vamed vitality world latin america vamed managing medical service portfolio vamed vitality world bridge equipment project nicaragua bolivia build gap preventive medicine health care tourism regional hospital market leader austria eight thermal spa wellness resort vamed also operates aqua world buda order intake order backlog project pest hungary largest thermal spa country facility recognized austria internationally million change innovative service high quality order intake order backlog december please refer page f management report financial outlook information please see fresenius vameds website wwwvamedcom service business vamed offer full range facility management service health care facility modular design service offering encompasses every aspect technical commercial infra structural facility management range building management report table content management report fundamental information group overall assessment business situation group business model important market competitive position legal economic factor outlook management control general midterm outlook capital shareholder article association future market goal strategy health care sector market corporate performance criterion group sale earnings fresenius cease voluntary u gaap reporting sale earnings business segment research development financing employee investment change supervisory board management board procurement procurement research development quality management planned change human resource social area responsibility environmental management sustainability dividend economic report opportunity risk report health care industry opportunity management dialysis market risk management market generic iv drug clinical nutrition risk area management report infusion therapy medical device assessment overall risk transfusion technology hospital market market project service hospital health care facility overall business development management board assessment effect general economic development health care sector fresenius management board assessment business result significant factor affecting operating performance comparison actual business result forecast result operation financial position asset liability result operation financial position asset liability corporate rating management report fundamental information group management report successful year fresenius met guidance achieved billion sale billion net income operating cash flow margin fundamental information renal pharmaceutical among important group product line addition fresenius medical care offer dialysisrelated service among others field care group business model coordination fresenius global health care group legal form fresenius kabi specializes intravenously adminis se co kgaa partnership limited share offer tered generic drug iv drug clinical nutrition infu product service dialysis hospital outpatient sion therapy company also supplier medi medical care addition fresenius focus hospital oper cal device product transfusion technology management report ations also manage project provide service company sell product mainly hospital hospital health care facility worldwide fresenius helios largest hospital operator ger operating business comprises four business segment many end fresenius helios operated legally independent entity managed total hospital around bed germany operating parent company fresenius se co kgaa busi addition acute care hospital including maxi ness segment regional decentralized structure mum care hospital berlinbuch duisburg erfurt krefeld schwerin wiesbaden wuppertal helios fresenius medical care offer service product group postacute care clinic following patient chronic kidney failure december closing acquisition quirónsalud january fresenius medical care treated patient fresenius helios also largest private hospital ope dialysis clinic dialyzer dialysis machine rator spain end quirónsalud operated hospital outpatient center around occupa tional risk prevention center group structure fresenius vamed manages project provides service hospital health care facility worldwide fresenius se co kgaa portfolio range along entire value chain project development planning turnkey construction via maintenance technical management total fresenius fresenius fresenius fresenius operational management medical care kabi helios vamed management report fresenius international sale network maintains fiscal year however slightly negative currency translation approximately production site large production site effect income statement resulted particular located united state china japan germany depreciation latin american currency chinese sweden production plant also located euro yuan euro fiscal year result pean country latin america asiapacific south exchange rate change u dollar decem africa ber u dollar december balance sheet total increased due currency trans important market competitive lation effect position legal aspect significantly affected busi fresenius operates country subsid ness performance iaries main market north america europe sale respectively management control fresenius medical care hold leading position world legal form kgaa company corporate body wide dialysis care serf dialysis general meeting supervisory board patient well dialysis product market share general partner fresenius management se fresenius man fresenius kabi hold leading market position agement se wholly owned else krönerfresenius europe significant market share growth stiftung kgaa twotier management system market asiapacific latin america united state management control strictly separated fresenius kabi one leading supplier generic general partner represented management iv drug fresenius helios largest hospital operator board conduct business represents company germany following closing acquisition dealing third party management board generally quirónsalud january also largest private seven member according management board hospital operator spain fresenius vamed one rule procedure member accountable world leading company field area responsibility however member joint responsibility management group addi legal economic factor tion supervisory board fresenius se co kgaa management report overall legal economic factor fresenius group fresenius management se supervisory board largely unchanged lifesaving lifesustaining management board required report supervisory product therapy group offer intrinsic board fresenius management se regularly particular importance people worldwide therefore market corporate policy strategy business profitability fundamentally stable relatively independent economic current operation matter could cycle detailed information market please see significance company profitability liquidity page ff supervisory board fresenius management se also advises furthermore diversification across four business supervises management board management segment global reach provide additional stability company prohibited managing company group directly however management board rule procedure fluctuating exchange rate particularly require obtain approval supervisory board u dollar euro effect income fresenius management se specific activity statement balance sheet euro exchange rate member management board appointed unchanged yearonyear u dollar dismissed supervisory board fresenius manage material effect income statement ment se appointment dismissal accordance article se regulation article association fresenius management se also provide deputy member management board may appointed management report fundamental information group supervisory board fresenius se co kgaa advises increase subscribed capital fresenius se co supervises management company business kgaa total amount million general partner review annual financial statement may single multiple issuance consolidated financial statement performs new bearer ordinary share cash contribution function assigned law company arti contribution kind authorized capital cles association involved corporate planning shareholder preemptive right subscription strategy matter fundamental importance excluded company supervisory board fresenius se co kgaa six shareholder representative six employee represen report general partner pursuant section tatives nomination committee supervisory board sentence german stock corporation act aktg fresenius se co kgaa instituted election pro conjunction section sentence aktg con posals shareholder representative activity junction section aktg partial utiliza aligned provision law corporate gover tion authorized capital resolved annual share nance code shareholder representative elected holder meeting may general meeting fresenius se co kgaa euro september management board general pean work council elect employee representative partner consent supervisory board com supervisory board fresenius se co kgaa pany resolved substantiated another reso supervisory board must meet least twice per calen lution january partially utilize autho dar halfyear supervisory board fresenius se co rization granted pursuant article article kgaa two permanent committee audit committee association increase company share capital consisting five member nomination committee issuing new nonpar value ordinary consisting three member member committee bearer share way capital increase contribu listed page annual report company tions kind excluding shareholder subscription right annual corporate governance declaration describes proce implementation capital increase dures supervisory board committee declara registered commercial register tion found page annual report january volume capital increase management report website wwwfreseniuscomcorporategovernance equivalent share capital time description compensation system utilization individual amount paid management board super new nonpar value share carry dividend entitle visory board fresenius management se super ments january issued hc investment visory board fresenius se co kgaa included bv contribution kind share idc salud slu compensation report page annual report quirónsalud capital increase made compensation report part group manage context acquisition share quirónsalud ment report aggregate amount billion cash debtfree basis implemented part capital shareholder article quirónsalud share issuance new association share apart cash purchase price subscribed capital fresenius se co kgaa amounted contributed share represent ordinary share december value quirónsalud december exclusion subscription right based share fresenius se co kgaa nonparvalue authorization pursuant article subsection bearer share share represents capital article association increase share capital stock shareholder right regulated german stock contribution kind acquisition company corporation act aktg aktiengesetz opportunity act quickly flexibly used best fresenius management se general partner authorized subject consent supervisory board fresenius se co kgaa management report interest company thereby requirement debt share capital conditionally increased financing purchase price could reduced value issuance new ordinary bearer contribution kind adequate relation value share conditional capital iv conditional capital new share due limited volume capital increase implemented extent increase shareholder wish maintain sharehold subscription right issued accor ing quota could acquire additional share via dance stock option program stock exchange thus interest shareholder term holder subscription right exercise right financial interest voting right appropri company grant share satisfy ately protected subscription right addition following conditional capital company authorized may purchase conditional capital ii adjusted stock use share maximum amount option exercised meantime subscribed capital addition purchasing share company authorized use equity derivative subscribed capital conditionally increased possible exclusion tender right company issuance new bearer ordi utilized authorization december nary share conditional capital conditional capi largest shareholder else krönerfreseniusstiftung tal increase executed extent con bad homburg germany informed company decem vertible bond ordinary share issued ber held ordinary share stock option plan holder con fresenius se co kgaa corresponds equity interest vertible bond exercise conversion right december subscribed capital conditionally increased amendment article association made issuance new bearer accordance section section ordinary share conditional capital ii conditional german stock corporation act aktg conjunction capital increase executed extent article article association fresenius se subscription right issued stock co kgaa unless mandatory legal provision require management report option plan holder subscription right exer wise amendment article association require sim cise right company use ple majority subscribed capital represented share service subscription right exer resolution voting result tie motion deemed cise right make payment cash rejected furthermore accordance section general partner authorized approval sentence german stock corporation act aktg supervisory board may issue option amendment article association require consent bearer bond convertible bearer bond general partner fresenius management se several time total nominal amount bil supervisory board entitled make amendment lion fulfill granted subscription right sub article association concern wording scribed capital fresenius se co kgaa increased without resolution general meeting conditionally issuance certain circumstance change control new bearer ordinary share conditional capital iii result takeover bid could impact longterm conditional capital increase shall implemented financing agreement contain customary change con extent holder convertible bond issued trol provision grant creditor right terminate cash warrant option bond issued agreement early request early repayment outstand cash exercise conversion option right long ing amount case change control termina form settlement used tion right partly become effective change control followed decline company rating respective financing instrument management report fundamental information group goal strategy ing product united state market share goal strengthen position fresenius lead expanded launch new product ing global provider product therapy critically field iv drug infusion therapy clinical nutrition chronically ill people four business segment well medical device transfusion technology concentrating limited number health care hospital fresenius helios operating area thanks clear focus developed unique nearly whole germany building fresenius competency following longterm strategy helios position develop new patient care consistently seizing opportunity model take advantage growth opportuni tie arising privatization consolidation pro key element fresenius group strategy goal cess german hospital market january fresenius helios closed acquisition quirónsalud spain largest operator private hospital open expand market position worldwide presence opportunity exploiting synergy expansion fresenius seek ensure expand longterm posi construction hospital potential tion leading international provider product consolidation highly fragmented private hospital service health care industry end geo market spain graphically expand business plan grow organi fresenius vamed expand position cally well selective small mediumsized global specialist project service hospital acquisition complementing existing portfolio health care facility focus market strong growth rate strengthen innovation fresenius strategy continue fresenius medical care worldwide leader building strength technology competence dialysis strong market position united state quality patient care ability manufacture future opportunity dialysis arise costeffectively want develop product system international expansion dialysis care product provide high level safety userfriendliness well expansion field care coordination enable tailoring individual patient need intend area fresenius medical care offer additional ser continue meet requirement bestinclass management report vice dialysis patient include eg vascular medical standard developing offering effec care service laboratory service well hospital tive product treatment method critically ist intensivist service expanding business chronically ill company address growing need integrated enhance profitability last least goal patient care improve group profitability contain cost con fresenius kabi market leader infusion therapy centrating particularly making production plant clinical nutrition europe key market efficient exploiting economy scale leveraging asiapacific latin america united state existing marketing distribution infrastructure fresenius kabi one leading player market intensively practicing strict cost control generic iv drug addition fresenius kabi one focusing operating cash flow employing effi important provider transfusion technol cient working capital management increase ogy fresenius kabi plan roll product investment flexibility improve balance sheet ratio existing portfolio growth market launch exist another goal optimize weighted average cost capital wacc deliberately employing balanced mix equity debt funding present capital market management report financial performance indicator growth profitability liquidity capital efficiency capital management sale growth operating income ebit operating cash flow ebit net debt constant currency financial result sale income tax ebitda income tax sale growth minority interest cash flow margin nopat leverage ratio organic invested capital net income roic ebit growth constant currency ebit operating asset net income growth rooa constant currency condition optimize cost capital hold liquidity net debt ebitda ratio within range please corporate level cash flow margin used main see following section corporate performance criterion liquidity indicator order analyze optimize page detail contribution business segment operating cash flow also use additional performance indicator dso report goal detail outlook section day sale outstanding soi scope inventory page show amount receivables inventory relation sale cost service rendered past corporate performance criterion reporting period management board make operational strategic management decision based groupwide performance capital efficiency indicator growth profitability liquidity capital efficiency work profitably efficiently possible capital management important financial per capital provided u shareholder lender order management report formance indicator u explained defini manage primarily calculate return invested tion provided glossary financial term page capital roic return operating asset rooa capital management growth sale use ratio net debt ebitda key parameter line growth strategy sale growth constant managing capital structure measure indicates currency group business segment organic degree company able meet payment sale growth particular central importance obligation business segment usually hold leading position growing mostly noncyclical market since profitability majority customer high credit quality use earnings interest tax ebit ebit generate mainly stable predictable cash flow group growth constant currency measure profitability therefore able use debt finance growth greater segment group level primarily use net income extent company industry net income growth constant currency order able better compare operating performance several period result also adjusted special item reflect core performance indicator detailed calculation roic rooa please see page management report fundamental information group investment process r expense segment investment carried using detailed coordination evaluation process first step management board set group investment target budget based fresenius medical care investment proposal next step respective busi fresenius kabi ness segment internal acquisition investment council aic determine proposed project measure taking account overall strategy total investment budget required potential return investment million evaluate investment project based commonly used method internal rate return irr net present value npv based investment volume project sub research development mitted approval executive committee respective product process development improvement management business segment management therapy core growth strategy fresenius board fresenius management se supervisory board focus r effort core competency following area fresenius cease voluntary u gaap reporting dialysis fresenius se co kgaa publicly traded company based generic iv drug european union member country required prepare infusion nutrition therapy publish consolidated financial statement accordance medical device international financial reporting standard ifrs pursu ant section german commercial code hgb apart new product concentrating develop addition compulsory ifrs accounting fresenius ing optimized completely new therapy treatment meth also publishes consolidated u gaap financial statement od service provided comparability group largest sub research development expense million management report sidiary fresenius medical care required report million approximately product accordance u gaap socalled pooling sale fresenius medical care increased r agreement however fresenius medical care annual spending fresenius kabi increased r spend general meeting lifted obligation ing detailed figure included segment report interest harmonizing management ing page f accounting fresenius group business seg december employee ments fresenius group business segment research development number report solely accordance ifrs starting employed fresenius medical care fiscal year fresenius kabi key figure research development r expense million product sale r employee management report main research site europe united state especially emerging market work india productrelated development activity also carried conducted development center china china r project mainly conducted location house external research commissioned limited scale fresenius kabi fresenius kabis research development activity concen fresenius medical care trate product therapy care critically complex interaction side effect lead kidney chronically ill patient product help support medical failure better explored today ever techno advancement acute postacute care improve logical advance develop parallel improve possibili patient quality life tie treating patient r activity fresenius development expertise includes related com medical care aim translate new insight novel devel ponents drug raw material pharmaceutical opments bring market quickly possible formulation primary packaging medical device thus make important contribution towards rendering needed application drug infusion produc treatment patient increasingly comfortable safe tion technology individualized area iv drug continuously working global r portfolio management seek extension drug portfolio aim launch new standardize basic function single component generic drug formulation directly patent therapy system internationally standardize process branded product expire also develop new formulation control structure allows u address local require nonpatented iv drug active pro ments reduce development time bundle jects area generic focus among item resource benefit vertical integration complex formulation active ingredient liposo development new technology application mal solution develop readytouse product give u access experience patient specialized especially convenient safe including example medical personnel readytouse solution freeflex infusion bag pre fresenius medical care continued filled syrinx drug prefilled syrinx simpler management report develop product introduce innovation including new safer use traditional application help therapy system care system optimizes dialysis improve patient care treatment minimizes operating step required clinical nutrition provides care patient cannot procedure consists new allinone cartridge system nourish normally sufficiently includes completely preconnected bloodline treatment example patient intensive care serious modality since also reduces amount waste dialysis chronic illness malnourishment early correct treatment care system simultaneously cost intervention help patient avoid malnutrition con efficient environmentally friendly sequence addition collected first clinical data parenteral nutrition devote effort product new dialyzer modified inner wall hollow make significant contribution improving clinical fiber produce hemocompatible fiber surface treatment nutritional condition patient inno enabled u reduce heparin requirement standard dialy vative container multichamber bag si treatment safe convenient everyday use contin working partner develop portfolio ued development parenteral formulation focus stateoftheart technology automated peritoneal dial formulation designed meet need individual ysis apd patient group addition researching new parenteral also developing portfolio product meet strictest requirement term quality efficiency liposome tiny capsule used vehicle active pharmaceutical ingredient allow targeted transportation ingredient location needed within organism management report fundamental information group nutrition product enable optimized absorption employee region nutrient research development work also includes development marketspecific parenteral formulation latin america region worked product united state asiapacific china among market development enteral nutrition concen europe trate new product packaging order take account thereof germany north america specific requirement local market would like break addition working development formulation facilitate daily intake enteral nutrition product patient work medical device transfusion technology included expansion product range application personnel expense fresenius group technology agilia brand make possible u offer million million equivalent broad portfolio safe efficient application technology sale increase mainly attri inpatient outpatient last year developed butable increase headcount salary increase infusion pump allows patient administer painkiller acquisition personnel expense per employee analgesic intravenously form pain thousand thousand thousand therapy usually used surgery new pump agilia constant currency germany fresenius company connect pca software link help simplify dayto signed tariff agreement ig bce marburger bund day operation patient safety medical care plan verdi labor union service significant introduce new pump structural change compensation employment agree ments employee knowledge experience commitment employ human resource management ee critical success reason fresenius constantly adapting human resource tool meet management report value culture diversity interplay wide range new requirement arising demographic transfor view opinion cultural background experience val mation service economy skill shortage compati ues help u achieve full potential contributes bility job family life example offer flexible success working hour longterm account longterm pro number employee increased employee fessional planning employee voluntarily contribute vacation end last year day make contribution salary long term account use training nursing care early retirement number employee dec dec change total fresenius medical care fresenius kabi fresenius helios fresenius vamed corporate total management report part identity health care company includes creating fresenius group devotes lot attention vocational right condition foster health employee training trained young people fresenius se co kgaa named healthy com different occupation german location pany gesundes unternehmen initiative award also put university student degree focus attention throughout germany company set program cooperation dual institution higher especially high standard promotion health learning order meet challenge digitization workplace work process fresenius increased number training study place offer related profes employee recruitment personnel sion offer new dual course study example development area digital medium alongside traditional channel order ensure longterm need highly quali direct job entry fresenius offer trainee program uni fied employee met recruit new employee versity graduate make use online personnel marketing regularly participate fresenius involved two initiative vocational recruiting event career fair organize integration young refugee bad homburg frankfurt recruiting event addition encourage longterm reten main aim initiative integrate refugee tion attractive development program vocational training voca approach measure employee recruitment tional orientation phase successfully completed personnel development business segment initial qualification based market requirement segment visit awardwinning career portal coordinated developed realized independently wwwcareerfreseniuscom business segment support development employee profes profitsharing scheme sional personal skill across group personal stock option plan career talk well comprehensive range many year paid stockbased profitsharing training session seminar continue expand bonus distributed fresenius group ebit hierarchy level earnings target defined program management report fresenius promotes longterm sustainable advance achieved table show development ment woman fresenius qualification profitsharing bonus last several year thing matter selection personnel consequently long term incentive program global com fresenius woman men comparable qualification pensation instrument linking management entrepreneurial continue career opportunity responsibility future opportunity risk comprises december proportion female employee stock option plan well phantom stock within fresenius group woman also held plan combine granting stock option senior management position based number granting phantom stock award informa worldwide participant stock option plan detailed infor tion stock option please see page ff annual mation statutory target participation woman report men management position available within corporate governance declaration pursuant section change supervisory board german commercial code hgb website see management board wwwfreseniuscomcorporategovernance well page general meeting may prof dr med iris annual report löwfriedrich hauke star elected profitsharing bonus profitsharing bonus eligible employee profitsharing bonus paid retroactively respective fiscal year form part compensation german group company without eligible employee fresenius medical care ag co kgaa management report fundamental information group cost material business segment quality management quality product service therapy fresenius vamed basis optimal medical care process subject highest quality safety standard benefit fresenius helios patient protect employee quality man fresenius medical care agement following three main objective fresenius kabi identify valueenhancing process oriented toward efficiency need customer monitor manage process basis million performance indicator consolidation improve procedure supervisory board shareholder representative stefanie fresenius medical care lang frauke lehmann mr oscar romero de paco lifesaving treatment highest demand placed elected european work council employee dialysis term safety quality applies representative board supervisory board production dialysis product administra fresenius se co kgaa law requires quota least tion dialysis treatment hospital rea woman men mandatory quota son fresenius medical care established quality manage met supervisory board election ment system production site dialysis clinic june fresenius se co kgaa announced commission regular external audit use supervisory board fresenius management se europe german technical certification organiza unanimously appointed stephan sturm chief executive tion tüv audit clinical organization annually verify officer fresenius july stephan sturm suc compliance iso quality management ceeds dr ulf mark schneider decided leave iso environmental management united state company effective june pursue another oppor clinic monitored center medicare management report tunity medicaid service cm public health care authority also regularly review quality management system procurement internal audit cost raw material supply pur measure compare quality performance chased component service million dialysis clinic using generally recognized quality standard million increased due business addition industryspecific clinical benchmark expansion include quality target set fresenius medical care linked service advice provide exam million ple fresenius medical care u quality parameter cost raw material supply generally recognized dialysis industry eg hemo cost purchased component service globin value total fresenius kabi efficient value chain important profitability global quality management system fresenius kabi environment characterized ongoing costcontainment pres based internationally recognized iso standard sure health insurer well price pressure security includes example good clinical practice gcp quality supply play crucial role within business good manufacturing practice gmp good distribution practice segment fresenius group procurement process gdp code federal regulation cfr u food coordinated centrally enabling u bundle similar require ments negotiate global framework agreement constantly monitor market price trend ensure safety quality material management report drug administration fda iso quality helios quality performance indicator extract management standard medical device global quality indication standardized mortality ratio management system certified audited tüv süd smr smr smr quality management comprises chronic obstructive pulmonary disease copd acute myocardial infarction ami global process standard specialist team develop heart failure enterprisewide standard guideline ischemic stroke implemented subsidiary country pneumonia early warning system established reporting hip fracture process standard procedure unforeseen event mr corresponds german average smr mean mortality german average evaluated key performance indicator adjusted helios hospital niederberg acquired german federal statistical office reference value converted giqi new reference value eg complaint rate information found wwwheliosklinikendemedizinqualitaetsmanagement global product risk management safety officer respond immediately informed problem quality patient safety manage product recall expanded helios quality management system centrally conversion giqi indicator version improved key figure updated reference rate used fresenius kabi inspection regulatory authority statistical abnormality arise helios examines audit independent organization customer per peer review process using patient data issue formed along entire value chain hygiene remains focus first time inter however quality management system professional team assembled address selected issue extend internal process also cover application area intensive care medicine example spe product service customer order able cially trained employee nursing occupation supported receive information issue timely manner medical team peer review process deal appropriately fresenius kabi set addition make intensive use pool quality global monitoring reporting system vigilance sys indicator eg obstetrics created part statutory quality management report tem responsible regulatory authority monitor sys assurance result peer review procedure instruction tem keep increasingly close eye interest training program initiated make childbirth even patient safety safer made progress transferring goal helios establish interdisciplinary quality management process electronic quality system group treatment patient malignant tumor global system support harmonization medical advisory board experienced helios chief process availability data risk prevention physician various discipline produce quarterly quality analysis monitor implementation helios wide fresenius helios decision helios u procedure combine internal measure addition helios involved initiative quality quality management use quality indicator medicine iqm exchange idea knowledge use key figure administrative data measure quality hospital operator iqm member committed observing medical outcome treatment quality medical three basic principle quality measurement adminis outcome resulting different treatment measured trative data publication result peer review process using key indicator compiled administrative data made transparent basis giqi quality indicator german inpatient quality indicator management report fundamental information group iqm member provide acute care approximately four different category vamed company respon million patient hospital germany sible technical operation akh vienna including switzerland germany share acute care excellence award prize winner exemplary european defined specific target giqi quality company employee success innovation indicator target set level national customer benefit average germany achieved target addition fresenius vamed company certified quality indicator success rate accordance numerous relevant technical standard convinced transparency creates best three facility managed vamed austria incentive improvement helios provides full transparency obtained certification jci joint commission inter quality data acute care hospital result national hospital certified highest medical treatment quality result patient survey level quality firstly regarding patient care secondly regar key indicator field hygiene published ding hygiene safety thirdly regarding patient website wwwheliosklinikende helios exceeds mandatory employee satisfaction status regularly confirmed legal requirement recertification process provided jci national quality institute iqtig commis sioned federal joint committee recommend quality responsibility environmental indicator form suitable basis qualityoriented management sustainability decision hospital planning initial indicator orient activity within fresenius group long area gynecological surgery obstetrics breast surgery term goal thus ensure work aligned collected external inpatient quality assu need patient employee well shareholder rance established tested business partner sustainable manner responsibil onwards quality management system helios ity health care group go beyond business opera prepared new procedure tions committed protecting nature basis life using resource responsibly mission fresenius vamed constantly improve performance area environ planning construction hospital fresenius vamed mental protection occupational health technical safety management report set high quality standard particular aimed product responsibility logistics comply optimizing process care level ensuring maximum legal requirement flexibility use building ward international iso standard environmental internally fresenius vamed design process effi management implemented various production plant ciency sustainability using interdisciplinary quality dialysis clinic among thing key standard based iso quality management environmental performance indicator instance system iso quality management system medical energy water consumption also volume device iso inspection medical device product waste recycling rate location iso competence testing calibration laborato europe production site subject eu reg ries iso environmental management iso com ulation reach registration evaluation authorization pliance management system iso systematic energy ch emicals aim reach protect human health management iso information security management environment hazard risk chemical system efqm standard european foundation substance quality management efqm already granted award decision specialist gynecology march indicator nonabdominal hysterectomy upgraded observed value target value total goal attainable management report fresenius established groupwide project expand fresenius kabi sustainability reporting part expansion integral component quality management fresenius carried extensive materiality analysis fourth quar kabi environmental management system complies ter involved relevant internal external international standard iso fresenius kabi ag stakeholder continue project plan several site certified standard also report extensively annual report implemented occupational health safety assessment system ohsas several site set guideline fresenius medical care site worldwide site fresenius kabi environmental management operation deutschland gmbh certified iso inter work comply environmental regulation make national standard energy management system internati product process resourceefficient also sup onally production unit wuxi china la châtre port business segment creating added value france also iso certified continued implement client ecofriendly product service environmental measure production site worldwide europe middle east africa emea tüvcerti specific focus outside europe fied environmental management part integrated site graz austria able keep energy management system end eight eight consumption previous year level despite higher pro european production site medical device develop duction volume expanded production area three heat ment department certified according iso exchanger installed recover heat flash steam use energy management system per iso boiler blowdown warmingup city water german production site st wendel schweinfurt fed steam boiler measure possible also implemented certified environmental manage reduce gas consumption steam boiler addi ment system european country tion gas burner renewed reduce gas con one central concern reduce sumption emission specifically nox recycling pack environmental effect dialysis treatment central aging material nearly ton co saved element managing resource efficiency dialysis recycling rate could maintained center emea latin america software econ uppsala site sweden energy consumption per management report use european liter solution produced unchanged kwh l latin american dialysis center approximately energy needed swedish environmental data management system allows site uppsala brunna provided renewable source u capture compare data resource efficiency take maintained recycling rate prompt advantage opportunity improvement production site pune india reduced reduced average water con briquette consumption compared previ sumption per dialysis treatment electricity con ous year period able reduce water sumption dialysis center additionally consumption haina site dominican able reduce amount contaminated blood waste republic reduced plastic waste last year significantly last year goal keep reduced electricity consumption using figure already low level comply existing new lighting airconditioning technology legal framework future moreover environmental program established aim reduce average water consumption per dialysis treatment electricity consumption management report fundamental information group fresenius helios fresenius vamed hospital require great deal energy water order project business already integrate national environ create awareness among employee economical mental standard regulation planning con use resource intensified environmental struction hospital health care facility vameds campaign within helios extensive expertise environmental management structural condition hospital building impor important success factor especially growth market africa tant influence energy consumption new construction asia sewage treatment disposal medical project modernization conform latest standard technology waste meet highest possible standard efficient heat insulation accordance current energy also achieved success service business saving regulation improvement based area environmental protection vamed instance comprehensive controlling system real estate manage responsible technical management akh ment enables u compare target actual value hospital vienna year period regularly promptly compared previous year adjusted energy water consumption significantly reduced energy consumption reduced represents energy consumption decreased demand long co reduction around mg save approximately distance heat drinking water consumption million usefully invested medicine volume waste classified hazardous medical system also formed basis certification waste akh fell helios hospital accordance requirement since energy management fresenius new energy service act energiedienstleistungsgesetz vamed austria certified compliant iso edlg continually review measure reduce resource required implement measure promptly possible addition continue shift heating renewable energy instance wood pellet form heating coneutral therefore ecofriendly gas oil heating helios still u electricity heat fossil fuel natural gas built combined heat power management report plant nine site thanks step taken saved approximately mg co mg co water consumption helios hospital majority water consumed sterilization process process cooling water recycling plant reduce consumption ho pitals using well water instance cooling tow er airconditioning system proper waste disposal great importance hospital helios view waste disposal management process start avoiding future waste end consis tent recycling environmentally friendly disposal requirement pertaining environmental protection occupational health safety infection protection hospital hygiene taken account relates particu larly major waste group clinical waste ie diagnosis treatment human disease total amount clinical waste generated helios ho pitals management report economic report previous year united state highest per caput spending u germany ranked sixth among health care industry oecd country per caput spending u health care sector one world largest industry germany health spending funded pub relatively insensitive economic fluctuation compared lic source average oecd sector posted aboveaverage growth country past several year oecd country enjoyed large gain life expectancy past decade thanks improved main growth factor living standard public health intervention progress medical care average life expectancy oecd rising medical need deriving aging population country year growing number chronically ill multimorbid health care structure reviewed costcutting patient potential identified order contain steadily rising stronger demand innovative product therapy health care expenditure however measure cannot advance medical technology compensate cost pressure marketbased element growing health consciousness increase increasingly introduced health care system demand health care service facility create incentive cost qualityconscious behavior overall treatment cost reduced improved emerging country additional driver quality standard addition evergreater importance placed disease prevention innovative reimbursement expanding availability correspondingly greater model linked treatment quality standard demand basic health care important market developed follows increasing national income hence higher spending health care dialysis market global dialysis market product service time cost health care rising claim worth approximately u billion constant currency management report ing everincreasing share national income health care global dialysis market grew spending averaged gdp oecd country worldwide approximately million patient chronic average u spent per caput renal failure treated patient around million received dialysis treatment living transplanted kidney treated hemodialysis peritoneal dialysis health care spending gdp usa france germany switzerland source oecd health data source oecd health data management report economic report major growth driver growing number patient dialysis patient region suffering diabetes high blood pressure two dis ea often precede onset chronic kidney failure latin america number dialysis patient worldwide increased u japan western central europe patient growth slower economically north america asiapacific weaker region growth mostly prevalence rate number people terminal kidney failure treated per million population differs europe middle east africa widely region region developing country patient well average country european union prevalence high country japan united state well dialysis reimbursement system differ country coun significant divergence prevalence rate due try often vary even within individual country public one hand difference age demographic incidence health care program center medicare medicaid renal risk factor genetic predisposition cultural habit service cm cover medical service majority nutrition hand access dialysis treat dialysis patient united state ment still limited many country great many individ uals terminal kidney failure receive treatment dialysis product therefore included prevalence statistic global dialysis product market worth approximately u billion dialysis care fresenius medical care leading provider dialysis global dialysis care market including renal product world market share pharmaceutical worth approximately u billion followed largest competitor baxter worldwide dialysis patient treated competitor held singledigit percentage market fresenius medical care dialysis clinic share management report dialysis patient country fresenius medical care fresenius medical care leading supplier worldwide operates far largest international network hemodialysis product market share clinic united state fresenius medical care treated market share approximately fresenius medical care approximately dialysis patient secondlargest provider worldwide product peri market dialysis care united state already toneal dialysis baxter highly consolidated taken together fresenius medical care davita another provider dialysis care treat care coordination u dialysis patient field care coordination currently includes service outside united state market dialysis care relating vascular cardiovascular endovascular surgery much fragmented fresenius medical care com nondialysis laboratory testing physician practice service petes mainly clinic chain independent clinic well coordinating hospitalist intensivist service clinic affiliated hospital specialist physician health plan service coordinated delivery pharmacy service care service example management report united state fresenius medical care provides care stay less nursing care estimate regarding euro coordination among others within network pean union situation indicate many million indi provider working across entire acute episode viduals risk malnutrition market clinical care emergency medicine hospitalists intensivists nutrition fresenius kabi one leading company transitional care provider around hospital worldwide parenteral nutrition company lead postacute facility company cared mil ing supplier worldwide market enteral nutrition lion patient fresenius kabi one leading supplier europe parenteral nutrition competitor include baxter b braun market generic iv drug clinical kelun pharmaceutical market enteral nutrition nutrition infusion therapy medical fresenius kabi competes among others danone device transfusion technology nestlé abbott global market generic iv drug clinical nutrition fresenius kabi considers global market infusion infusion therapy medical device transfusion technology therapy worth billion worth billion growth european market due restriction thereof global market generic iv drug worth imposed use blood volume substitute region billion fresenius kabi able enter addi asiapacific latin america africa market infu tional market segment global addressable market due sion therapy grew selected market infusion thera targeted investment expansion product pie electrolyte standard medical product portfolio among others area complex formulation hospital worldwide market growth mainly driven increas liposomal solution prefilled syrinx ing product demand emerging market fresenius kabi europe united state market iv drug market leader infusion therapy europe competitor grew growth mainly achieved product include baxter b braun brought market original drug go global market medical device transfusion patent well original offpatent product technology worth billion including offered steady price due unique selling proposition approximately billion medical device additionally market growth based sharp price increa billion transfusion technology market grew management report single molecule individual competitor approximately medical device market united state important generic iv drug market main growth driver itbased solution focus fresenius kabi company one leading supplier application safety therapy efficiency transfusion competitor include pfizer sandoz teva pharmaceutical technology market growth driven generally increased industry demand blood bag emerging market new therapy global market clinical nutrition worth treatment reduced demand blood bag europe billion europe market grew united state related overcapacities involve price emerging market asiapacific latin america reduction africa clinical nutrition market saw growth medical device segment fresenius kabi rank individual country growth potential offered among leading supplier worldwide international com often insufficient administration nutrition therapy within petitors include baxter b braun becton ickinson patient care although study demonstrated medi company well icu medical transfusion technol cal economical benefit case health ageinduced ogy fresenius kabi one world leading compa nutritional deficiency example administration ny competitor include haemonetics macopharma clinical nutrition reduce hospital cost shorter terumo arket data based company research refers fresenius kabis addressable market subject annual volatility due currency fluctuation patent expiry original drug iv drug market among thing market definition adjusted compared prior year among others sale volume nonpatented branded drug included german society nutritional medicine dgem ljungqvist clinical nutrition management report economic report hospital market hospital bed operator market acute care hospital germany billion personnel cost accounted private hospital hospital cost material cost personnel material cost rose approximately increase admission organic growth public hospital acute care hospital market around addition independent nonprofit potential growth private hospital operator arises hospital hospital acquisition privatization although economic situation improved com pared previous year third german hospital source german federal statistical office recorded loss broke even able generate profit year difficult economic financial situation often accompanied fresenius helios leading hospital operator germany significant investment need due large part share acute care market ho investment backlog accumulated pitals fresenius helios compete mainly individual past federal state failed meet statutory obligation hospital local regional hospital association among finance necessary investment major maintenance private hospital chain main competitor asklepios measure sufficiently due budget constraint rhönklinikum sana kliniken time investment need driven technological advance socalled change value figure relevant higher quality requirement necessary modernization increase reimbursement hospital treatment rheinischwestfälisches institut für wirtschaftsforschung used compensate rising cost hospital market rwi estimate annual investment requirement particularly regard personnel material cost german hospital including university hospital least change value figure redetermined year fol billion twice funding investment cur lowing year year rently provided federal state postacute care market germany comprised management report number hospital clinic total bed twothirds number bed figure ger private preventive postacute care clinic man hospital market please see table independent nonprofit clinic public clinic number treated patient nationwide remained nearly unchanged million average length stay day day key figure inpatient care germany change hospital bed bed per population length stay day number admission million average cost per admission total cost gross source german federal statistical office recent data available german hospital market total cost gross german hospital less academic research teaching source german federal statistical office german hospital institute dki krankenhaus barometer oecd health data rheinischwestfälisches institut für wirtschaftsforschung rwi krankenhaus rating report management report closing acquisition spain largest private process outsourcing medicaltechnical support hospital group quirónsalud january private service external specialist enables hospital con spanish hospital market become relevant market centrate core competency treating patient billion particular increasing emerging market focus building developing number privately insured patient opening growth infrastructure improving level health care opportunity private operator spain private health fresenius vamed one world leading company insurance required order make use service market company competitor cover private hospital among factor comparatively short comprehensive portfolio service across entire life waiting time scheduled treatment make private ho cycle worldwide competitor offer part fresenius pitals attractive private supplemental insurance spain vameds service portfolio depending service com relatively inexpensive pany competes international company consortium opportunity private hospital operator expand well smaller local provider network building additional new hospital open potential since market highly fragmented overall business development also considerable consolidation potential quirónsalud clear market leader market management board assessment share private hospital market term effect general economic development sale quirónsalud competes large number stand health care sector alone private hospital well smaller regional hospi fresenius tal chain asisa hm hospitales hospiten ribera overall development world economy salud sanitas vithas negligible impact industry whole health care sector mature growth market market project service developed positively continued increasing demand hospital health care facility health service positive effect business market project service hospital development health care facility fragmented therefore management report market size cannot determined market country management board assessment specific depends large extent factor b usiness result significant factor public health care policy government regulation level affecting operating performance privatization well demographic economic management board opinion fresenius political condition market established health care group performance excellent sale system mounting cost pressure challenge ho earnings growth across business segment pitals health care facility increase effi fresenius medical care sale increased ciency demand especially high sustainable plan u million increase mainly due good ning energyefficient construction optimized hospital development health care service net income attributable shareholder fresenius medical care excluding onetime item increased fresenius kabi achieved organic market data based company research related addressable market quirónsalud market definition neither include public private partnership ppp occupational risk prevention center orp market definition may differ definition context eg regulatory definition acquisition u million tax settlement cost agreement principle granuflo naturalyte case u million tax acquisition u million tax management report economic report sale growth increased ebit con expectation especially fresenius kabi united stant currency million new product launch state improved group earnings guidance twice united state led better expected development year region organic sale growth fresenius helios forecast currencyadjusted sale growth increase admission price increase hospi achieved fresenius group well line tal service contributed organic growth company targeted range net income increased increased ebit million fresenius vamed constant currency well line targeted achieved organic sale growth ebit grew range million fresenius invested million property plant equipment million line comparison actual business result budgeted level percentage sale forecast operating cash flow million assumed strong demand prod million cash flow margin ucts service would continue proved case therefore expectation expected table show guidance development achieve cash flow margin group well business segment based strong business development exceeding original achieved group target target guidance guidance announced announced announced achieved february august october group sale growth constant currency net income growth constant currency fresenius medical care management report sale growth constant currency net income growth fresenius kabi sale growth organic low singledigit ebit growth constant currency roughly flat fresenius helios sale growth organic ebit fresenius vamed sale growth organic ebit growth n et income attributable shareholder fresenius se co kgaa integration cost million tax hospital acquired rhönklinikum ag cost efficiency program fresenius kabi million tax disposal gain divestment two helios hospital million tax saving global efficiency program included acquisition net income attributable shareholder fresenius medical care ag co kgaa acquisition u million tax settlement cost agreement principle granuflo naturalyte case u million tax acquisition u million tax hence basis net income outlook u million cost efficiency program fresenius kabi million tax special item net income attributable shareholder fresenius se co kgaa special item detailed overview special item please see reconciliation table page special item reported group corporate segment management report group net debt ebitda thus level sale growth analysis approximately level originally expected group roic increased group rooa hence expected level result operation financial position asset liability result operation organic sale acquisition divestiture currency total sale sale growth growth increased group sale constant cur rency actual rate million million chart right show various million dialysis product sale increased influence fresenius group sale million due improved sale dialyzer major effect due change product acute care treatment dialysis machine product mix expected organic sale growth acquisition net con price effect occurred fresenius medical care medi tributed care reimbursement rate remained virtually unchanged fresenius kabi increased sale million personnel cost increased million sale growth mainly driven sale growth region shown table new product launch united state company achieved organic sale growth divestiture reduced sale growth business segment follows sale negative currency translation effect mainly related euro appreciation fresenius medical care increased sale latin american currency chinese yuan constant currency million fresenius helios increased sale million management report million mainly due good development million increase admission health care service sale increased price increase hospital service contributed organic million care coordination north america sale growth acquisition contributed sale increased constant currency growth sale region currency organic translation acquisition total million change sale growth effect divestiture sale north america europe asiapacific latin america africa total average exchange rate last month net debt ebitda pro forma acquisition pro forma acquisition special item management report economic report fresenius vamed increased sale million group ebitda increased million million divestiture reduced sale million corresponds increase sale project business increased mil constant currency group ebit increased lion million sale service business million million corresponds grew million million increase constant currency increase sale due new existing business order intake project business developed well ebit development business segment follows increased level billion first time million fresenius vamed increased fresenius medical care ebit increased con order backlog million december stant currency million million fresenius vamed busi million unchanged medicare reimbursement rate ness segment within fresenius group whose business north america offset cost saving procure significantly determined order intake order ment side pharmaceutical product cost saving backlog global efficiency program ebit margin fresenius medical care group increased earnings structure adjusted onetime item ebit increased group net income rose million u million million growth constant currency fresenius kabis ebit increased constant earnings per share rose rep currency million million resents increase actual rate increase mainly driven new product launch constant currency weighted average number share solid sale earnings growth united state million ebit margin increased inflation significant effect result operation fresenius helios increased ebit million million ebit margin increased increase attributable increased admission continuous cost efficiency management report improvement hospital clinic sale business segment organic currency sale translation acquisition total million change growth effect divestiture sale fresenius medical care fresenius kabi fresenius helios fresenius vamed order intake order backlog fresenius vamed million order intake order backlog december net income attributable shareholder fresenius se co kgaa special item acquisition u million tax settlement cost agreement principle granuflo naturalyte case u million tax acquisition u million tax detailed overview special item please see reconciliation table page special item reported group corporate segment management report fresenius vamed increased ebit million earnings structure special item million ebit margin increased reconciliation group net income group u gaap financial result december comprise special item whereas financial result december comprise special item order show operating performance group reporting period relevant position profit group gross loss statement adjusted special item profit margin table show special item reconciliation ebit margin net income special item earnings according u gaap sale cost operating sale expense development major item statement income group gross profit rose million exceeding group sale decreased compared previous year gross profit million constant currency gross margin increased selling general administrative expense consisted cost sale rose primarily personnel cost marketing distribution million million cost sale percentage cost depreciation amortization expense rose million million increase primarily due business expansion ratio management report reconciliation q q q integration disposal according q integration disposal according cost gain cost gain kabi acquired two u gaap kabi acquired two u gaap special efficiency rhön helios incl spe special efficiency rhön helios incl spe million item program hospital hospital cial item item program hospital hospital cial item sale ebit interest result net income tax income tax net income less noncontrolling interest net income net income attributable shareholder fresenius se co kgaa cost reported group corporate segment management report economic report percentage group sale therefore decreased financial position r expense million million targeted range financial management policy goal approximately product sale depreciation financing strategy fresenius group follow amortization million million ing main objective ratio percentage sale group personnel cost increased million ensure financial flexibility million personnel cost ratio optimize weightedaverage cost capital chart left show earnings structure ensuring financial flexibility key financing strategy group net interest decreased million fresenius group achieved broad million mainly due favorable financing term spectrum financing instrument taking market capacity interest rate saving lower net debt investor diversification flexibility credit covenant group tax rate special item current maturity profile consideration group hence prioryear level maturity profile characterized broad spread maturi noncontrolling interest increased million tie large proportion mid longterm financing million attributable also take account currency earnings noncontrolling interest fresenius medical care cash flow generated selecting financing table page show profit margin development instrument match appropriate debt struc tures respective currency statement income summary change million change constant currency sale cost good sold management report gross profit selling general administrative expense research development expense ebit net interest income tax noncontrolling interest profit net income special item net income earnings per ordinary share special item earnings per ordinary share ebitda depreciation amortization net income attributable shareholder fresenius se co kgaa detailed overview special item please see reconciliation table page special item reported group corporate segment management report financing mix fresenius group line group structure financing fresenius medical care rest fresenius group con commercial paper ducted separately joint financing facility equityneutral mutual guarantee fresenius kabi fresenius helios convertible bond fresenius vamed business segment financed prima financial rily fresenius se co kgaa order avoid liability senior note structural subordination schuldschein loan syndicated loan financing fresenius meet financing need combination dec million operating cash flow generated business segment short mid longterm debt addition bank group main debt financing instrument shown loan important financing instrument include issuance chart including financing activity related senior note schuldschein loan convertible bond acquisition quirónsalud slight shift commercial paper program receivable securitization within financing mix program sufficient financial cushion assured fresenius financing activity past fiscal year group unused syndicated bilateral credit line addi mainly related acquisition idc salud holding slu tion fresenius se co kgaa fresenius medical care quirónsalud total purchase price billion ag co kgaa maintain commercial paper program billion debtfinanced million paid fresenius medical care receivable securitization program form new fresenius se co kgaa share issued offer additional financing option authorized capital following financing activity another main objective fresenius group financing carried strategy optimize weightedaverage cost capital employing balanced mix equity debt due october senior credit agreement company diversification within health care sector increased billion incremental facility management report strong market position business segment global consist incremental revolving credit facility growing noncyclical market predictable sustain million incremental term loan million able cash flow generated allow reasonable due incremental facility disbursed proportion debt ie use comprehensive mix january financial instrument capital increase may also consid ered exceptional case ensure longterm growth example finance major acquisition ebitda margin ebit margin return sale tax noncontrolling interest special item detailed overview special item please see reconciliation table page special item reported group corporate segment management report economic report december fresenius se co kgaa placed maturity profile fresenius group billion schuldschein loan tranche five seven financing facility ten year fixed variable interest rate fund million ing schuldschein loan took place january january fresenius finance ireland plc issued senior note aggregate volume billion split four tranche maturity five year million coupon issue price seven year million coupon issue price year million coupon issue price year million cou pon issue price senior note drawn newly established fresenius european medium term note emtn program also january fresenius se co kgaa issued december major financing instrument pro forma quirónsalud acquisition billion senior note billion senior credit million equityneutral convertible bond due agreement incremental facility billion schuldschein loan million equityneutral convertible bond bond bear interest issued price initial conversion price represents premium fresenius reference share price concurrently december fresenius medical care extended placement bond fresenius purchased maturity receivable securitization program call option share fully hedge risk high repay u million december ment obligation instrument result issuance new share upon conversion bond chart show maturity profile due successful closing longterm financing fresenius group management report acquisition quirónsalud december fresenius se co kgaa fresenius medical care january bridge facility fresenius se co kgaa ag co kgaa maintain commercial paper program place since september billion shortterm debt voluntarily terminated arranged small issued december million fresenius group bank amount billion se co kgaas commercial paper program utilized fresenius medical care ag co kgaas commercial addition measure related acquisition quirón paper program million outstanding salud following financing activity general corporate fresenius group drawn billion bilat purpose took place eral syndicated credit line addition decem ber group approximately billion march fresenius u finance ii inc issued unused credit line available including committed credit schuldschein loan aggregate volume line billion credit facility generally u million tranche five seven year used covering working capital need excep fixed floating interest rate tion syndicated credit agreement fresenius se co kgaa fresenius medical care usually unsecured management report december fresenius se co kgaa cash flow million fresenius medical care ag co kgaa including sub sidiaries complied covenant debt arrange ments detailed information fresenius group financing found page note information financing requirement included outlook section page effect offbalancesheet financing instrument financial position liability fresenius involved offbalancesheet transaction could significant impact financial position expense income result operation liquidity investment asset liability capitalization cash flow change operating capex net cash flow acquisition cash flow working cash flow acqs dividend acqs liquidity analysis capital dividend dividend key source liquidity operating cash flow cash inflow financing activity including short mid longterm debt cash flow operation influ funding mostly provided syndicated credit facility enced profitability business fresenius fresenius se co kgaa fresenius medical care net working capital especially account receivable cash well senior note schuldschein loan convertible inflow financing activity generated shortterm bond fresenius convinced existing credit facili borrowing commercial paper program tie inflow senior note issuance well oper drawing bilateral bank credit agreement additionally ating cash flow additional source shortterm fund receivables fresenius medical care account receiv ing sufficient meet company foreseeable liquidity management report able securitization program sold mid longterm need financial position fiveyear overview million operating cash flow sale working capital sale investment property plant equipment net cash flow acquisition dividend sale trade account receivable inventory less trade account payable payment received account management report economic report dividend investment operating cash flow depreciation general partner supervisory board propose amortization million fiveyear overview dividend increase annual general meeting dividend per share proposed increase total dividend distribution increase million million cash flow analysis cash flow increased million million change working capital million million mainly due business expansion oper ating cash flow increased million million despite u million discretionary cash contribution fresenius medical care pension plan asset united state cash flow margin operating cash flow sufficient investment acquisition operating cash flow meet financing need investment activity excluding depreciation amortization acquisition whereby cash used capital expenditure million proceeds sale property plant equipment million million fresenius medical care shareholder dividend million respectively paid third party million primarily relating cash flow acquisition dividend fresenius medical care payment offset million million sufficient finance dividend million fresenius se co kgaa group dividend million group dividend con received shareholder fresenius medical care net sisted dividend payment million sharehold acquisition expenditure million financed er fresenius se co kgaa payment million cash flow management report cash flow statement summary million change margin earnings tax depreciation amortization change pension provision cash flow change working capital operating cash flow property plant equipment proceeds sale property plant equipment cash flow acquisition dividend cash used acquisition proceeds disposal dividend cash flow acquisition dividend cash provided used financing activity without dividend paid effect exchange rate change cash cash equivalent change cash cash equivalent detailed cash flow statement shown consolidated financial statement management report cash used financing activity without dividend pay investment region ments million million predominantly characterized reduction debt region due strong free cash flow refinancing measure asiapacific cash cash equivalent increased million million december december north america europe million cash cash equivalent posi tively influenced currency translation effect mil lion million million investment acquisition fresenius group provided million million investment acquisition investment fresenius helios acquisition spending mainly property plant equipment increased mil purchase share klinikum niederberg lion million sale ggmbh germany well acquisition outpatient well depreciation level million facility serf basis enabling expansion preserving company value long term total million main investment property plant equipment invested acquisition million total follows capital expenditure invested property plant equipment spent acquisition optimization expansion production facility pri table show distribution investment marily north america europe fresenius medical acquisition business segment chart right show care fresenius kabi primarily europe north regional breakdown america asia cash outflow acquisition primarily related modernization existing equipping new dialysis following business segment clinic fresenius medical care management report fresenius medical care invested mainly acquisition new building modernization hospital fresenius dialysis clinic expansion care coordi helios accounting million significant nation business individual project hospital schleswig duis fresenius kabi invested primarily acquisition burg pforzheim wiesbaden u production facility portfolio seven iv drug investmentsacquisitions business segment thereof property plant thereof million equipment acquisition change total fresenius medical care fresenius kabi fresenius helios fresenius vamed corporate total management report economic report investment acquisition asset liability million change investment property asset liability structure plant equipment total asset group rose million thereof maintenance dec million constant currency thereof expansion increase increase mainly driven busi investment property plant equipment ness expansion currency translation effect latter sale resulted increase balance sheet total acquisition billion inflation significant impact asset total investment acquisition fresenius current asset increased million dec million within current asset trade account investment property plant equipment million receivable increased million dec made continue major ongoing invest million day average day sale outstanding ment project reporting date investment previous year level day obligation mainly hospital fresenius helios well inventory rose million dec investment expand optimize production facility million scope inventory day fresenius medical care fresenius kabi project dec day ratio inventory total asset financed operating cash flow increased dec noncurrent asset increased million acquisition idc salud holding slu dec million constant currency quirónsalud increase addition property plant equipment september fresenius helios announced sign goodwill effect goodwill amount ing purchase agreement acquire share million dec million proven capital idc salud holding slu quirónsalud spain sustainable increased mainly due acquisition total purchase price billion made fiscal year due currency translation effect management report seller private equity group cvc capital part fiscal year addition goodwill acqui ners víctor madera founder ceo quirónsalud sitions million please see page ff note member quirónsaluds management board quirón information salud spain largest private hospital operator cover shareholder equity including noncontrolling inter full spectrum inpatient outpatient care est rose million dec approval relevant antitrust authority received million constant currency shareholder equity including december transaction closed noncontrolling interest rose group net income january quirónsalud consolidated feb ruary management report attributable fresenius se co kgaa increased sharehold million liability due one year er equity million equity ratio including million dec million noncontrolling interest december group net debt decreased constant cur dec rency million dec million liability equity side balance sheet show net debt equity ratio including noncontrolling inter solid financing structure total shareholder equity includ est gearing dec ing noncontrolling interest cover noncurrent asset return equity tax equity attributable dec shareholder equity noncontrolling shareholder fresenius se co kgaa decreased interest longterm liability cover noncurrent asset dec return total asset inventory tax noncontrolling interest increased longterm liability decreased million december dec million group roic increased shortterm liability increased million group rooa within posi dec million tion invested capital goodwill billion sig group major accrual major signifi nificant effect calculation roic important cance individual item take account approximately goodwill group debt remained nearly unchanged mil attributable strategically significant acquisition lion dec million constant currency national medical care renal care group helios decrease relative weight balance sheet kliniken app pharmaceutical liberty dia dec approximately lysis holding hospital rhönklinikum ag group debt denominated u dollar liability due significantly strengthened competitive less one year million dec position fresenius group asset liability fiveyear overview million management report total asset shareholder equity total asset shareholder equity noncurrent asset debt total asset gearing including noncontrolling interest pro forma excluding advance made amount billion fiduciary agreement acquisition hospital rhönklinikum ag adjusted due debt issuance cost restatement u gaap standard asu special item pro forma acquisition detailed overview special item please see reconciliation table page special item reported group corporate segment management report economic report summary show roic rooa business segment corporate rating credit quality fresenius assessed regularly roic rooa reviewed leading rating agency moody standard poor fitch july rating agency fitch fresenius medical care upgraded corporate credit rating fresenius bb fresenius kabi bbb stable outlook standard poor moody fresenius helios fresenius vamed raised fresenius rating investmentgrade status group pro forma acquisition table show company rating respective special item roic invested capital insignificant due prepayment cash cash equivalent outlook december rating fresenius se co kgaa fresenius group return invested capital dec dec roic substantially exceeded cost capital wacc standard poor weighted average cost capital fresenius medical corporate credit rating bbb bbb care wacc business segment outlook stable stable moody corporate credit rating baa baa outlook stable stable currency interest risk management fitch nominal value foreign currency hedging contract corporate credit rating bb b bb million december con outlook stable stable tract market value million nominal value interest rate hedging contract million contract market value million please see risk report page f note page detail management report fiveyear overview financing key figure dec dec dec dec dec debt ebitda net debt ebitda net debt ebitda ebitda net interest efore special item b pro forma acquisition pro forma excluding advance made amount billion fiduciary agreement acquisition hospital rhönklinikum ag special item ltm average exchange rate net debt ebitda net debt yearend exchange rate ebitda ltm average exchange rate pro forma quirónsalud acquisition net debt ebitda pro forma quirónsalud acquisition net debt ebitda management report overall assessment care technical advance driven also still business situation insufficient access health care developing emerging country aboveaverage growth time group management report prepared opportunity u market asia management board continued assess development latin america also africa efficient health care sys fresenius group positive demand prod tems appropriate reimbursement structure ucts service continues grow steadily around world evolve time country economic condi tions improve strengthen activity outlook region introduce product portfolio market successively management report contains forwardlooking statement expansion regional presence fastgrow including statement future sale expense invest ing market asiapacific latin america africa ments well potential change health care sector especially offer potential strengthen market competitive environment financial situation position china instance offer excellent growth statement made basis expectation opportunity longterm infusion assessment management board regarding event nutrition therapy iv drug medical device could affect company future basis fresenius kabi also fresenius medical care midterm planning forwardlooking statement dialysis plan roll additional product subject matter course risk uncertainty assump therapy existing portfolio country tions factor actual result including yet offer comprehensive range acquisition financial position profitability fresenius could largest private hospital operator spain quirón therefore differ materially positively negatively salud give fresenius helios presence outside germany expressly implicitly assumed described growth opportunity spain arise exploiting syn statement information please see opportu ergies expansion construction hospital nities risk report page ff consolidation potential highly fragmented spanish private hospital market particular management report general midterm outlook broadening service business fresenius outlook fresenius group coming year con medical care opportunity extend new market tinues positive able treat patient supply expand market share arise country open customer reliably continuously striving optimize cost private dialysis provider allows cooperation adjust capacity improve product mix public private provider publicprivate part well expand product service business nerships whether private company offer dial expect effort increase earnings coming ysis treatment form depends health year addition good growth opportunity fresenius care system country operate presented following factor legal framework addition dialysis product treatment dialysis patient fresenius medical care sustained growth market oper see significant growth potential future medical ate fresenius still see good opportunity benefit service related dialysis expanding coordi growing health care need arising aging nation care include eg vascular care service population growing demand comprehensive laboratory service hospitalist intensivist service fresenius helios extensive nationwide hospital management report overall assessment business situation outlook network based platform fresenius helios aim also exploiting opportunity potential within develop offer innovative integrated care offering operation costmanagement efficiency patient care improved enhancement measure include plan costefficient exchange knowledge experience best practice production furtheroptimized procurement process fresenius helios quirónsalud cross outlook take account event known time selling quirónsaluds facility occupational risk pre annual financial statement prepared could vention within spanish hospital network offer addi influence operating performance beyond sig tional growth opportunity nificant risk discussed risk report past broadening product business fresenius utmost achieve possible exceed medical care see renal pharmaceutical growth target driver complement dialysis portfolio add horizontal expansion portfolio offer future market growth potential line strategic goal expect consolidation process continue among com growing trend offering integrated care petitors market europe asiapacific latin fresenius kabi plan expand iv drug product america consequently expect opportu business develop generic drug formulation nities u penetrate new market expanding ready launch time market formation directly regional presence extending product portfolio patent branded product expire also new market open fresenius medical care suc develop new formulation nonpatented drug cessively roll product service portfolio especially develop readytouse product espe emerging country addition fresenius medical care cially convenient safe including example prefilled continues expand care coordination business ser syrinx readytouse solution freeflex infu vice related dialysis care coordination fresenius sion bag medical care address need dialysis patient even development innovative product therapy comprehensively create potential expand fresenius kabi plan introduce product already market position region addition innovation offered outside united state country well management report bestinclass quality reliability convenience also aim roll product portfolio interna product therapy key factor dial tionally especially fastgrowing market asiapacific ysis business expect home therapy gain latin america market share expanded importance leading growth potential fresenius launch new product field iv drug medical care home dialysis corresponding tech medical device infusion therapy clinical nutri nologies product continue major focus tion well transfusion technology r activity addition fresenius kabi devel broad hospital network across germany oping new dosage form product fresenius helios able develop new patient care model selective acquisition besides retaining organic sale addition acquisition opportunity expected growth basis business continue arise german hospital market increasing num utilize opportunity grow making small mid ber privately insured patient spain opening sig sized acquisition expand product portfolio nificant opportunity private operator like quirónsalud strengthen regional presence fresenius vamed expecting grow life cycle ppp project area regard project service business moreover company intends fur ther expand position followup order well enter new target market management report health care sector market driven development infrastructure establish health care sector considered widely indepen ment health care system growing number dent economic cycle demand especially life chronically ill patient overproportional growth expected saving lifesustaining product service expected asia latin america eastern europe middle east increase given medically needed africa fact large part world population population aging moreover medical advance large life region underscore strong growth poten number disease still difficult cure tial entire spectrum dialysis service product incurable expected remain growth driver overall factor aging population grow emerging country availability basic health ing number people suffering diabetes hyperten care growing demand highquality medical treat sion ailment often preceding terminal kidney fail ment increasing percapita income increase individu ure contributing toward continued growth dialysis al increasingly cope illness associated market age expectancy dialysis patient also rising lifestyle disease thanks ongoing advance treatment quality ri hand expert estimate ﬁnancial ing standard living especially emerging country constraint public sector could result pricing market care coordination open additional pressure slowdown revenue company growth opportunity fresenius medical care health care industry country experiencing signiﬁ information provided page ff cant ﬁnancing problem health care sector due management report strained public finance situation especially industrial ized country increased pressure encourage saving market generic iv drug clinical expected health care cost constitute large portion nutrition infusion therapy medical budget device transfusion technology increasingly important company increase expect global market generic iv drug clinical patient benefit improve treatment quality offer nutrition infusion therapy medical device transfusion preventive therapy addition especially product technology grow approximately therapy medically also economically market generic iv drug europe united management report advantageous increasing importance state expected grow demand generic drug likely grow signifi dialysis market cantly lower price comparison originator drug price global dialysis market expected grow growth dynamic continue driven originator constant exchange rate drug going offpatent well original offpatent pro number dialysis patient worldwide expected duct offered steady price due unique selling rise approximately although signiﬁcant proposition factor working opposite direction regional difference remain united state japan price erosion original offpatent drug generic drug country central western europe already market prevalence already relatively high forecast patient growth expected clinical nutrition growth region economically weaker market europe however given ﬁnancial con region growth rate even higher straints country effort contain cost arket data refers fresenius kabis addressable market subject annual volatility due currency fluctuation patent expiry original drug iv drug market among thing source company research management report outlook health care sector pursued undiminished contin effect since helios group well prepared quality ued high growth potential projected asiapaciﬁc latin based remuneration thanks clear focus quality america africa expect growth transparency medical outcome individual country despite higher revenue expectation hospital expect market infusion therapy europe rather pessimistic respect economic situa remain prior year level besides slightly tion according krankenhausbarometer decreasing blood volume substitute market due restriction survey german hospital institute dki quarter imposed use product continuous price hospital expect economic situation pressure tenderdriven standardsolutions business improve whereas expect worsen moreover invest expected affect growth outside europe also expect ment need growing government support declin market infusion therapy remain prior year ing rheinischwestfälisches institut für wirtschafts level whereby latin america expected grow forschung rwi forecast hospital respond economic pressure joining together network worldwide market medical device transfusion bundling service network offer opportunity indi technology expected grow vidual hospital reduce cost example purchasing anticipate privatization consolidation hospital market continue german hospital market expect acute care hospital market germany expect private hospital market spain grow grow slightly admission forecast increase continuing increase number approximately privately insured patient also open opportuni socalled change value figure relevant tie private operator future important market data increase reimbursement hospital treatment example nationwide health care spending bed den set addition hospital funding sity indicates spanish health care system lagging system provides various increase reduction behind eu country also provides oppor acute hospital tunities establishment new hospital addition hospital accept discount fragmented private hospital market expected see management report surplus service agreed advance health insurance consolidation company starting discount replaced socalled fixed cost degression discount surplus service market project service exact amount discount negotiated hospital health care hospital health insurance company facility reduction continues apply surplus service expect worldwide demand project agreed upon service hospital health care facility grow care supplement replace extra charge low singledigit rate invoiced hospital treatment beginning central european market established health intended support care hospital granted based care system expect solid growth demand proj cost care individual hospital funding vol ect service hospital health care facility ume around million expect overall continue grow due demographic change effect increase discount helios earnings rising investment modernization need public health neutral facility focus service ranging mainte beginning medical outcome factor nance repair medical hospital equipment facility amount funding purpose federal joint com mittee define quality indicator end specific financial impact helios cannot cur rently quantified however expect adverse rwi krankenhaus rating report source company research rheinischwestfälisches institut für wirtschaftsforschung rwi management report management technical operation total oper group financial target ational management infrastructure process optimization target fiscal year especially within framework publicprivate partnership sale growth ppp model additional growth opportunity presented constant currency increasing number nonmedical service net income growth constant currency outsourced public facility private service provider capital expenditure sale emerging market anticipate overall dynamic profitdriven proposal development growth market africa latin america dividend dividend policy per share southeast asia initially driven demand data according ifrs net income attributable shareholder fresenius se co kgaa efﬁcient needsoriented medical care china middle east growth driven development infrastruc ture creation new care service well research sale earnings business segment training facility expect sale earnings development business segment shown group sale earnings fresenius group business segment financial target business segment report solely accordance ifrs starting fiscal target fiscal year year hence following outlook show figure fresenius medical care well target according ifrs detail sale growth please also see page constant currency net income growth constant currency group midterm target fresenius kabi sale growth organic target ebit growth sale bn constant currency net income bn fresenius helios management report sale growth organic data according ifrs current ifrs rule comparable exchange rate including small midsize acquisition sale bn net income attributable shareholder fresenius se co kgaa ebit fresenius vamed sale growth organic end fiscal year group sale expected ebit growth reach billion group net income expected data according ifrs increase billion effect agreement u department veteran affair justice excluded expect increase group sale net income attributable shareholder fresenius medical care ag co kgaa helios kliniken germany excluding quirónsalud constant currency project group net income quirónsalud month consolidated increase constant currency thereof quirónsalud billion thereof quirónsalud million net income attributable shareholder fresenius se co kgaa management report outlook fiscal year fresenius medical care expects sale fresenius kabi primarily invest expanding main grow constant currency net income taining production facility well introducing new attributable shareholder fresenius medical care manufacturing technology fresenius helios pri ag co kgaa expected increase con marily investing new building modernizing stant currency effect agreement u equipping existing hospital newly acquired department veteran affair justice excluded hospital fresenius kabi expects organic sale growth regional focus group investment spending ebit growth constant currency europe north america account fresenius helios expects organic sale growth respectively remainder sale bn thereof quirónsalud bn invested asia latin america africa total ebit expected increase million fund invested germany thereof quirónsalud million assume return operating asset rooa fresenius vamed expects achieve organic return invested capital roic level sale growth ebit growth due acquisition quirónsalud financing procurement expect continued strong cash flow cash continue optimizing procurement management flow margin price term especially quality key factor addition unused credit line syndicated securing earnings growth bilateral credit facility bank provide u suffi based development financial real cient financial cushion market assume price fluctuation continue refinancing activity limited due well despite tension easing commodity market balanced maturity profile short medium term end expect group net debt ebitda within bottom half fresenius selfimposed target research development range r activity continue play key role secur management report concluded debt financing acquisition idc ing group longterm growth innovation salud holding slu quirónsalud spain largest private new therapy hospital operator january plan increase group r spending approximately product sale reinvested investment research development expect invest sale property marketoriented research development strict plant equipment capital expenditure timetomarket management process crucial suc planned invested fresenius medical care cess new product continually review r result fresenius kabi fresenius helios remai using clearly defined milestone innovative idea product ning fund intended investment expan development therapy high level quality sion group headquarters fresenius medical care continue provide basis future marketleading posi investment primarily used expansion pro tions given continued costcontainment effort duction capacity optimizing production cost estab health care sector costefficiency combined strong qual lishment new dialysis clinic ity focus acquiring evergreater importance product development improvement treatment concept therapy helios kliniken germany excluding quirónsalud quirónsalud consolidated month calculated expected annual average exchange rate net debt ebitda without large unannounced acquisition management report fresenius medical care continue expand planned change human resource global r product platform home dialysis well asso social area ciated technology product focal point number employee group continue rise activity continue expand range innovative future result expected expansion antic product technology future react growth ipate number employee increase approxi opportunity also aim best meeting demand mately december number integrated care employee expected increase business seg infusion nutrition therapy generic iv drug ments approximately located europe approx primary focus area development fresenius kabi imately north america approximately particular concentrating position offer asiapacific latin america africa corresponding generic drug formulation promptly upon expiration patent originator drug also work dividend ing expand portfolio include additional readytouse dividend increase provided fresenius last product example prefilled syrinx readytouse year show impressive continuity dividend policy solution freeflex infusion bag aim align dividend earnings per share growth fresenius kabi portfolio medical device make special item thus broadly maintains payout contribution safe effective application infusion ratio based positive earnings fore solution clinical nutrition continue develop cast expect offer shareholder earningslinked new product improve existing one segment dividend transfusion technology focusing development work device disposable enable safe efficient userfriendly production blood product treat ment specific disease including autoimmune disease management report figure includes quirónsalud employee take account approximately contract employee independent doctor management report opportunity risk report opportunity risk report risk management fresenius group exposed number risk due supervisory board complexity dynamic business risk inevitable consequence entrepreneurial activity audit committee opportunity exploited supervisory board ingness take risk provider product service severely management board chronically ill relatively independent economic cycle diversification four business segment operate different segment health care mar group controlling ket global footprint minimize group risk profile experience well strong market posi risk management information system tion serve solid basis reliable assessment risk status report time continue take advantage wideranging opportunity sustainable growth adhoc reporting relevant change risk profile expansion health care market offer fresenius new risk group risk management risk controlling control system opportunity management business segment group segment managing opportunity ongoing integral part cor porate activity aimed securing company longterm success way explore new prospect con solidate improve already achieved responsibility risk management process organization management fresenius group monitoring risk business segment decentralized regional structure enables u recog assigned follows management report nize analyze trend requirement opportunity often fragmented market focus action accord using standardized process risk situation evalu ingly maintain regular contact dialogue research ated regularly compared specified requirement group scientific institution keep close watch negative development emerge response initi market competitor order identify opportunity ated early stage within group opportunity synergy exploited manager responsible required report continuous communication involving exchange relevant change risk profile management information knowhow business segment board without delay anticipated future opportunity fresenius group market kept constant observation close discussed outlook starting page contact maintained customer supplier institution policy allow u swiftly identify risk management react change business environment fresenius risk management system risk management system supported group risk management continuous process identifying con level business segment risk controlling trolling managing risk key tool solid corporate measure management information system governance fresenius risk management system closely linked corporate strategy opportunity recognized risk management system management report detailed monthly quarterly report used identify assumption estimate relevance analyze deviation actual versus planned business externally reported group segment result discussed development addition risk management system includes intensively department responsible preparing control system consists organizational safeguarding group consolidated financial statement matter measure well internal control audit also reviewed discussed quarterly supervisory identify significant risk early stage coun board audit committee teract one individually control mechanism automated manual functionality effectiveness risk management reconciliation procedure precaution put place system reviewed regularly management board assure financial reporting reliable trans internal auditing department conclusion arising action correctly accounted consolidated entity audit taken account ongoing refinement report according groupwide standard deter system allow prompt reaction change environ mined head office regularly adjusted allow ment system thus far proved effective control change made accounting regulation con system also regularly reviewed management board solidation proposal supported system internal auditing department moreover external context reference made comprehensive consolidation auditor review whether control system set internal group balance prevent abuse take care management board suitable early identification maintain strict separation function management con risk would put continued existence company trol evaluation also help ensure risk danger insight gained audit regarding direct impact financial reporting identified con internal financial reporting control taken account trols place minimize moreover change continued development system accounting principle monitored employee involved fresenius ensured scope focus financial reporting instructed regularly compre organizational structure system identifying assessing hensively external expert specialist engaged controlling risk developing countermeasure necessary treasury tax controlling legal depart avoidance risk aligned suitably ments involved supporting preparation finan companyspecific requirement properly cial statement finally information provided verified management report functional however absolute certainty department responsible preparing enable risk fully identified controlled consolidated financial statement fresenius medical care subject control sec internal financial reporting control tion sarbanesoxley act numerous measure internal control assure correct ness reliability accounting process financial risk area reporting thus preparation annual financial statement consolidated financial statement management report general economic risk risk compliance applicable principle fourtier report general operating framework ing process especially promotes intensive discussion present development global economy present ensures control financial result reporting significant risk fresenius group level ie largely expect overall economic growth continue fresenius affected small extent general local entity economic fluctuation expect demand lifesaving region lifesustaining product service continue business segment grow furthermore fresenius striving firm balance group business main region established emerging market financial data key figure reported discussed compared regular monthly basis prioryear figure budget latest forecast addition parameter management report opportunity risk report risk situation business segment also depends payment amount subject annual adjustment based development market countryspecific political increase cost market basket certain health legal financial condition therefore monitored care item service less productivity adjustment evaluated carefully particularly current macroeconomic esrd ppss quality improvement program qip environment applies example country affect medicare payment based performance budget problem result sovereign debt crisis facility set quality measure dialysis facility particular regard account receivable also fail achieve established quality standard could pay applies possible impact business activity ments particular year reduced based resulting decision united kingdom leave year performance underlying quality measure reviewed european union extended amended annually cm material applies particular initiative new u failure fresenius medical care achieve minimum administration possibly increase import duty potential client quality standard qip could materially change current health care program possible adversely affect business financial condition result reduction corporate tax operation fresenius medical care mitigated impact esrd risk health care sector pps legislative initiative referenced risk related change health care market two broad measure first work medical director major importance fresenius group main risk treating physician make clinical protocol change financing health care system corresponding used treating patient consistent qip good reimbursement system well development new clinical practice negotiates pharmaceutical acquisition product therapy cost saving addition fresenius medical care achieved greater efficiency better patient outcome introduc financing health care ing new initiative improve patient care upon initiation reimbursement system dialysis increasing percentage patient using home largely regulated business environment change therapy achieving additional cost reduction law also respect reimbursement major clinic management report impact business sucess applies especially working health care provider group also known united state large portion sale gener esrd seamless care organization escos cm plan ated change government reimbursement test new comprehensive esrd care model payment system particular example reimbursement care delivery seek deliver better health outcome dialysis treatment could considerable impact esrd patient lowering cm cost cm allows dialy business approximately fresenius medical si clinic physician form called ecso care sale united state attributable u fed comprehensive esrd care model escos achieve eral health care benefit program medicare program minimum quality threshold generate reduc medicaid cm reduction reimbursement rate reim tions cmss cost care certain threshold bursed service could result significantly lower sale esrd patient covered esco receive share operational result cost saving escos include dialysis chain effective medicare implemented endstage renal facility required share risk cost disease esrd prospective payment system esrd pps increase reimburse cm share increase expanded scope product service covered model commenced october includes six bundled rate resulted lower reimbursement per organization initial agreement period model treatment previous system esrd pps last three year management report addition fresenius medical care currently take part monitor legislative change intensively also various valueoriented program bundled payment work together governmental health care institution care improvement program bpci medicare result acquisition spanish private ho advantage chronic special need plan macsnp well pital chain quirónsalud fresenius helios operation claim payment negotiation insurer side germany first time quirónsalud operates hospi bpci fresenius medical care ability receive addi tals ppp contract publicprivate partnership tional payment fresenius medical care able deliver part public health system spain com quality care cost lower certain established pany thus given responsibility certain area benchmark also risk incurring financial pen health care citizen spain statutory health alties fresenius medical care successful insurance quirónsalud receives compensation service fresenius medical care fail perform required form per caput lump sum remuneration bpci initiative agreement cm cm specific service rendered quirónsalud lose may among remedy terminate right participate concession operate hospital ppp contract renego bpci program whole part tiations public private insurance company resulted new u administration expected revise even worse condition hospital able repeal affordable care act time stance compensate lower reimbursement rate cutting cm towards kind program could well differ cost could material adverse effect net previous administration develop asset financial position result operation ments could impact program unpredictable way reduction health care spending could also negatively future affect pricing fresenius kabi product furthermore portion dialysis care business change law reimbursement method could united state currently reimbursed private insurer affect scope payment service well managed care organization organization enforce insurance coverage product business could reduction reimbursement would significantly significant adverse impact asset liability reduce revenue earnings product ser financial position result operation generally vice fresenius medical care fresenius medical aim counter possible regulatory risk management report care privately insured dialysis patient rely charitable enhanced performance cost reduction support cover insurance premium could shortly forced switch state health insurance recent development new product therapy effort u restrict away option introduction new product service charitable financing successful resulting development new technology competitor could render lower reimbursement rate could substantial negative one product service less competitive impact fresenius medical care operating result even obsolete thus significant negative impact applies hospital market germany future sale price product range ser drg system diagnosis related group intended vice includes introduction generic patented increase efficiency hospital reducing health drug competitor may impact sale care spending company constantly monitor legislative operational result development patient largely assigned hospital cooperation medical doctor scientist allows public health pension insurer therefore important u identify support relevant technological innovation fresenius helios contract hospital keep abreast development alternative treatment insurer health care institution maintained method enable u evaluate adjust cor porate strategy necessary management report opportunity risk report operating risk audited fda public authority deficiency business operation around world exposed detected complaint filed company required number risk extensive regulation remedy example following inspection include among others prior year u production facility grand island facility kalyani india quality safety efficacy medical pharma noncompliance requirement ceutical product supply therapy authority production facility supplier operation hospital manufacturing facility could lead regulatory action warning product laboratory recall production interruption monetary sanction planning construction equipping management delay new product approval regulatory health care facility action could adversely affect ability generate sale rate accurate reporting billing govern result significant expense ment thirdparty reimbursement potential risk arising startup labeling designation pharmaceutical product new production site introduction new tech marketing nologies countered careful planning regular compensation medical director financial analysis continual progress review production capaci arrangement physician referral source tie manufacturing plant could adversely affected event technical failure natural disa fresenius fails comply law regulation may ters regulatory ruling supply disruption eg raw give rise number legal consequence including mone material tary administrative penalty increased compliance cost performing medical treatment patient ho exclusion governmental program complete pitals rehabilitation clinic dialysis clinic subject partial curtailment authorization conduct business inherent risk example disruption process involve could material adverse effect risk patient clinic addition opera business financial condition result operation tional risk example regarding hygiene sterile condi tions counteract risk strict operating proce management report significant risk operation fresenius group dures continual personnel training patientoriented described following section working procedure furthermore constantly striving improve standard patient treatment production product service quality management system compliance product manufacturing regulation performance risk associated fresenius vameds ensured quality management system project business countered professional project structured accordance internationally recognized management control proven system tailored quality standard iso taking account large number business activity identifying evaluating mini national international regulation imple mizing risk system consists organizational mented internal standard quality work proce measure standard pricingin risk prepar dure manual regular internal external audit car ing quotation risk assessment accepting order ried group production site distribution company regular project controlling continual risk assessment dialysis clinic audit test compliance regu lations area management administration production clinical service patient satisfaction production facility comply good manufacturing practice gmp market supply facility management report update avert risk default financial measure competition taken checking creditworthiness rule safe growing competition among thing induced guarding prepayment letter credit secured reentry competitor u market generic credit iv drug production halt could materially affect development new product therapy always future pricing sale product service adversely carry risk target might achieved might introduction generic patented drug competi take longer planned regulatory authority either tor may impact sale operational result grant delay product approval iv drug product also crucial new product continually brought generally health care market characterized market timely manner product development process price pressure including tender competition controlled basis detailed project roadmaps effort contain cost factor could result lower tight focus achievement specific milestone sale adversely affect business financial position defined target called question countermeasure operational result initiated united state almost fresenius kabi injectable pharmaceutical product sold customer procurement arrangement group purchasing organization gpo procurement side counter risk mainly distributor majority hospital undertake con involve possible price increase availability raw tract gpo choice purchasing need material good appropriately selecting working currently fewer five gpo control large majority together supplier longterm framework sale united state hospital customer fresenius agreement certain purchasing segment bundling kabi derives large percentage revenue united volume within group state small number gpo purchasing medicare bundled reimbursement system pay agreement important maintain ment erythropoietin stimulating agent esas gener business relationship fresenius kabi need reli ally included bundled rate interruption supply able supplier comprehensive highquality product material increase utilization acquisition cost line remain pricecompetitive comply regulation management report esas could materially affect sale profitability adversely u food drug administration fda gpo patent certain esas expired enables u also purchasing agreement manufacturer diversify procurement source reduce risk bidding process product highly competitive arising supply interruption price increase agreement fresenius gpo united counter risk poorquality purchased raw mate state terminated short medium notice main rial semifinished product component mainly requir customer area transfusion technology plasma ing supplier meet strict quality standard addi company blood center four major plasma tion certification external institute regular supplier company serving united state blood center audit includes exhaustive evaluation advance united state consolidating response bloodsaving sample regular quality control purchase high effort hospital effect pricing quality product proven safety suitability qualified supplier conform specification payment default standard rule assess creditworthiness new customer order limit risk late payment default customer also conduct followup assessment review credit line ongoing basis monitor receivables management report opportunity risk report outstanding existing customer assess risk detailed project roadmaps tight focus achieve default particularly applies country budgetary ment specific milestone defined target called problem country exposed political risk question countermeasure initiated worked status receivables taking measure factoring risk integration acquisition acquisition integration company carry risk personnel adversely affect asset liability financial company address potential shortage qualified position result operation fresenius following personnel externally utilizing personnel marketing acquisition acquired company structure must inte measure internally offering comprehensive personnel grated clarifying legal question contractual obliga development program also seek retain employ tions marketing patient service logistics must also ee introducing lifework time account various area unified integration phase key manager leave furthermore employee entitled attractive fringe company course ongoing business pro benefit part bonus using targetgroupspecific cesses relationship customer employee measure fresenius address overall shortage spe harmed addition changeofcontrol clause may cialized hospital personnel thereby recruit qualified ded claimed integration process may prove difficult icated specialized personnel thus ensuring high require time resource expected risk standard treatment quality time supporting arise operation newly acquired company training young employee seek commitment fresenius regarded insignificant unaware fresenius result measure risk personnel acquisition may also prove less beneficial initially considered significant expected future acquisition may strain finance management business moreover conse risk associated research quence acquisition fresenius may become directly development indirectly liable toward third party claim third development new product therapy always party may turn nonassertable carry risk ultimate goal might achieved counter risk acquisition detailed inte management report might take longer planned regulatory approval gration roadmaps strict integration project manage new product requires comprehensive costintensive preclin ment countermeasure initiated good time ical clinical study furthermore risk deviation expected development regulatory authority either grant delay product risk also apply acquisition spanish approval addition adverse effect product private hospital chain quirónsalud fresenius helios may discovered regulatory approval registration may aforementioned countermeasure con lead partial complete withdrawal market tinue taken due either regulatory action voluntary decision addition risk hospital operated stop marketing product fresenius group spread quirónsalud via ppp contract quirónsalud lose risk widely conducting development activity various concession operate hospital ppp contract product segment also counteract risk research renegotiations public private insurance company development project regularly analyzing assess resulted worse condition hospital ing development trend examining progress research able compensate lower reimbursement rate project also strictly comply legal regulation cutting cost could material adverse effect clinical chemicalpharmaceutical research devel net asset financial position result operation opment iv drug also crucial new product continually brought market timely manner product development process controlled basis management report information technology risk financial risk company process growing ever complex result fresenius group steady growth increasing currency interestrate risk internationalization correspondingly dependence international operation fresenius group expose information communication technology u variety currency risk addition financing system used structure procedure increasingly business expose u certain interest rate risk harmonize internationally intensifies failure use derivative financial instrument part risk manage system could temporarily lead interruption ment avoid possible negative impact risk part business thus cause serious damage loss however limit nonexchangetraded market sensitive data noncompliance data protec able instrument used exclusively hedge operation tion law regulation standard could damage com trading speculative purpose transaction petitive position reputation entire company conducted bank high rating fresenius counter risk various security mea fresenius group foreign exchange risk manage sures control audit addition counter ment based policy approved management risk constant investment hardware software board defines target organization handling well improving system knowhow potential risk risk management process particular guideline covered detailed contingency plan regularly assign responsibility risk determination execution improved tested redundant system maintained hedging transaction regular reporting risk man key system system communication agement responsibility coordinated infrastructure password system place minimize management structure residual business process organizational risk tampering unauthorized group decision use derivative financial access addition company guideline regulating instrument interest rate management taken close granting access authorization compliance consultation management board hedging trans rule monitored also conduct operational action using derivative carried corporate securityrelated audit treasury department fresenius group apart addition increased integration system exception order adhere foreign currency regula management report business process mean cyber attack could tions transaction subject stringent internal con penetrate internal external system attacker could trols policy ensures management board fully cause damage gain sensitive information existing informed significant risk current hedging activity security architecture various security measure dif fresenius group protected large extent ferent level protects system data center access currency interest rate risk december sensitive critical data outside protected data approximately fresenius group debt center network prevented use secure protocol protected increase interest rate either cryptographic measure addition annual penetration fixedrate financing arrangement interest rate hedge test carried application critical data exposed interest rate risk ratio example patient personnel data slightly affected longterm finance agreement quirónsalud acquisition sensitivity analysis show rise reference rate relevant fresenius would less impact group net income global company fresenius widely exposed translation effect due foreign exchange rate fluctuation exchange rate u dollar euro parti cular importance extensive operation united state translation risk hedged sensitivity management report opportunity risk report analysis show one cent change exchange rate tax regulation resulting tax audit could lead u dollar euro would annualized effect higher tax payment information status tax million group sale million audit found page f note ebit million group net income globally active company production facility debt liquidity main currency area service business fresenius debt million december revenue cost base largely coincide fresenius group debt could limit company ability pay divi u cashflowatrisk cfar model order estimate dends arrange refinancing compliance credit quantify transaction risk foreign currency covenant implement corporate strategy financ foreign currency cash flow reasonably expected ing risk could arise fresenius case ongoing arise within following month less hedge general financial market crisis reduce risk form basis analysis currency risk high proportion mid longterm funding december fresenius group cash flow risk balanced maturity profile financing agreement contain million hence probability poten covenant requiring u comply certain financial tial loss relation forecast foreign exchange cash ratio additional financial criterion noncompliance flow next month higher million covenant could result default acceleration detail financial risk found page debt agreement note additional information condition maturity found page ff note page ff recoverability asset management report financial risk could arise acquisition investment property plant equipment intangible asset compliance legal risk assessed careful indepth review assisted external consultant amount intangible asset compliance risk including goodwill product right trade name manage fresenius subject comprehensive government regulation ment contract represents considerable part total control nearly country especially true management report asset fresenius group goodwill intangible united state germany future true asset indefinite useful life carried group spain addition fresenius must comply general consolidated balance sheet tested impairment rule law differ country country could year significant deterioration prospect farreaching legal repercussion fresenius fail future general economic environment could result comply law regulation additional depreciation necessary asset must comply rule regulation depreciated could significant adverse impact particularly monitor safety effectiveness medical asset liability financial position result product service therefore special importance operation information found page ff u compliance program guideline note adhered compliance aim meet expectation partner orient tax business activity generally accepted standard local global corporation fresenius subject numerous tax law regulation code regulation risk arising therefrom identified evaluated ongoing basis fresenius group company subject regular tax audit change management report corporate compliance department report chief risk compliance officer management board member risk environmental risk risk involving legal affair compliance human resource management control system considered accountable establishing implementing com significant pliance guideline procedure compliance officer appointed business segment sup assessment overall risk ported additional compliance officer appointed based basis evaluating overall risk risk management organizational business structure regularly audited management potential risk corporate compliance department support com group include factor beyond control evolution pliance officer business segment regional economy constantly monitored fresenius country level compliance program guideline set risk also include factor immediately within control binding rule conduct employee believe operating risk company anticipates reacts taken adequate measure ensure national appropriately required currently recog international rule observed complied nizable risk regarding future performance appear pres ent longterm material threat group asset legal risk liability financial position result operation risk arise legal dispute continually identified created organizational structure provide analyzed communicated within company condition needed rapidly alert u possible risk situation company health care industry regularly exposed able take suitable countermeasure action breach duty due care product lia bility breach warranty obligation patent infringement risk affecting treatment error claim result high oneyear forecast period claim damage substantial cost legal defense chart beside show significant risk could lead regardless whether claim damage actually justi deviation expected business performance within fied legal dispute also result inability insure oneyear forecast period compared last year risk kind acceptable term future prod change occurred grouping potential effect management report ucts health care industry also subject risk within regulatory environment due initiative recall action could negative effect asset new u administration exposed risk relat liability financial position result operation ing import duty change existing present group health care program regarding reimbursement rate possi information regarding legal matter ongoing ble change patient structure u increase internal compliance review fresenius medical care risk regard reimbursement private health insurance found page note scheme fresenius group also involved various legal dispute resulting business operation although possible predict outcome dispute none expected significant adverse impact asset liability financial position result operation group management report opportunity risk report classifying risk qualitative assessment applied first risk affecting year forecast period followed quantitative factor scale classifi cation potential impact probability shown potential impact following two table urrencies c high potential impact description impact interest rate significant negative impact high year forecast moderate negative impact medium year forecast insignificant negative impact egulatory r low year forecast lobal economic g environment medium condition uality q constitution financial market eimbursement r rate price probability classification high medium low procurement itigations nformation low l technology probability tax effect mediumterm goal fundamentally risk area risk listed risk low medium high report could lead failing achieve mediumterm target believe following particularly important risk relating quality safety effectiveness product service risk operating risk management report see page f risk arising financing health system potential change reimbursement system risk healthcare sector see page f risk arising regulatory environment com pliance law regulation general economic risk risk general operating framework see page f corporate governance corporate governance declaration report supervisory board management board committed responsible management focused achieving sus tainable increase value company longterm corporate strategy solid financial man agement strict adherence legal ethical business standard transparency corporate communication key factor corporate governance declaration supervisory partner fresenius management se legal corporate board fresenius se co kgaa management body change group manage board general partner fresenius se co kgaa ment supervision structure reporting period fresenius management se management board report chart following page provides overview pursuant section german commercial code group structure hgb corporate management pursuant number article association fresenius se co kgaa german corporate governance code addition legal provision define respon corporate governance company corporate gover sibilities individual corporate body corporate governance nance report corporate governance declaration loaded website see wwwfreseniuscomcorporate corporate governance report published governance website see wwwfreseniuscomcorporategovernance shareholder shareholder uphold right annual general corporate governance meeting exercise voting right every ordi declaration nary share fresenius se co kgaa confers one vote none share carry multiple preferential voting right group management supervision report detail investor relation activity structure corporate body page section fresenius share page group management supervision annual general meeting structure annual general meeting agm held may company legal form kgaa kommanditgesell frankfurt main approximately share schaft auf aktien partnership limited share annual capital represented general meeting supervisory board general corporate governance corporate governance declaration agm shareholder approved proposal management board supervisory made general partner supervisory board board procedure increase dividend per ordinary responsibility distributed follows fresenius share majority vote cast se co kgaa management board general partner clear majority shareholder elected candidate responsible conducting business fresenius se new supervisory board clear majority co kgaa supervisory board fresenius se co kgaa respectively shareholder approved supervises management company business action management supervisory board general partner regard certain subject matter legally required voting right exclusion exist general partner general partner management instance sole shareholder else kröner supervisory board freseniusstiftung pertain example appoint general partner fresenius management se represented ment supervisory board fresenius se co kgaa management board manages fresenius se co kgaa approval action general partner responsibility conduct business man member supervisory board selection agement board formulates company strategy discusses auditor guarantee remaining shareholder supervisory board fresenius management se retain sole authority decide matter especially fresenius se co kgaa oversees implementa pertain supervision management tion action decision aligned best document information annual general meet interest fresenius se co kgaa management board ing well voting result available website committed increasing value company wwwfreseniuscomannualgeneralmeeting sustainable basis rule procedure management structure fresenius se co kgaa reduced voting power else krönerfreseniusstiftung free float annual general meeting annual general meeting fresenius management se fresenius se co kgaa elect elect corporate governance supervisory board supervisory board fresenius management se fresenius se co kgaa supervises supervises appoints board management fresenius management se manages fresenius se co kgaa general partner selected item voting power eg election supervisory board fresenius se co kgaa discharge general partner supervisory board f fresenius se co kgaa election auditor corporate governance board established supervisory board fresenius member management board appointed max management se define activity within board imum period five year following recommendation specifically especially regard individual duty code firsttime appointment period five year responsibility member matter reserved rule principle firsttime appointment rather full management board resolution passed threeyear period full management board meeting management european company se societas europaea board convened required least month fresenius management se supervisory board chaired chairman management board consists six member chairman dr gerd incapacitated chief financial officer krick supervisory board appoints member also incapacitated management board member management board fresenius management se super present senior age however management vise advises management board conducting board meeting usually held twice month person business necessary eg order discus decide chairing meeting decides order item matter concerning management board super agenda dealt form voting visory board meet without management board estab conducted management board pa resolution lished rule procedure following recommendation simple majority vote cast outside meeting number code simple majority member except case supervisory board member fresenius manage mandatory provision law impose stricter requirement ment se found page annual report chairman management board casting vote vote tied chairman incapacitated absent supervisory board fresenius se co kgaa motion deemed rejected vote tied rule supervisory board fresenius se co kgaa supervises procedure management board also govern rela management company business general tions management board supervisory partner supervises business operation ensure corpo board general partner well general rate decision compliant suitable financially sound partner supervisory board fresenius se co kgaa member management board general partner also matter require approval general part appointed supervisory board fresenius man ners supervisory board agement se already explained supervisory management board generally consists seven mem board fresenius se co kgaa bers chairman chief financial officer chief supervisory board fresenius se co kgaa con legal compliance officer labor relation director sists member half member elected chief executive officer four business seg agm proposal member supervisory corporate governance ments ensures full management board board primarily take account knowledge ability kept constantly informed important event plan expert experience required perform task election development measure within business segment proposal provided supervisory board take management board committee owing account company international activity potential con fresenius se co kgaas role operating holding com flicts interest number independent member pany stephan sturm appointed chairman fresenius supervisory board within meaning number management se july succeeds ulf mark code diversity supervisory board fresenius schneider decided leave company effective se co kgaa law requires quota least woman june since july stephan sturm held men mandatory quota met dual role chairman chief financial officer supervisory board election company supervisory board appoints new chief financial officer interest limit selection qualified candidate management board consists six member general way supervisory board confines gen management board listed page eral declaration intent particularly refrain annual report age limit well regular limit length membership corporate governance corporate governance declaration statutorily required declaration conformity concern strategy supervisory board supervises company ing code accordingly includes justified limitation management taking account auditor report nomination committee instituted election pro review group annual financial statement another im posals shareholder representative activity portant part supervisory board activity work aligned provision law code euro conducted within committee formed accordance pean work council elect employee representative requirement german stock corporation act supervisory board fresenius se co kgaa recommendation code supervisory board includes deems appropriate number independent member supervisory board training education business personal relationship company measure corporate body controlling shareholder party member supervisory board take related latter may give ground material necessary training education measure required merely temporary conflict interest article task keep regularly informed association fresenius se co kgaa regulate detail internal external source latest require regard supervisory board election constitution ments regard supervisory activity super term office meeting resolution right duty visory board time ensures member suitably published website see wwwfreseniuscom qualified keep professional knowledge date corporategovernance develop judgment expertise sup supervisory board fresenius se co kgaa ported appropriately company accordance established rule procedure accordance number number paragraph code various external expert code chairman supervisory board well expert company provide information responsible coordinating activity supervisory important development example strate board chairing meeting representing interest gic orientation company growth market relevant externally supervisory board convene new law precedent change u gaap calendar quarter must convene twice calendar half ifrs accounting auditing standard addition year meeting convened chaired chair company hold onboarding event new member man incapacitated chairperson named supervisory board chairman person chairing meeting decides order member supervisory board fresenius se item agenda dealt form co kgaa found page annual voting conducted unless majority report page annual report super mandatory law supervisory board pa resolu visory board report main focus activity corporate governance tions simple majority vote submitted voting committee vote tied chairman casting vote take part voting matter decided supervisory board efficiency evaluation vote deputy chairman shareholder repre supervisory board fresenius se co kgaa deliber sentative ated efficiency evaluation accordance number supervisory board fresenius se co kgaa con code meeting march duct business accordance provision law reviewed efficiency activity open article association fresenius se co kgaa discussion within full supervisory board company rule procedure management board general specific questionnaire covering salient point self partner fresenius management se continuously informs evaluation served basis discussion among supervisory board corporate development planning thing included organization structuring meeting amount information infor mation provided selfevaluation showed supervisory board assesses organization well work efficient corporate governance cooperation general partner committee rule procedure committee supervisory board fresenius se co kgaa regulated rule procedure supervisory board good corporate governance requires trusting efficient fresenius se co kgaa committee cooperation management supervisory rule procedure board management board general partner member supervisory board committee supervisory board fresenius se co kgaa closely coop listed page annual report erate benefit company open communication essential common goal sustainably increase audit committee company value line corporate governance com audit committee function among thing pliance principle management board general prepare supervisory board approval financial partner supervisory board fresenius se co kgaa statement consolidated financial statement coordinate especially regard supervisory board proposal agm appoint company strategic focus monitoring body super ment auditor financial statement make visory board fresenius se co kgaa also need fully preliminary review proposal allocation dis informed operating performance corporate plan tributable profit also review quarterly report ning well risk situation risk management com published following discussion pliance management board general partner pro management board engages auditor financial vided information full compliance duty statement concludes agreement auditor representative shareholder fee determines main focus audit defines employee may prepare supervisory board meeting sep auditor reporting duty relation supervisory arately applicable member management board fresenius se co kgaa matter within board premeetings employee representative well remit review effectiveness internal control consultation shareholder representative take place system risk management system internal audit regular basis necessary supervisory board meet system compliance without management board since constitutive meeting supervisory board may audit committee consists klaus composition procedure peter müller chairman konrad kölbl dr gerd krick hauke upervisory board committee star rainer stein klauspeter müller independent supervisory board fresenius se co kgaa form two required expertise field stated section permanent committee among member audit german stock corporation act aktg well committee consisting five member nomination specialist knowledge experience application corporate governance committee consisting three member committee accounting principle internal control process member elected duration term mem close annual general meeting may ber supervisory board fresenius se co kgaa audit committee consisted prof dr roland berger chair accordance article association fresenius se man konrad kölbl dr gerd krick gerhard roggemann co kgaa member audit committee receive addi rainer stein tional compensation section personnel audit committee also examined detail non committee kgaa supervisory board audit service rendered additionally auditor kpmg ag fresenius se co kgaa responsible appointing mem wirtschaftsprüfungsgesellschaft berlin bers management board general partner contract responsibility personnel matter lie supervisory board general partner provision supervisory board fresenius se co kgaa apply analogously committee commit tee hold meeting required meeting convened committee chairman report following supervisory board meeting work respective corporate governance corporate governance declaration nomination committee relevant disclosure corporate nomination committee proposes suitable candidate governance practice supervisory board nomination make general partner represented management board agm election supervisory board member manages company business due care dili shareholder side consists solely shareholder represen gence prudent conscientious company director tatives making proposal nomination committee compliance provision law article asso guided requirement code ciation rule procedure management board since constitutive meeting supervisory board resolution passed full management board may nomination committee consists supervisory board general partner corporate gover dr gerd krick chairman michael diekmann klaus nance practice extending beyond requirement law peter müller close annual general meeting defined fresenius code conduct code con may nomination committee consisted duct contains key principle rule conduct dr gerd krick chairman prof dr roland berger within company relation external partner michael diekmann public published fresenius code conduct website wwwfreseniuscomcompliance mediation committee code conduct binding company employee fresenius se co kgaa mediation commit must complied regarding type business tee provision german codetermination relationship executive regard ensuring compliance act require committee apply partner principle code conduct part manage ship limited share code require rial responsibility committee either compliance joint committee global health care group sustainable success matter defined detail sec business key providing highquality yet affordable tion c article association fresenius se healthcare long term compliance ensures sus co kgaa general partner requires approval tainable growth determines corporate culture joint committee consolidated sale consol integral part daytoday work understanding idated balance sheet total consolidated profit compliance basis corporate value reflected affected matter include example dive fresenius code conduct code conduct titure acquisition large investment business unit management board commits without limitation divestiture large business unit asset binding principle rule conduct within company corporate governance fresenius se co kgaa wholly owned company course business include professionalism approval joint committee also required certain honesty integrity relation patient customer legal transaction fresenius se co kgaa affil supplier employee shareholder furthermore iates else krönerfreseniusstiftung code conduct fresenius commits fair competition dr gerd krick michael diekmann member dealing honestly business partner general joint committee member dr dieter schenk public fresenius expects employee manager chairman dr karl schneider appointed comply applicable law regulation well general partner joint committee meet fresenius guideline policy breach toler ated pursued fresenius business segment implemented code conduct specific business information position held committee member stat reflecting value fresenius code conduct utorily required supervisory board comparable dome tic foreign control body business enterprise found page annual report corporate governance compliance management system cm department corporate compliance department report chief compliance officer fresenius se co kgaa member management board responsible legal p r ev e n compliance labor relation compliance steering committee central con risk assessment sultative committee fresenius se co kgaa compli ode conduct c ance topic facilitates exchange relevant gover policy procedure communication training nance function main agenda topic include continuous advice consultation status development group compliance management system important report handling compliance audit compliance initiative investigation review discussion severe case potential misconduct remediation internal control continuous structure remediation action well improvement reporting presentation compliancerelevant topic ct governance function internal audit planning po te internal audit report nd de comprises following participant fresenius se co kgaa chief compliance officer chief financial officer head legal internal audit corpo rate compliance department business segment provide compliance steering committee annual update organization compliance management system compliance steering business segment appointed chief com committee meeting held every six eight week mini pliance officer charge developing implementing mum six time per year monitoring compliance management system supervisory board fresenius se co kgaa business segment line business structure general partner fresenius management se regularly organization business segment established compli informed least per year compliance within ance responsibility respective organizational level group topic include compliance management local management responsible compliance system current future compliance initiative case corporate governance respective legal entity besides employ relevant ee working fulltime compliance function within fresenius group compliance management system corporate compliance department fresenius fresenius implemented riskbased compliance se co kgaa support compliance function busi management system business segment ness segment standardized tool process fresenius se co kgaa corporate level system con methodology develop group compliance sider market fresenius operating tailored management system global compliance initiative specific requirement business segment developed corporate compliance department compliance management system comprise three pillar fresenius se co kgaa consultation compliance prevent detect respond emphasis placed pre function business segment addition corpo venting act noncompliance occur rate compliance department fresenius se co kgaa noncompliant behavior detected adequate process responsible developing implementing monitoring place respond short notice compliance management system related corporate function fresenius se co kgaa treasury corporate governance corporate governance declaration prevent avoid potential violation beginning fresenius prevention includes thorough risk assessment adequate give top priority training employee including effective policy procedure regular training manager receive relevant compliance training training continuous advice schedule follow riskbased approach new employee compliance risk regularly assessed using standard receive relevant compliance training standardized basis ized methodology business segment fresenius part onboarding process key compliance training se co kgaa risk assessment include group code conduct mandatory compliance risk group depending business structure employee repeated regularly addition management across business segment corruption one focus specific compliance training performed highrisk com risk area fresenius group perspective antitrust pliance area process place ensure every data privacy additional focus risk area employee join relevant compliance training regular dealing health care professional organization basis well public customer worldwide every day living compliance function provide continuous advice model forward thinking health care demand high stan employee compliancerelated question business seg dard honesty integrity interaction ments established compliance responsibility fore compliance anticorruption regulation worldwide organizational level local compliance function pro basis daytoday action business segment vide employee answer case question defined anticorruption measure central element support employee decision daily work locally compliance management system regional divisional compliance function provide guid measure include diligence interacting ance advice local compliance function business business partner worldwide business segment segment corporate compliance function develop global riskbased due diligence process place deter compliance initiative business segment support mine risk related business partner based regional divisional compliance function risk profile implement appropriate mitigation measure compliance initiative corporate compliance department including contractual commitment prevent corruption fresenius se co kgaa support compliance func business partner putting patient first commits u tions business segment required highest standard fair competition data privacy daytoday business detect business segment fresenius se co kgaa compliance organization regularly performs functional compliance function established policy pro review implemented compliance initiative review cedures provide tailored guidance applying held workshop strengthen implemen corporate governance respective code conduct rule practice purpose tation policy rollout procedure advise help employee making right decision employee live value integrity hon daytoday work example transparency guideline esty daytoday business prevent conflict interest doctor helios group compliance cockpit fresenius kabi tool policy compliant transparent interaction place display compliance risk profile legal health care professional fresenius kabi entity tool u objective internal external regular classroom online training respective indicator fresenius kabi review compliance cockpit code conduct company policy general spe entity annually determines required monitoring cific topic anticorruption antitrust help measure entity higher risk profile employee comply applicable rule aim make addition internal audit department fresenius participant aware importance compliant behavior perform independent audit compliance management system auditing business segment group company also including compliancerelevant topic internal audit examines implementation policy procedure corporate governance effectiveness compliance management system respond result review audit reveal potential improve reported otherwise detected compliance violation ment necessary action defined consultation followedup based severity potential miscon responsible management internal audit compli duct corporate level fresenius se co kgaa ance function performed multiple compliancerelated business segment case potential misconduct review workshop audit business segment across objectively assessed plausibility potential severity world duly followedup ensure violation man compliance function fresenius se co kgaa aged consistent fair comprehensive manner nec business segment support management imple essary investigation performed either internal ment solid control structure order guarantee compliant investigation team external support transaction daytoday business solid control struc assessment potential misconduct reveals tures assure potential case noncompliance avoided change improvement internal control structure detected early relevant control described compli required measure duly implemented man ance policy business segment group level agement close cooperation responsible compli implemented control cash bank trans ance function required targeted remediation action action requiring dual approval complete monitoring defined reduce risk misconduct future money transfer certain threshold guarantee disciplinary action taken required money transfer properly authorized executed order ensure ethical conduct continuously based legitimate purpose internal control form review question current practice try learn integral part established business process employee best practice four business segment focusing enabled act compliance rule regulation different area compliance mean learning potential improvement resulting audit review continuous exchange idea duly implemented compliance function within group aim achieve employee fresenius expected report continuous improvement compliance activity potential case noncompliance law regulation daytoday operation order live commitment internal policy superior responsible com professionalism honesty integrity relation pliance function fresenius code conduct explicitly patient customer supplier employee state employee may incur disadvantage shareholder result reporting potential misconduct therefore noncom pliance may also reported anonymously whistle blower hotlines email address set purpose corporate governance business segment fresenius se co kgaa corporate governance corporate governance declaration risk management control system declaration management board general view responsible handling risk element partner fresenius se co kgaa fresenius manage good corporate governance fresenius systematic ment se supervisory board fresenius se risk management control system allows manage co kgaa german corporate governance code ment board make early identification risk market pursuant section german stock corporation act trend react promptly relevant change risk aktiengesetz profile risk management control system efficiently designed process help enhance company perfor management board general partner fresenius mance risk management reviewed part annual se co kgaa fresenius management se hereafter man audit financial statement control system regu agement board supervisory board fresenius se larly reviewed management board internal co kgaa declare since issuance previous dec audit division information found page laration conformity december recommenda management report tions government commission german corpo internal audit division support management rate governance code published federal ministry board independent function outside company day justice consumer protection bundesministerium der today operation division assesses internal process justiz und für verbraucherschutz official section objective viewpoint necessary distance federal gazette bundesanzeiger hereafter code goal create added value fresenius thus version may met met help achieve organizational goal improved internal future following recommendation code control optimized business process cost reduction version may met efficiency increase well prevention corruption fresenius medical care ag co kgaa inter code number paragraph sentence nal risk management control system cap regarding specific compensation amount pursuant code number paragraph sentence orporate governance german c compensation amount management board member declaration conformity shall capped overall variable compensa german corporate governance code aim provide tion component transparency investor regard existing regula recommendation met service agree tions covering management monitoring company ments member management board valueenhancing strategy well majority provide cap regarding specific amount com guideline recommendation suggestion respon pensation component accordingly cap corporate governance sible management contained code basic regarding specific amount overall compensation component activity many year extensive infor performanceoriented shortterm compensation mation corporate governance found website variable bonus capped regard stock option wwwfreseniuscomcorporategovernance phantom stock compensation component management board general partner fresenius longterm incentive service agreement member se co kgaa fresenius management se supervi management board provide possibility sory board fresenius se co kgaa issued required limitation cap regarding specific amount intro declaration conformity pursuant section ducing cap regarding specific amount relation german stock corporate act aktg made available stockbased compensation component would con shareholder website company tradict basic idea member management board participating appropriately economic risk opportunity company instead fresenius pursues flexible concept according individ ual case considered event extraordinary devel opments relation stockbased compensation related performance management board supervisory board may cap stockbased compensation corporate governance code number paragraph severance payment cap specific amount overall compensation pursuant code number paragraph con target value comparable value oneyear cluding management board contract care shall taken variable compensation deferrable portion ensure payment made management board oneyear variable compensation deferral oneyear member premature termination contract variable compensation determined basis bonus including fringe benefit exceed value two curve applicable several year respect year compensation severance payment cap com compensation report cannot meet recommendation pensate remaining term service code irrespective thereof fresenius continue agreement severance payment cap shall calculated comprehensively transparently present compen basis total compensation past full sation system amount paid member fiscal year appropriate also expected total com management board compensation report com pensation current fiscal year pensation report include table relating value recommendation met insofar ser benefit granted well allocation year vice agreement member management review follow structure largely also board contain severance payment arrangement specification model table case premature termination contract consequently contain limitation severance code number paragraph sentence age limit payment amount extent uniform severance pay member management board ment arrangement kind would contradict con pursuant code number paragraph sentence cept practiced fresenius accordance ger age limit shall specified member man man stock corporation act aktiengesetz according agement board past fresenius continue service agreement member manage refrain specifying age limit member ment board principle concluded period management board complying recommen appointment would also allow well dation would unduly limit selection qualified balanced assessment individual case didates code number paragraph presentation code number sentence independence compensation report chairman audit committee pursuant code number paragraph presen pursuant code number sentence chairman tation compensation individual member audit committee shall independent pursuant management board compensation report shall code number sentence supervisory board corporate governance present maximum minimum achievable compensa member considered independent particular tion variable compensation component using personal business relation model table presentation compensation granted company executive body controlling shareholder pursuant description model table shall also enterprise associated latter may specify target value comparable value aver cause substantial merely temporary conflict age probability scenario oneyear variable com interest pensation deferrable portion oneyear term prof dr h c roland berger chairman variable compensation deferral audit committee ended annual general fresenius deviation code number para meeting concluded may term graph sentence provide cap regarding specific amount variable compensation compo nents therefore provide cap regarding corporate governance corporate governance declaration chairman audit committee also partner enterprise potential conflict interest number roland berger strategy consultant holding gmbh independent supervisory board member within mean honorary chairman supervisory board roland ing code number diversity berger strategy consultant holding gmbh interest enterprise generally limit tenure prof dr h c berger chairman audit selection qualified candidate supervisory committee fresenius group made use consultancy ser board however confines complying statutory vice provided roland berger strategy consultant requirement particularly refrain specifying gmbh affiliated enterprise management consultancy age limit regular limit length membership roland berger strategy consultant holding gmbh management board supervisory board believe code number paragraph sentence perfor business relation neither constituted substantial mancerelated compensation member longterm conflict interest interfere supervisory board oriented toward sustainable growth task chairman audit committee enterprise ever precaution deviation code number pursuant code number paragraph sentence sentence declared given legal view performancerelated compensation promised regard question independence time member supervisory board shall oriented prof dr hc roland berger withdrew supervisory toward sustainable growth enterprise variable board since election mr klauspeter müller compensation supervisory board member chairman audit committee constitutive meet fresenius se co kgaa multiyear calcu ing supervisory board may rec lation basis thus sense oriented toward ommendation met sustainable growth enterprise instead super visory board receives performancerelated compen code number paragraph paragraph sation component depends dividend pursuant specification concrete objective regarding section paragraph article association composition supervisory board fresenius se co kgaa compensation model consideration making recommendation existence since continues bring forth competent election body adequate compensation supervisory board pursuant code number paragraph para line law interest shareholder graph supervisory board shall specify concrete objective regarding composition making bad homburg v h december recommendation competent election body take management board general partner corporate governance objective account objective specified fresenius se co kgaa fresenius management se supervisory board status implementa supervisory board fresenius se co kgaa tion shall published corporate governance report accordance section para aktg number recommendation met composi sentence code declaration tion supervisory board must align interest past declaration published website see enterprise ensure effective supervision wwwfreseniuscomcorporategovernance consultation management board thus matter principle prime importance member suitably qualified discussing recommendation competent election body supervisory board take account international activity corporate governance information met december call proportion corporate governance woman second management level target corresponds proportion december diversity management board belief inclusion management board take diversity account companywide stock option program strong indicator filling executive position fresenius individual qual individual hold leading executive position propor ifications paramount consideration hiring tion woman group top executive promotion decision mean woman men december comparable qualification suitability information diversity well personnel career opportunity fresenius continue consistently development personnel management included act upon principle course comply group management report page f law equal participation woman men executive position private company public service legal relationship member supervisory board fresenius se co kgaa corporate body law requires quota least woman general partner supervisory board fresenius men mandatory quota met supervisory se co kgaa duty act best interest board election company performing activity pursue legally stipulated target management board personal interest bestow unjustified benefit others apply fresenius management se fresenius sideline activity transaction company se co kgaa due legal form fresenius se co kgaa member corporate body must reported management board fresenius manage approved supervisory board supervisory board ment se listed stock exchange also fresenius se co kgaa report agm con subject codetermination flicts interest dealt accordance legal requirement manage fresenius se co kgaa report following relation ment board specifies composition two management ship existing fresenius group company level directly management board follows company member supervisory board first management level includes senior vice presi fresenius se co kgaa member supervisory dent vice president employment contract management board fresenius management se held fresenius se co kgaa report directly executive function member management board decision effec prof dr med michael albrecht member tive january management board set target supervisory board fresenius se co kgaa medical corporate governance met december call director spokesman management board proportion woman first management university hospital carl gustav carus dresden well level target corresponds proportion member supervisory board university hospital december aachen fresenius group maintains business relation second management level includes vice president hospital ordinary course business employment contract fresenius se customary condition co kgaa report directly member first man klauspeter müller member supervisory board agement level decision effective january fresenius management se fresenius se co kgaa management board set target chairman supervisory board commerz bank ag fresenius group maintains business relationship customary condition michael diekmann corporate governance information corporate governance member supervisory board fresenius manage payment mentioned section legal relation ment se deputy chairman supervisory board ship member corporate body net amount fresenius se co kgaa currently nonexecutive addition vat paid director board director allianz australia ltd consulting service contract fresenius group paid insurance premium neither directly indirectly supervisory board allianz customary condition member company consultancy service relationship mem fresenius disclosed information related party bers supervisory board company existed quarterly report page annual regard dr dieter schenk deputy chairman super report visory board fresenius management se dr schenk partner law firm noerr llp entity inter disclosure director dealing nationally acting law firm noerr provided legal advice manager transaction fresenius group fresenius group paid shareholding total million law firm noerr july market abuse regulation mar became million corresponds less total applicable instead former section german amount paid fresenius group service legal security trading act wphg regarding director dealing advice amount paid also includes provision art mar regarding manager payment service already provided transaction applicable therefore person discharging paid total amount fiscal year managerial responsibility well person closely asso less million attributable service group ciated shall notify transaction conducted company related business segment fresenius account relating share debt instrument medical care service rendered group company fresenius se co kgaa derivative financial business segment fresenius medical care require instrument linked thereto separate approval supervisory board fresenius manager transaction disclosed web medical care management ag fresenius medical care site wwwfreseniuscomcorporategovernance ag co kgaa supervisory board fresenius manage pursuant number code ownership share ment se examined mandate closely approved company financial instrument based mandate dr schenk take part voting must disclosed management board supervisory approval made basis written submission board member share issued supervisory board listed individual mandate company held either directly indirectly none corresponding individual invoice invoice management supervisory board member general corporate governance paid supervisory board gave approval partner supervisory board fresenius se co supervisory board fresenius se co kgaa dealt kgaa directly indirectly hold share amount legal service paid law firm noerr rela issued fresenius related financial instrument tion amount paid law firm member management supervisory board fresenius management se member super visory board fresenius se co kgaa together hold share fresenius se co kgaa outstanding december form share related financial corporate governance instrument stock option fresenius se co financial accounting reporting kgaa stock option plan held member fresenius prepares consolidated financial statement management board fresenius management se accordance united state generally accepted member supervisory board fresenius manage accounting principle u gaap fresenius publicly ment se member supervisory board traded company based member country european fresenius se co kgaa due fact person union required prepare publish consolidated member supervisory board amount financial statement accordance international finan share related financial instrument stock option held cial reporting standard ifrs pursuant section board fresenius se co kgaa fresenius german commercial code hgb largest subsidiary management se total smaller cumulative hold fresenius medical care prepares financial statement ings three board reported herein accordance u gaap therefore publish consol notification shareholding idated financial statement accordance u gaap member management supervisory board statutory consolidated financial statement accor reached exceeded fallen reporting threshold dance ifrs enables u disclose financial stipulated german security trading act result shareholder comparable transpar ent manner starting fiscal year fresenius transparency communication report solely accordance ifrs company fresenius adheres recommendation number provide additional financial information according u code transparency guaranteed continuous com gaap information provided group manage munication public way able validate ment report page deepen trust given u particular importance leading auditor marcus rohrbach kpmg ag wirt u equal treatment recipient ensure schaftsprüfungsgesellschaft responsible audit market participant receive information consolidated financial statement since time post important publication website wwwfreseniuscom report detail investor rela tions activity page annual report corporate governance corporate governance information corporate governance compensation report addition pension commitment member compensation report summarizes main element management board compensation system member management effect june dr ulf schneider board fresenius management se general partner resigned management board fresenius manage fresenius se co kgaa regard notably explains ment se received nonperformancebased compensa amount structure compensation paid tion pro rata fiscal year plus bonus management board well principle determining ever granted stock option phantom stock compensation supervisory board amount fiscal year participation stock option compensation compensation report part plan provide case mutually agreed resignation management report annual financial statement member exercise stock option within calendar day annual consolidated financial statement fresenius se resignation potentially plus blackout period co kgaa compensation report prepared basis provided waiting period expired performance recommendation german corporate governance target achieved dr ulf schneider took advan code well consideration declaration tage arrangement exercised stock option resenius se co kgaa december conformity f following resignation stock option also includes disclosure required pursuant phantom stock already assigned forfeited without applicable statutory regulation notably accordance replacement waiting period yet expired german commercial code dr ulf schneiders contractual pension entitlement affected resignation compensation management board design individual element based entire supervisory board fresenius management se following criterion responsible determining compensation man fixed compensation paid monthly install agement board supervisory board assisted ments fiscal year mr rice powell paid part task personnel committee personnel committee fixed compensation fresenius medical care north composed dr gerd krick dr dieter schenk dr karl america installment moreover member schneider management board received additional benefit consisting objective compensation system enable mainly insurance premium private use company member management board participate reason car special payment rent supplement reim ably sustainable development company business bursement certain charge tuition fee cost reward based duty performance operation intrusion detection system well contribu well success managing company eco tions pension health insurance corporate governance nomic financial position giving due regard peer performancebased compensation also granted environment fiscal year shortterm cash component one compensation management board year variable compensation compensation component whole performancebased composed three ele longterm incentive effect stock option sharebased ments fiscal year compensation cash settlement phantom stock postponed payment oneyear variable compensation nonperformancebased compensation fixed compensa amount oneyear variable compensation tion fringe benefit case dependent certain target parameter oriented shortterm performancebased compensation oneyear net income attributable fresenius se co kgaa variable compensation bonus relevant business segment achieved case component longterm incentive effect several member management board functional year variable compensation comprising stock option responsibility entire group member sharebased compensation cash settlement phan mr sturm dr schneider dr götz amount tom stock postponed payment oneyear variable compensation dr ulf schneider resigned management board fresenius management se effective june receives shortterm performancebased compensation pro rata june accordance contract corporate governance oneyear variable compensation based entirety oriented net income attributable fresenius se respective net income attributable fresenius se co kgaa co kgaa deduction noncontrolling interest well deduction noncontrolling interest mr henriksson net income tax extraordinary income dr de meo approximately half amount expenditure vamed group mr rice powell receives oneyear variable compensation depends development compensation exclusively fresenius medical care net income attributable fresenius se co kgaa furthermore supervisory board may grant member remainder development net income management board discretionary bonus extraordi business segment case deduction non nary performance controlling interest respective member fiscal year amount cash management board responsible approximately half payment management board general partner amount oneyear variable compensation dr wastler fresenius se co kgaa consisted following shortterm cash compensation nonperformancebased performancebased without longterm compensation compensation incentive component fixed compensation fringe benefit bonus thousand stephan sturm dr ulf schneider june dr francesco de meo dr jürgen götz mat henriksson rice powell dr ernst wastler total r rice powell received compensation fresenius medical care fresenius se co kgaa held around total subscribed capital member management board fresenius management se compensation included compensation report fresenius group includes insurance premium private use company car contribution pension health insurance well benefit amount contains discretionary bonus mr rice powell amount thousand fiscal year fiscal year oneyear variable compensation annually converted pro rata variable compensation excluding payment mr rice powell amounted component based multiyear assessment order thousand equal total oneyear variable compen also take account negative development within sation assessment period done way matu corporate governance ensure overall system compensation rity yearly oneyear variable compensation earned member management board oriented towards variable basis postponed discretion super longterm sustained corporate development compen visory board either pro rata basis entirety sation system provides share longterm variable two year time ensured payment compensation component least equal amount made member management board expira half total variable compensation component granted tion multiyear period subsequent adjust respective member management board ment net income adjusted extraordinary effect mean ensuring minimum ratio favor compen attributable fresenius se co kgaa deduction sation component oriented towards long term noncontrolling interest decisive assessing oneyear expressly provided supervisory board may determine variable compensation beyond amount equal tolerance oneyear variable compensation paid rule range made ii amount net income corporate governance information corporate governance attributable fresenius se co kgaa adjusted extraor exercise stock option phantom stock dinary effect two relevant subsequent year resenius se co kgaa subject granted ltip f substantially less net income attributable several condition expiry fouryear waiting fresenius se co kgaa adjusted extraordinary effect period observance vesting period achievement deduction noncontrolling interest respective specified performance target continuance service preceding fiscal year event aforementioned con employment relationship vested stock option ditions payment missed minor exercised within period four year vested phantom partial extent supervisory board may resolve corre stock settled march year following end sponding pro rata payment converted portion waiting period oneyear variable compensation interest payable amount cash settlement pursuant phan converted oneyear variable compensation claim tom stock plan based volumeweighted average time first arises time effective payment market price share fresenius se co kgaa way oneyear variable compensation con three month preceding exercise date verted pro rata entirety genuine variable com respective performance target reached pensation component multiyear assessment basis adjusted consolidated net income company net also participates negative development income attributable shareholder company relevant assessment period increased minimum per year comparison fiscal year portion oneyear variable previous year within waiting period adjustment compensation converted component based foreign currency effect performance target also multiyear assessment achieved average annual growth rate adjusted fiscal year benefit ltip consolidated net income company fouryear fresenius se co kgaa mr rice powell benefit waiting period least adjusted foreign currency ltip fresenius medical care ag co kgaa effect respect one four reference granted another component longterm incentive period within waiting period neither adjusted con effect benefit consist one hand share solidated net income company increased mini based compensation cash settlement phantom stock mum per year comparison previous year hand stock option basis adjustment foreign currency effect average stock option plan fresenius se co kgaa annual growth rate adjusted consolidated net income mr rice powell performance share basis company fouryear waiting period resenius medical care ag co kgaa ltip ltip f least adjusted foreign currency effect respective available member management granted stock option phantom stock forfeited corporate governance board executive accordance division prorata basis according proportion perfor power stock corporation law grant member mance target achieved within waiting management board made supervisory board period ie one fourth two fourth three fourth fresenius management se grant executive completely made management board number stock principle ltip fresenius se co kgaa option phantom stock management board mem ltip fresenius medical care ag co kgaa bers granted determined supervisory board described detail note note supervisory board due discretion provided fresenius group sharebased compensation plan generally management board member receive member management board excep amount stock option phantom stock excep tion dr ulf schneider mr rice powell tion chairman management board receives granted entitlement sharebased compensation double respective amount stock option phan cash settlement phantom stock equiva tom stock time grant participant ltip lent value thousand per management board member may elect whether wish receive stock option fiscal year regard performance tar phantom stock ratio ratio get waiting period condition pertain phantom stock granted ltip apply dr ulf schneider resigned management board fresenius management se effective june corporate governance fiscal year number value twice number period july stock option issued value sharebased compensa became chairman management board stated value tion cash settlement phantom stock performance correspond fair value time grant namely share value postponed performancebased value per stock option f resenius compensation shown following table se co kgaa exercise price granted stock option number stock option granted member fresenius se co kgaa management board ltip fiscal year higher value comparison well higher exer basically unchanged compared however cise price reflect excellent fresenius share price devel dr ulf schneider receive stock option opment phantom stock fiscal year due fact fair value phantom stock granted member left company june stephan sturm management board fiscal year corre received regular number stock option phantom sponds value time grant stock pro rata period june per phantom stock fresenius se co kgaa u regular member management board per performance share fresenius medical care ag co kgaa granted first time longterm incentive component postponed sharebased payment compensation oneyear variable cash settlement stock option compensation phantom stock total number value thousand value thousand value thousand value thousand stephan sturm dr ulf schneider june dr francesco de meo dr jürgen götz mat henriksson rice powell dr ernst wastler total tock option granted fresenius se co kgaa stock option plan mr rice powell received stock option fresenius medical care stock option plan performance share share based award fresenius medical care ag co kgaa corporate governance end fiscal year member manage stock fresenius se co kgaa well ment board held total performance share granted first time stock option fresenius se co kgaa phantom stock fresenius medical fresenius medical care ag co kgaa care ag co kgaa held total phantom corporate governance information corporate governance development status stock option management board fiscal year shown following table stephan dr francesco dr jürgen mat rice dr ernst sturm de meo götz henriksson powell wastler total option outstanding january number average exercise price option granted fiscal year number exercise price option exercised fiscal year number average exercise price n n n n average stock price n n n n option forfeited fiscal year number average exercise price n n n n n n option outstanding december number average exercise price average remaining life year range exercise price exercisable option december number average exercise price n n mr rice powell hold stock option fresenius medical care stock option plan stock option fresenius se co kgaa excluding stock option mr rice powell following table show total compensation management board general partner fresenius se co kgaa year cash compensation total compensation without longterm longterm including longterm incentive component incentive component incentive component corporate governance thousand stephan sturm dr ulf schneider june dr francesco de meo dr jürgen götz mat henriksson rice powell dr ernst wastler total corporate governance stock option entitlement sharebased com stated following table value pensation phantom stock exercised shown year dr ulf schneider include expiry minimum term vesting period value correction expense prior year stock option recognized vesting period expense respec phantom stock expire due resignation tive fiscal year expense attributable fiscal year expense longterm incentive component sharebased compensation cash settlement total expense stock option phantom stock sharebased compensation thousand stephan sturm dr ulf schneider june dr francesco de meo dr jürgen götz mat henriksson rice powell dr ernst wastler total includes expense performance share share based award fresenius medical care ag co kgaa shortterm performancebased compensation limited contractual pension commitment based former contract amount regard stock option phantom stock employment general partner fresenius se co contractually agreed limitation possibility kgaa management board member dr ernst wastler make possible adequately take account particular pension commitment vamed ag vienna fresenius se extraordinary development relevant co kgaa issued guarantee commitment proportion performance management board management board member mat henriksson compensation system amount fixed individual contractual pension commitment fresenius total compensation member manage kabi ag management board member mr rice powell ment board assessed giving particular regard received individual contractual pension commitment relevant comparison value dax company fresenius medical care management ag furthermore similar company comparable size performance acquired nonforfeitable entitlement participating corporate governance relevant industrial sector pension plan employee fresenius medical care north america fiscal year participated commitment member usbased k saving plan plan generally management board event enables employee united state invest part termination appointment gross income retirement plan regard pen individual contractual pension commitment sion commitment acting management board member management board member mr stephan sturm december fresenius group pension obliga dr francesco de meo dr jürgen götz based tions thousand december service agreement general partner fresenius thousand addition pension liability se co kgaa management board member leaving fiscal year amounted thousand june dr ulf schneider individual thousand corporate governance information corporate governance pension commitment follows thousand january addition december stephan sturm dr francesco de meo dr jürgen götz mat henriksson rice powell dr ernst wastler total pension commitment provides pension board member compared potential length service survivor benefit depending amount recent age year year mr rice powell fixed compensation rd year life th year pension commitment dr ernst wastler provides mr rice powell case termination normal pension early retirement pension profes professional occupational incapacity time end sional incapacity pension widow orphan pen ing active work sion normal pension payable earliest age pension starting percentage last fixed year early retirement pension earliest compensation increase every full year service age year pension benefit equivalent management board member percentage point per year service based last fixed compensa attainable maximum tion cap widow pension current pension increase according legal requirement orphan pension capped aggregate section german law improve company pension dr ernst wastlers pension entitlement plan betravg time death pension retirement benefit gross amount postretirement income third party set pension benefit occupation management board member management board member mr mat henriksson offset pension professional occupational solely pension commitment fresenius kabi ag incapacity period previous service pension commitment event death one management board resenius remained unaffected service agreement f member widow receives pension equivalent management se beginning january based pension entitlement accruing time death pension policy fresenius company janu addition legitimate biological child deceased manage ary provides retirement incapacity survi corporate governance ment board member individual case biological vors pension set forth deduction child deceased management board member wife income pension benefit widow pension amount adopted deceased management board incapacity retirement pension granted member child receive orphan pension equivalent time death orphan pension amount pension entitlement accruing time halforphans orphan incapacity retire death completion vocational training ment pension granted time death total age year however orphan pen entitlement widow orphan limited sion widow pension capped aggregate mr mat henrikssons pension entitlement management board member pension entitlement postemployment noncompetition covenant agreed management board member service member upon management board member cove management board fresenius management se nant becomes applicable management board member mr rice powell member management board receive waiting allowance generally equivalent fresenius medical care management ag end age half respective annual fixed compensation year year year mr rice powell reason respective application noncompetition covenant professional occupational incapacity right maximum two year said pension benefit vest pension payable service agreement management board mem upon occurrence pensionable event reduced pro bers contain explicit provision event rata according actual length service management change control corporate governance miscellaneous fresenius se co kgaa undertook indemnify man member management board received individ agement board member legally permitted extent ual contractual commitment continuation claim may asserted compensation event sickness maximum period course service company affiliated month provided six month sickness group company extent claim exceed related absence insurance benefit may paid liability german law cover obligation deducted continued compensation company purchased director officer insurance event death member management board deductible complying requirement stock cor surviving dependent receive three monthly payment poration law indemnification cover period month death occurred maximum respective member management board however expiry respective employment agree hold office well claim regard termination ment service management board fiscal year loan advance pay based pension commitment former member ment future compensation component granted management board thousand paid fiscal member management board fresenius man year thousand thousand agement se thousand paid dr ben lipps result stephan sturm dr ulf schneider dr francesco de meo chairman management board chairman management board ceo fresenius helios since july june board member since january board member since may board member since january benefit granted value thousand min max min max min max fixed compensation fringe benefit total nonperformancebased compensation oneyear variable compensation multiyear variable compensation component longterm incentive effect n n n thereof postponed oneyear variable compensation n n n thereof stock option plan corporate governance part ltip year term n n n thereof phantom stock part ltip year term n n n thereof phantom stock n n n total nonperformancebased performancebased compensation n n n service cost value benefit granted n n n f oneyear variable compensation target value comparable value board member receive remuneration fresenius management se oneyear variable compensation calculated basis bonus curve valid several year reason allocation oneyear variable remuneration stated amount contains discretionary bonus mr rice powell amount thousand fiscal year mr rice powell granted stock option phantom stock performance share program fresenius medical care follows thousand share based award new incentive bonus plan thousand long term incentive program performance share plan thousand share based award new incentive bonus plan thousand long term incentive program stock option plan thousand long term incentive program phantom stock plan corporate governance information corporate governance consultancy agreement entered fresenius following table contain disclosure value medical care management ag benefit obligation benefit granted allocation conform person amounted thousand structure large degree specification thousand thereof thousand relates model table german corporate governance code dr ulf schneider table displaying allocation additionally show alloca tion fiscal year without multiyear variable table displaying value benefit compensation component longterm incentive effect granted allocation illustrates clearly allocation attributed german corporate governance code stipulates spe activity respective year review cific information shall presented compensation allocation result compensation component report pertaining benefit granted year granted previous even several reporting year review well allocation service cost differentiation comparability respective year review model table provided appen development compensation also increased dix german corporate governance code shall used present information dr jürgen götz mat henriksson rice powell dr ernst wastler chief legal compliance officer ceo fresenius kabi ceo fresenius medical care ceo fresenius vamed labor relation director board member since july board member since january board member since january board member since january min max min max min max min max n n n n n n n corporate governance n n n n n n n n n n n n n n n n n corporate governance stephan sturm dr ulf schneider dr francesco de meo chairman management board chairman management board ceo fresenius helios since july june board member since january board member since may board member since january allocation value thousand fixed compensation fringe benefit total nonperformancebased compensation oneyear variable compensation multiyear variable compensation component longterm incentive effect thereof postponed oneyear variable compensation thereof stock option plan year term issue thereof stock option plan year term issue issue issue thereof phantom stock issue total nonperformancebased performancebased compensation service cost allocation including multiyear variable compensation compo nents longterm incentive effect allocation year review including multiyear variable compensation component longterm incentive effect amount contains discretionary bonus mr rice powell amount thousand fiscal year mr rice powell allocation stock option fresenius medical care stock option program corporate governance thousand share based award new incentive bonus plan issue thousand stock option plan issue thousand stock option plan issue thousand long term incentive program phantom stock plan issue thousand share based award new incentive bonus plan issue thousand stock option plan issue allocation relates stock option dr ulf schneider exercised resignation management board june accordance condition participation stock option plan corporate governance information corporate governance dr jürgen götz mat henriksson rice powell dr ernst wastler chief legal compliance officer ceo fresenius kabi ceo fresenius medical care ceo fresenius vamed labor relation director board member since july board member since january board member since january board member since january corporate governance corporate governance compensation supervisory board operation intrusion detection system amount compensation supervisory board determined thousand fresenius se co kgaa provides annual general meeting subject provi member supervisory board insurance coverage sion contained section article association adequate amount relating function excess fresenius se co kgaa member supervisory equal management board board shall receive fixed compensation thousand member supervisory board fresenius se full fiscal year co kgaa time member supervisory member audit committee fresenius se board general partner fresenius management se co kgaa receive additional thousand receives remuneration service supervisory chairman committee thousand resenius management se remuneration shall board f full fiscal year remuneration increase reduced half applies respect percentage point three time dividend paid additional part remuneration chairman one ordinary share year gross dividend according deputy time chairman resolution annual general meeting exceeds one deputy supervisory board fresenius amount equal subscribed capital divided management se deputy chairman super number nonpar value share residual amount inter visory board fresenius se co kgaa time polated general meeting resolve higher remunera chairman supervisory board fresenius man tion view annual result increased amount shall agement se shall receive remuneration service applicable chairman receives twice amount deputy chairman supervisory board fresenius deputy chairman one half time se co kgaa according section article asso amount supervisory board member member ciation fresenius se co kgaa remuneration supervisory board receive appropriate compensation supervisory board fresenius management se charged cost travel accommodation incurred connection fresenius se co kgaa duty member supervisory board includ fiscal year compensation ing applicable valueadded tax additionally capac member supervisory board fresenius se ity chairman supervisory board fresenius man resenius management se excluding expense co kgaa f agement se dr krick reimbursed cost reimbursement including compensation committee service follows corporate governance corporate governance information corporate governance compensation variable total fixed compensation committee service compensation compensation fresenius se fresenius fresenius se fresenius fresenius se fresenius co kgaa management se co kgaa management se co kgaa management se thousand dr gerd krick michael diekmann since may dr dieter schenk niko stumpfögger prof dr med michael albrecht prof dr h c roland berger may dr kurt bock since may dario ilossi may konrad kölbl stefanie lang since may frauke lehmann since may prof dr med iris löwfriedrich since may klauspeter müller dieter reuß may gerhard roggemann may oscar romero de paco since may dr karl schneider stefan schubert may hauke star since may rainer stein total corporate governance director officer insurance ffiliates co kgaa well representative body fresenius se co kgaa taken consequential loss germany elsewhere policy applies throughout liability insurance policy insurance excess world run end june policy cov amount basis member management board er legal defense cost member representative supervisory board general partner fresenius se body claim made relevant dam resenius se co kgaa supervisory board f age paid covered policy consolidated financial statement table content consolidated financial statement consolidated statement income consolidated statement change equity consolidated statement comprehensive income consolidated segment reporting consolidated statement financial position note consolidated statement cash flow financial statement consolidated financial statement consolidated statement income consolidated statement comprehensive income fresenius se co kgaa consolidated statement income million note sale cost sale gross profit selling general administrative expense research development expense operating income ebit interest income interest expense income income tax income tax net income less noncontrolling interest net income attributable shareholder fresenius se co kgaa earnings per share fully diluted earnings per share following note integral part consolidated financial statement fresenius se co kgaa consolidated statement comprehensive income million note net income comprehensive income loss foreign currency translation cash flow hedge change fair value available sale financial asset actuarial gain loss defined benefit pension plan income tax related component comprehensive income loss comprehensive income net financial statement total comprehensive income comprehensive income attributable noncontrolling interest subject put provision comprehensive income attributable noncontrolling interest subject put provision comprehensive income attributable shareholder fresenius se co kgaa following note integral part consolidated financial statement consolidated financial statement fresenius se co kgaa consolidated statement financial position asset december million note cash cash equivalent trade account receivable less allowance doubtful account account receivable loan related party inventory current asset total current asset property plant equipment goodwill intangible asset noncurrent asset deferred tax ii total noncurrent asset total asset liability shareholder equity december million note trade account payable shortterm account payable related party shortterm accrued expense shortterm liability shortterm debt shortterm debt related party current portion longterm debt capital lease obligation current portion senior note shortterm accrual income tax total shortterm liability longterm debt capital lease obligation less current portion senior note less current portion convertible bond longterm accrued expense longterm liability pension liability longterm accrual income tax deferred tax b total longterm liability financial statement total liability ii noncontrolling interest subject put provision noncontrolling interest subject put provision subscribed capital capital reserve reserve accumulated comprehensive income b total fresenius se co kgaa shareholder equity iii total shareholder equity total liability shareholder equity following note integral part consolidated financial statement consolidated financial statement consolidated statement financial position consolidated statement cash flow fresenius se co kgaa consolidated statement cash flow january december million note operating activity net income adjustment reconcile net income cash cash equivalent provided operating activity depreciation amortization gain sale investment divestiture change deferred tax loss sale fixed asset change asset liability net amount business acquired disposed trade account receivable net inventory current noncurrent asset account receivable payable related party trade account payable accrued expense shortterm longterm liability accrual income tax net cash provided operating activity investing activity purchase property plant equipment proceeds sale property plant equipment acquisition investment net cash acquired net purchase intangible asset proceeds sale investment divestiture net cash used investing activity financing activity proceeds shortterm debt repayment shortterm debt proceeds longterm debt capital lease obligation repayment longterm debt capital lease obligation proceeds issuance senior note repayment liability senior note change account receivable securitization program proceeds exercise stock option dividend paid change noncontrolling interest exchange rate effect due corporate financing net cash used financing activity effect exchange rate change cash cash equivalent financial statement net increase decrease cash cash equivalent cash cash equivalent beginning reporting period cash cash equivalent end reporting period following note integral part consolidated financial statement consolidated financial statement fresenius se co kgaa consolidated statement change equity subscribed capital reserve number capital ordinary share amount amount reserve reserve note thousand thousand million million million december proceeds exercise stock option compensation expense related stock option vested subsidiary stock incentive plan dividend paid sale noncontrolling interest subject put provision noncontrolling interest subject put provision comprehensive income loss net income comprehensive income loss cash flow hedge change fair value available sale financial asset foreign currency translation actuarial gain defined benefit pension plan comprehensive income december proceeds exercise stock option compensation expense related stock option vested subsidiary stock incentive plan dividend paid purchase noncontrolling interest subject put provision noncontrolling interest subject put provision comprehensive income loss net income comprehensive income loss cash flow hedge change fair value available sale financial asset foreign currency translation actuarial loss defined financial statement benefit pension plan comprehensive income december consolidated financial statement consolidated statement change equity accumulated total fresenius noncontrolling com se co kgaa interest total prehensive shareholder subject put shareholder income loss equity provision equity note million million million million december proceeds exercise stock option compensation expense related stock option vested subsidiary stock incentive plan dividend paid sale noncontrolling interest subject put provision noncontrolling interest subject put provision comprehensive income loss net income comprehensive income loss cash flow hedge change fair value available sale financial asset foreign currency translation actuarial gain defined benefit pension plan comprehensive income december proceeds exercise stock option compensation expense related stock option vested subsidiary stock incentive plan dividend paid purchase noncontrolling interest subject put provision noncontrolling interest subject put provision comprehensive income loss net income comprehensive income loss cash flow hedge change fair value available sale financial asset foreign currency translation actuarial loss defined financial statement benefit pension plan comprehensive income december following note integral part consolidated financial statement consolidated financial statement fresenius se co kgaa consolidated segment reporting business segment fresenius medical care fresenius kabi million change change sale thereof contribution consolidated sale thereof intercompany sale contribution consolidated sale ebitda depreciation amortization ebit net interest income tax net income attributable shareholder fresenius se co kgaa operating cash flow cash flow acquisition dividend total asset debt capital expenditure gross acquisition gross investment research development expense employee per caput balance sheet date key figure ebitda margin ebit margin depreciation amortization sale operating cash flow sale rooa cost efficiency program integration cost disposal gain two helios hospital cost efficiency program integration cost disposal gain two helios hospital underlying ebit include cost efficiency program integration cost disposal gain two helios hospital region europe north america million change change sale financial statement contribution consolidated sale ebit depreciation amortization total asset capital expenditure gross acquisition gross investment employee per caput balance sheet date consolidated financial statement consolidated segment reporting fresenius helios fresenius vamed corporate fresenius group change change change change consolidated segment reporting business segment integral part note following note integral part consolidated financial statement asiapacific latin america africa fresenius group change change change change financial statement consolidated segment reporting region integral part note following note integral part consolidated financial statement consolidated financial statement table content note general note debt capital lease obligation principle senior note group structure convertible bond ii basis presentation pension similar obligation iii summary significant accounting policy noncontrolling interest iv critical accounting policy fresenius se co kgaa shareholder equity acquisition divestiture investment comprehensive income loss note consolidated statement income note special item commitment contingent liability sale financial instrument cost sale supplementary information capital management cost material supplementary information consolidated personnel expense statement cash flow selling general administrative expense note consolidated segment reporting net interest sharebased compensation plan tax related party transaction noncontrolling interest subsequent event earnings per share note accordance german commercial code hgb note consolidated statement financial position compensation management board cash cash equivalent supervisory board trade account receivable auditor fee inventory corporate governance current noncurrent asset proposal distribution earnings property plant equipment responsibility statement goodwill intangible asset accrued expense liability financial statement consolidated financial statement general note general note center quirónsalud treat approximately inpa tients approximately million outpatient annually principle hospital spain operates total approximately bed group structure fresenius vamed manages project provides service fresenius global health care group product ser hospital health care facility worldwide vice dialysis hospital outpatient medical care portfolio range along entire value chain proj addition fresenius group focus hospital operation ect development planning turnkey construction via also manages project provides service hospi maintenance technical management total operational tals health care facility worldwide besides management activity parent company fresenius se co kgaa fresenius se co kgaa owned sub bad homburg v h operating activity split scribed capital fresenius medical care ag co kgaa following legally independent business segment fmcag co kgaa end fiscal year fiscal year fresenius medical care management ag general partner fmcag co kgaa wholly owned subsidiary fresenius medical care fresenius se co kgaa structure fresenius fresenius kabi se co kgaa right give fresenius se co kgaa fresenius helios ability direct relevant activity hence fresenius vamed earnings fmcag co kgaa therefore fmcag co kgaa fully consolidated consolidated financial statement fresenius medical care world largest integrated pro fresenius group vider product service individual renal dis fresenius se co kgaa continued hold ea december fresenius medical care management company business segment fresenius treating patient dialysis clinic along kabi fresenius kabi ag well fresenius helios core business company seek expand range fresenius vamed held fresenius proserve medical service field care coordination gmbh december fresenius proserve fresenius kabi offer infusion therapy intravenously gmbh fresenius se co kgaa hold helios administered generic drug clinical nutrition seriously kliniken gmbh stake vamed ag addition chronically ill patient hospital outpatient fresenius se co kgaa hold interest company environment company also leading supplier medi holding function regarding real estate financing insur cal device transfusion technology product ance well fresenius netcare gmbh offer fresenius helios germany largest hospital operator service field information technology end helios group operated hospital reporting currency fresenius group euro thereof acute care hospital including maximum care order make presentation clearer amount hospital berlinbuch duisburg erfurt krefeld schwerin mostly shown million euro amount million wiesbaden wuppertal postacute care clinic rounding marked fresenius helios treat million patient per year thereof approximately million inpatient operates ii basis presentation financial statement approximately bed accompanying consolidated financial statement following closing acquisition quirónsalud prepared accordance united state generally january fresenius helios also largest private accepted accounting principle u gaap hospital operator spain quirónsalud offer full spectrum fresenius se co kgaa stock exchange listed com inpatient outpatient care hospital outpatient pany domicile member state european center around occupational risk prevention consolidated financial statement union fulfills obligation prepare publish consol item property plant equipment inventory acquired idated financial statement accordance interna group entity also eliminated deferred tax tional financial reporting standard ifrs applying section asset liability recognized temporary difference german commercial code hgb simultaneously resulting consolidation procedure fresenius group voluntarily prepares publishes noncontrolling interest subject put provision recog consolidated financial statement accordance u gaap nized liability equity consolidated state due requirement fresenius medical care ag ment financial position noncontrolling interest subject co kgaa report accordance u gaap put provision comprised interest noncontrolling socalled pooling agreement shareholder consolidated equity group entity may annual general meeting fresenius profit loss attributable noncontrolling sharehold medical care ag co kgaa rescinded obligation pre er separately disclosed consolidated statement pare report u gaap financial statement therefore income noncontrolling interest subject put provision fresenius group managed solely accordance acquired entity valuated fair value ifrs starting fiscal year longer pro associated company fresenius se vide consolidated financial statement according u gaap co kgaa significant exercisable influence generally voluntarily hold less voting order improve readability various item aggre right consolidated using equity method invest gated consolidated statement financial position ments classified associated company consolidated statement income item recorded acquisition cost fair value respectively shown separately note provide useful information reader consolidated financial statement b composition group consolidated statement financial position classi consolidated financial statement include material fied basis maturity asset liability company fresenius se co kgaa legal consolidated statement income classified using cost effective control includes variable interest entity ofsales accounting format resenius group deemed primary vies f beneficiary iii summary significant accounting fresenius medical care entered various arrange policy ments certain legal entity whereby entity equity principle consolidation holder lack power direct activity signifi financial statement consolidated entity cantly impact entity performance obligation prepared using uniform accounting method acquisi absorb expected loss receive expected residual return tions company accounted applying purchase legal entity arrangement entity method vie fresenius medical care determined capital consolidation performed offsetting invest primary beneficiary therefore ments subsidiary underlying revaluated equity fully consolidated fresenius medical care provided date acquisition identifiable asset liabili following service vies management tie subsidiary well noncontrolling interest financing product supply generated approximately recognized fair value remaining debit balance million us million million us mil financial statement investment subsidiary plus noncontrol lion sale respectively fresenius ling interest revaluated equity recognized good medical care provided funding vie loan tested least year impairment account receivable million u million significant intercompany sale expense income million us million respec receivables payable eliminated profit loss tively relating vies fresenius medical care consolidated financial statement general note consolidated asset amount million u fiscal year following fully consolidated million liability amount million u german subsidiary fresenius group apply million million u million equity exemption provided section b respec million u million asset million u tively german commercial code hgb million liability million u million equity consolidated due firsttime implementation name company registered office accounting standard update number corporate fresenius biotech beteiligungs gmbh bad homburg v h entity consolidated vies decreased prior year fresenius immobilienverwaltungs figure adjusted accordingly see note iiiff recent pro gmbh co objekt friedberg kg bad homburg v h nouncements applied interest held share fresenius immobilienverwaltungs gmbh co objekt st wendel kg bad homburg v h holder consolidated vies reported noncontrolling fresenius immobilienverwaltungs interest consolidated statement financial position gmbh co objekt schweinfurt kg bad homburg v h fresenius vamed participates project entity fresenius netcare gmbh bad homburg v h set longterm defined period time fresenius proserve gmbh bad homburg v h fps immobilien verwaltungs specific purpose constructing operating thermal cen gmbh co reichenbach kg bad homburg v h ters project entity qualify vie proserve krankenhaus beteiligungs fresenius vamed primary beneficiary based gesellschaft mbh co kg münchen fresenius kabi cash flow analysis involved party project enti fresenius hemocare gmbh bad homburg v h tie generated approximately million sale fresenius hemocare beteiligungs gmbh bad homburg v h million vie finance mainly fresenius kabi ag bad homburg v h debt profit participation right investment grant fresenius kabi deutschland gmbh bad homburg v h asset liability relating vie material fresenius kabi logistik gmbh friedberg fresenius kabi fresenius vamed made payment vies vermögensverwaltung gmbh bad homburg v h contractually stipulated today perspective due mc medizintechnik gmbh alzenau contractual situation fresenius vamed exposed medione medical gmbh waiblingen material risk loss vies fresenius helios helios agneskarllkrankenhaus gmbh bad schwartau consolidated financial statement included helios aokklinik bad em gmbh bad em addition fresenius se co kgaa helios aukammklinik wiesbaden gmbh wiesbaden fully consolidated company company helios beteiligungs aktiengesellschaft berlin accounted equity method helios bördeklinik gmbh oschersleben bode material change scope consolidated enti helios care gmbh berlin helios fachkliniken tie except mentioned note acquisition hildburghausen gmbh hildburghausen divestiture investment helios hanseklinikum stralsund gmbh stralsund complete list investment fresenius se helios kid pflege gmbh geesthacht co kgaa registered office bad homburg v h helios klinik berching gmbh berching helios klinik bergischland gmbh wuppertal elsekrönerstraße registered commercial register helios klinik blankenhain gmbh blankenhain local court bad homburg v h b helios klinik bleicherode gmbh bleicherode submitted electronic federal gazette financial statement helios klinik für herzchirurgie electronic company register karlsruhe gmbh karlsruhe helios klinik geesthacht gmbh geesthacht helios klinik hagen ambrock gmbh hagen helios klinik hattingen gmbh hattingen helios klinik hohenstücken gmbh brandenburg helios klinik jerichower land gmbh burg helios klinik leezen gmbh leezen consolidated financial statement name company registered office c classification fresenius helios certain item consolidated financial statement helios klinik leisnig gmbh leisnig reclassified conform presentation helios klinik lengerich gmbh lengerich helios klinik schkeuditz gmbh schkeuditz helios klinik schloss pulsnitz gmbh pulsnitz deferred tax classified current helios klinik schloss schönhagen gmbh damp december reclassified noncurrent helios klinik schwedenstein january accordance accounting standard pulsnitz gmbh pulsnitz helios klinik volkach gmbh volkach update financial accounting standard board helios klinik wipperfürth gmbh wipperfürth accounting standard codification topic income tax helios klinik zerbst anhalt gmbh zerbst balance sheet classification deferred tax helios kliniken breisgauhochschwarzwald gmbh müllheim helios kliniken gmbh berlin sale recognition policy helios kliniken bad grönenbach gmbh bad grönenbach sale service recognized amount estimated helios kliniken mansfeldsüdharz gmbh sangerhausen receivable reimbursement arrangement helios kliniken taunus gmbh bad schwalbach third party payors sale recognized date service helios klinikum aue gmbh aue related product provided customer obli helios klinikum bad saarow gmbh bad saarow gated pay helios klinikum berlinbuch gmbh berlin helios klinikum erfurt gmbh erfurt product sale recognized title product helios klinikum gotha gmbh gotha ohrdruf pa customer either time shipment helios klinikum krefeld gmbh krefeld upon receipt customer upon term helios klinikum meiningen gmbh meiningen clearly define passage title product return helios klinikum pirna gmbh pirna typical return provision recognized event helios klinikum schwelm gmbh schwelm helios klinikum siegburg gmbh siegburg return required appropriate reduction sale helios klinikum uelzen gmbh uelzen cost sale account receivable made sale pre helios klinikum wuppertal gmbh wuppertal sented net discount allowance rebate helios ostseeklinik damp gmbh damp business segment fresenius vamed sale long helios parkklinikum leipzig gmbh leipzig term production contract recognized using percent helios privatkliniken gmbh bad homburg v h ostseebad age completion poc method accounting condi helios rehaklinik ahrenshoop gmbh ahrenshoop tions met sale recognized calculated helios rehaklinik damp gmbh damp percentage cost already incurred based esti helios rehakliniken bad berleburg gmbh bad berleburg mated total cost contract milestone laid helios rehakliniken gmbh damp heliosservice gmbh berlin contract percentage completion profit helios spital überlingen gmbh überlingen recognized earnings production contract helios st elisabethkrankenhaus accounted using poc method measured reliably bad kissingen gmbh bad kissingen expected excess total contract cost total helios st josefshospital gmbh bochum helios versorgungszentren gmbh berlin contract revenue contract recognized expense helios versorgungszentrum immediately bad saarow gmbh bad saarow tax assessed governmental authority financial statement helios vogtlandklinikum plauen gmbh plauen incurred result sale transaction e g sale tax helios weißeritztalkliniken gmbh freital herzzentrum leipzig gmbh leipzig excluded sale related sale reported klinik kipfenberg gmbh neurochirur net basis gische und neurologische fachklinik kipfenberg ostsee resort damp gmbh damp poliklinik helios klinikum buch gmbh berlin senioren und pflegeheim erfurt gmbh erfurt verwaltungsgesellschaft endoklinik mbh hamburg consolidated financial statement general note e government grant h capitalized interest fresenius group primarily receives governmental funding fresenius group includes capitalized interest part hospital germany finance building medical cost asset directly attributable acqui equipment public sector grant recognized sition construction manufacture qualifying asset reasonable assurance respective condition fiscal year interest million met grant received initially grant million based average interest rate recorded liability soon asset acquired respectively recognized component grant offset acquisition cost expense cost asset related grant recognized income period related cost occur income tax current tax calculated based earnings f research development expense fiscal year accordance local tax rule research independent planned investigation respective tax jurisdiction expected executed addi taken prospect gaining new scientific techni tional tax payment tax refund prior year cal knowledge understanding development techni also taken account cal commercial implementation research result deferred tax asset liability recognized occurs start commercial production use future consequence attributable temporary difference research development expense expensed financial statement carrying amount existing incurred asset liability respective tax basis deferred tax recognized certain consolidation g impairment procedure affecting net income attributable shareholder fresenius group review carrying amount prop fresenius se co kgaa deferred tax asset also include erty plant equipment intangible asset non claim future tax reduction arise current asset impairment whenever event change likely expected usage existing tax loss available circumstance indicate carrying amount carryforward recognition deferred tax asset asset may recoverable recoverability asset net operating loss utilization based measured comparing carrying amount asset budget planning fresenius group implemented future net cash flow directly associated asset tax strategy asset considered impaired impairment rec deferred tax computed using enacted adopted tax ognized amount carrying amount exceeds rate relevant national jurisdiction amount fair value asset fresenius group u dis recovered tax rate valid future counted cash flow approach method appropriate adopted till date statement financial posi assess fair value longlived asset disposed tion considered sale reported lower carrying amount fair value realizability carrying amount deferred tax less cost sell depreciation ceased asset reviewed date statement financial position assessing realizability deferred tax asset management considers whether likely portion deferred tax asset real financial statement ized ultimate realization deferred tax asset depen dent upon generation future taxable income period temporary difference tax loss carryforwards become deductible management considers expected reversal deferred tax liability projected future taxable income making assessment consolidated financial statement longer likely sufficient taxable trade account receivable income available allow benefit part trade account receivable stated nominal value entire deferred tax asset utilized carrying amount less allowance doubtful account allowance deferred tax asset reduced certain extent estimate comprised customerspecific evaluation regard reduction reversed date extent becomes ing payment history current financial stability probable sufficient taxable profit available applicable countryspecific risk receivables fresenius group policy asset uncertain due one year time time account receiv tax position recognized extent likely able reviewed change historic collection expe tax recovered also fresenius group rience ensure appropriateness allowance policy recognize interest penalty related tax position income tax expense n inventory inventory comprised asset held sale j unrecognized tax benefit normal course business finished good pro recognition measurement tax position taken cess production sale work process consumed expected taken tax return requires two step production process rendering service raw approach fresenius group determines whether material purchased component likely tax position sustained upon inventory stated lower acquisition examination including resolution related appeal manufacturing cost determined using average first litigation process based technical merit firstout method net realizable value manufacturing position threshold met tax position measured cost comprised direct cost production material largest amount tax benefit overhead including depreciation charge likely realized upon settlement recognized consolidated financial statement available sale financial asset investment equity instrument debt instrument k earnings per share fund share classified available sale financial asset basic earnings per share computed dividing net measured fair value fresenius group regularly income attributable shareholder fresenius se co kgaa review objective substantial evidence occurs would weightedaverage number ordinary share indicate impairment financial asset portfolio standing year diluted earnings per share include financial asset testing recoverability asset effect potentially dilutive instrument ordinary possible impairment loss recorded consolidated share would outstanding fiscal year statement financial position gain loss available equitysettled award granted fresenius sale financial asset recognized directly con fresenius medical care stock option plan result solidated statement equity financial asset dis dilutive effect posed considered impaired case impairment accumulated net loss retrieved l cash cash equivalent consolidated statement equity recognized con cash cash equivalent comprised cash fund solidated statement income shortterm liquid investment original maturity financial statement three month time deposit security consolidated financial statement general note p property plant equipment useful life trade name acquired purchase property plant equipment stated acquisition method business combination recognized reported manufacturing cost less accumulated depreciation signifi apart goodwill recorded acquisition cost cant improvement capitalized repair maintenance goodwill intangible asset indefinite useful life cost extend useful life asset amortized tested impairment annually charged expense incurred depreciation property event becomes known could trigger impairment plant equipment calculated using straightline impairment test method estimated useful life asset ranging perform annual impairment test goodwill year building improvement fresenius group identified several reporting unit deter weightedaverage life year year mined carrying amount assigning asset lia machinery equipment weightedaverage life bilities including existing goodwill intangible asset year reporting unit reporting unit usually defined one level segment level based region q intangible asset finite useful life nature business activity reporting unit identi intangible asset finite useful life patent prod fied segment fresenius medical care fresenius uct distribution right noncompete agreement tech kabi respectively europe latin america asiapacific nology well license manufacture distribute sell north america according regional organizational pharmaceutical drug amortized using straightline structure segment fresenius helios consists report method respective useful life residual val ing unit managed central division ues reviewed impairment see note iii g impair segment fresenius vamed consists reporting unit proj ment useful life patent product distribution right ect business service business least year range year average useful life year fresenius group compare fair value reporting useful life customer relationship vary unit reporting unit carrying amount fair value year average useful life year noncompete agree reporting unit determined using discounted cash flow ments finite useful life useful life ranging approach based upon cash flow expected gener year average useful life year technology ated reporting unit case fair value finite useful live year license manufacture reporting unit less carrying amount difference distribute sell pharmaceutical drug amortized first recorded impairment fair value contractual license period intangible asset goodwill amortized individual estimated useful life evaluate recoverability separable intangible year asset indefinite useful life fresenius group com loss value lasting nature recorded pares fair value intangible asset impairment carrying amount intangible asset fair value deter mined using discounted cash flow approach r goodwill intangible asset method appropriate indefinite useful life recoverability goodwill separable intan resenius group identified intangible asset indefi f gible asset indefinite useful life recorded group nite useful life based analysis consolidated statement financial position verified financial statement relevant factor foreseeable limit period result fresenius group record impairment asset expected generate net cash inflow loss group identified intangible asset indefinite consolidated financial statement excess net fair value identifiable asset according character fresenius group classifies liability cost badwill still existing reassessing financial instrument following class cash purchase price allocation recognized immediately cash equivalent asset recognized carrying amount lia profit loss bilities recognized carrying amount derivative hedging purpose well asset recognized fair value liability lease recognized fair value noncontrolling interest subject leased asset assigned fresenius group based put provision recognized fair value risk reward approach finance lease recognized relationship class category well property plant equipment measured receipt reconciliation consolidated statement finan date present value lease payment long cial position shown tabular form note financial fair value lower leased asset depreciated instrument straightline useful life doubt fresenius group potential obligation purchase whether title asset pa later stage noncontrolling interest held third party certain opportune purchase option asset depreciated consolidated subsidiary obligation lease term shorter impairment loss rec form put provision exercisable thirdparty ognized recoverable amount lower amor owner discretion within specified period outlined tized cost leased asset specific put provision put provision exercised finance lease liability measured present fresenius group would required purchase value future lease payment recognized part thirdparty owner noncontrolling interest financial liability appraised fair value time exercise estimate property plant equipment rented fair value noncontrolling interest subject put provi fresenius group accounted purchase cost depre sion fresenius group recognizes higher net book ciation calculated using straightline method value multiple earnings based historical earnings leasing time expected residual value development stage underlying business factor additionally put provision valued financial instrument external valuation firm external valuation esti financial instrument contract give rise mate fair value using combination discounted cash financial asset one entity financial liability equity flow multiple earnings revenue depending instrument another entity market condition estimated fair value purchase sale financial asset accounted noncontrolling interest subject put provision trading day fresenius group make use also fluctuate discounted cash flow implicit fair value option allows financial asset finan multiple earnings revenue noncontrol cial liability classified fair value profit ling interest subject put provision may ultimately loss upon initial recognition settled could vary significantly fresenius group current following category according international estimate accounting standard financial instrument recognition derivative financial instrument primarily include measurement relevant fresenius group foreign currency forward contract interest rate swap loan receivables financial liability measured amor recognized fair value asset liability consol financial statement tized cost available sale financial asset well financial idated statement financial position change fair liability asset measured fair value consolidated value derivative financial instrument classified fair value statement income category immaterial hedge corresponding underlying asset lia existing fresenius group financial instrument bilities recognized periodically earnings effective reclassified fiscal year portion change fair value cash flow hedge recog nized accumulated comprehensive income loss shareholder equity secured underlying transaction consolidated financial statement general note realized see note financial instrument ineffec past event probable obligation settled tive portion cash flow hedge recognized current earn future amount reliably estimated ings change fair value derivative accrual warranty complaint estimated based designated hedging instrument recognized periodically historical experience earnings tax accrual include obligation current year derivative embedded host contract accounted prior year separate derivative economic characteristic risk closely related host contract x pension liability similar obligation host contract held trading designated fresenius group recognizes underfunded status fair value profit loss embedded derivative defined benefit plan measured difference measured fair value change fair value recog fair value plan asset present value nized income statement benefit obligation liability funded status fresenius group u december measure u liability ment date measuring funded status plan liability generally stated present value change funded status plan resulting actu mally corresponds value product service arial gain loss prior service cost credit delivered general policy shortterm liability recognized component net periodic benefit measured repayment amount cost recognized accumulated comprehen sive income loss net tax year occur v legal contingency fresenius group u corridor method ordinary course fresenius group operation recognition actuarial gain loss actuarial gain fresenius group involved litigation arbitration adminis loss exceed corridor present value trative procedure investigation relating various defined benefit obligation spread expected aspect business fresenius group regularly analyzes average remaining working life employee participat current information claim probable loss ing plan adjusted fluctuation provides accrual matter including estimated actuarial gain loss prior service cost sub legal expense consulting service connection sequently recognized component net periodic benefit matter appropriate fresenius group utilizes cost realized internal legal department well external resource assessment making decision regarding need debt issuance cost loss accrual fresenius group considers degree debt issuance cost related recognized debt liability probability unfavorable outcome ability presented consolidated statement financial position make reasonable estimate amount loss direct deduction carrying amount debt filing suit formal assertion claim liability cost amortized term disclosure suit assertion necessarily related obligation indicate accrual loss appropriate w accrued expense financial statement accrual tax obligation recognized present obligation third party arising consolidated financial statement z sharebased compensation plan professional liability claim coverage fmc line standard sharebased payment ag co kgaa assumes responsibility incurred claim fresenius group u modified prospective transition predetermined amount third party insur method transition method ance applies reported liability year represent esti fresenius group recognized compensation cost mated future payment anticipated expense claim sharebased payment subsequent january incurred reported incurred reported based grantdate fair value estimated based historical experience existing claim activity measurement date fair value cashsettled phantom experience includes rate claim incidence stock granted member management board number claim severity cost combined indi executive employee fresenius group except vidual claim expectation estimate reported amount fresenius medical care cashsettled performance share granted member management board bb foreign currency translation executive employee fresenius medical care calculated reporting currency euro substantially asset using monte carlo simulation corresponding liability liability foreign subsidiary use functional cur based measurement date fair value accrued rency euro translated yearend exchange vesting period phantom stock performance share rate income expense translated annual plan average exchange rate fiscal year adjustment due measurement date fair value cashsettled phantom foreign currency translation fluctuation excluded stock granted member management board net earnings reported accumulated com executive employee fresenius medical care calculated prehensive income loss addition translation adjust using binomial model corresponding liability based ments certain intercompany borrowing measurement date fair value accrued vesting longterm nature also reported accumulated period phantom stock plan comprehensive income loss gain loss arising translation foreign aa selfinsurance program currency position well arising elimination insurance program professional product foreign currency intercompany loan recorded general liability auto liability worker compensation claim general administrative expense far medical malpractice claim largest subsidiary considered foreign equity instrument fiscal year fresenius medical care ag co kgaa fmcag co kgaa immaterial gain resulted translation located north america partially selfinsured exchange rate main currency affecting foreign currency translation developed follows yearend exchange rate average exchange rate dec dec u dollar per chinese renminbi per japanese yen per financial statement brazilian real per pound sterling per argentinean peso per swedish krona per russian ruble per consolidated financial statement general note cc fair value hierarchy fresenius group applied following standard threetier fair value hierarchy defined financial far relevant fresenius group business accounting standard board accounting standard codifica first time tion topic fair value measurement disclosure november financial accounting standard classifies asset liability recognized fair value based board fasb issued accounting standard update input used estimating fair value level asu fasb accounting standard codification asc defined observable input quoted price active topic income tax balance sheet classification market level defined input quoted price deferred tax focus reducing complexity active market directly indirectly observable classifying deferred tax balance sheet asu level defined unobservable input little eliminates current requirement organization market data exists therefore requiring company present deferred tax liability asset current non develop assumption threetier fair value hierar current classified balance sheet requires classifi chy used note pension similar obligation cation deferred tax asset liability noncurrent note financial instrument update effective fiscal year interim period within year beginning december earlier dd use estimate adoption permitted fresenius group adopted preparation consolidated financial statement con asu march accordance asu formity u gaap requires management make esti deferred tax recorded december within mate assumption affect reported amount current asset liability reclassified non asset liability disclosure contingent asset current asset liability amount million liability date consolidated financial statement million respectively result deferred tax reported amount income expense netting noncurrent asset liability adjusted reporting period actual result could differ amount million estimate estimate discretionary decision required february fasb issued accounting standard particular position trade account receivable update asu fasb asc topic con deferred tax asset pension liability well solidation amendment consolidation analysis examining recoverability goodwill focus clarifying guidance related evaluation var iou type legal entity limited partnership limited ee receivables management liability corporation certain security transaction con entity fresenius group perform ongoing eval solidation update effective fiscal year interim uations financial situation customer gener period within year beginning december ally require collateral customer fresenius group implemented asu supply product provision service approximately full retrospective basis information given regard fresenius group sale earned variable interest entity vies segment subject regulation governmental health care pro fresenius medical care year based gram medicare medicaid administered united vies see note iii b composition group state government respectively financial statement ff recent pronouncement applied resenius group prepared consolidated financial f statement december conformity u gaap applied fiscal year beginning janu ary u gaap applied earlier vol untary basis consolidated financial statement gg recent pronouncement yet applied sale volume cost determining discounted cash fresenius group longer voluntarily prepare flow fresenius group utilizes every reporting unit u gaap financial statement starting fiscal year approved threeyear budget projection year interim period within year beginning january corresponding growth rate remaining year therefore new u gaap standard applied growth rate fresenius medical care future financial statement fresenius group fresenius kabi fresenius helios fresenius exception asu fresenius group vamed growth rate main reporting unit apply new u gaap standard earlier fresenius medical care fresenius kabi north amer ica carrying amount goodwill december iv critical accounting policy million million respectively opinion management fresenius group respectively projection year po following accounting policy topic critical sible due historical experience stability consolidated financial statement present economic envi fresenius group business largely independent ronment influence judgment well uncer economic cycle discount factor determined tainties affect also important factor wacc respective reporting unit fresenius considered looking present future operating earn medical care wacc consisted basic rate ings fresenius group wacc business segment fresenius kabi con sisted basic rate respectively recoverability goodwill intangible asset basic rate adjusted countryspecific risk rate indefinite useful life appropriate factor reflect higher risk associated amount goodwill nonamortizable intangible cash flow recent material acquisition asset indefinite useful life represents considerable appropriately integrated within reporting unit part total asset fresenius group decem wacc tax reporting unit ber december carrying amount fresenius medical care ranged million million respectively waccs tax reporting unit fresenius kabi represented respectively total asset ranged business segment impairment test goodwill nonamortizable intan fresenius helios fresenius vamed wacc tax gible asset indefinite useful life performed least countryspecific adjustment occur year event occur circumstance change waccs tax main reporting unit fresenius would indicate carrying amount might impaired medical care fresenius kabi north america impairment test respectively fair value report determine possible impairment asset ing unit less carrying amount difference fair value reporting unit compared carrying recorded impairment fair value goodwill amount fair value reporting unit determined first increase wacc tax percentage using estimated future cash flow unit discounted point would resulted recognition weightedaverage cost capital wacc specific impairment loss reporting unit estimating discounted future cash flow additional sensitivity analysis carried involves significant assumption especially regarding future reporting unit latin america increase wacc financial statement reimbursement rate sale price number treatment reporting unit fresenius medical care latin america carrying amount goodwill december consolidated financial statement general note million percentage point would led rec c allowance doubtful account ognition impairment loss million increase trade account receivable significant asset allow wacc percentage point would led ance doubtful account significant estimate made fair value equal carrying amount increase management trade account receivable mil wacc reporting unit fresenius kabi latin america lion million respectively net carrying amount goodwill december allowance approximately receivables derive million percentage point would led recog business segment fresenius medical care mainly nition impairment loss million increase relate dialysis care business north america wacc percentage point would led fair major debtor debtor group trade account value equal carrying amount ceivable u medicare medicaid health care pro prolonged downturn health care industry gram private insurer united state lower expected increase reimbursement rate december fresenius price higher expected cost providing group significant risk concentration due inter health care service manufacture product could national heterogeneous customer structure adversely affect estimated future cash flow certain allowance doubtful account million country segment future adverse change reporting million december december unit economic environment could affect discount rate respectively decrease estimated future cash flow allowance estimate comprised customer decline reporting unit economic environment could specific evaluation regarding payment history current result impairment charge goodwill intangi financial stability applicable countryspecific risk ble asset indefinite useful life could materially overdue receivables fresenius group opinion adversely affect fresenius group future operating result analysis result wellfounded estimate allowance doubtful account time time fresenius group b legal contingency review change collection experience ensure fresenius group involved several legal matter arising appropriateness allowance ordinary course business outcome valuation allowance calculated specific circum matter may material effect financial posi stance indicate amount collectible tion result operation cash flow fresenius effort collect receivable including use outside group detail please see note commitment con source required allowed exhausted tingent liability appropriate management review receivable deemed fresenius group regularly analyzes current informa uncollectible considered bad debt written tion claim probable loss provides accru deterioration aging receivables collection al matter including estimated expense legal difficulty could require fresenius group increase service appropriate fresenius group utilizes inter estimate allowance doubtful account additional nal legal department well external resource expense uncollectible receivables could significant assessment making decision regarding need negative impact future operating result loss accrual fresenius group considers degree probability unfavorable outcome ability make financial statement reasonable estimate amount loss filing suit formal assertion claim disclosure suit assertion necessarily indicate accrual loss appropriate consolidated financial statement selfinsurance program furthermore third quarter fresenius medial insurance program professional product care sold european marketing right certain renal general liability auto liability worker compensation pharmaceutical joint venture vifor fresenius medical claim medical malpractice claim largest subsidiary care renal pharma transaction resulted aftertax fresenius medical care ag co kgaa located north gain million u million america partially selfinsured professional liability claim detail regarding accounting policy fresenius kabi selfinsurance program please see note iii aa self resenius kabi spent million acquisition f insurance program including acquisition u pharmaceutical manufac turing plant line seven iv drug acquisition divestiture investment fresenius kabi spent million acquisition mainly related purchase share acquisition divestiture investment medione medical gmbh germany purchase fresenius group made acquisition investment share fresenius kabi bidiphar jsc vietnam purchase intangible asset million mil february fresenius kabi sold german lion respectively amount oncology compounding business september million paid cash million assumed obli fresenius kabi also sold compounding business au gations tralia transaction resulted book gain imma terial amount respectively fresenius medical care fresenius medical care spent million acquisi fresenius helios tions mainly acquisition dialysis clinic well fresenius helios spent million acquisition purchase medical technology company focusing mainly purchase share klinikum treatment lung cardiac failure niederberg ggmbh germany purchase patient clinic fresenius medical care spent million acqui sitions mainly purchase dialysis clinic acquisition idc salud holding slu loan associated company third quarter quirónsalud fresenius medical care sold dialysis service business january fresenius helios closed acquisi venezuela transaction resulted aftertax loss tion share capital idc salud holding slu million u million quirónsalud spain largest private hospital operator quirónsalud consolidated february billion total purchase price amount billion already financed mean different debt instrument paid cash see note debt capital lease obligation senior note convertible bond balance million paid form financial statement consolidated financial statement general note new share fresenius se co kgaa issued impact fresenius group january authorized capital excluding consolidated financial statement subscription right resulting acquisition due relatively short interval closing fiscal year acquisition accounted date acquisition reporting date purchase applying purchase method accordingly price allocation yet completed based first internal consolidated starting date acquisition analysis fresenius group expects opening balance excess total acquisition cost fair value sheet quirónsalud include goodwill billion net asset acquired million million tangible asset billion well net asset bil respectively lion quirónsalud generated sale billion purchase price allocation yet finalized ebitda million acquisition current year based preliminary pur quirónsaluds network comprised hospital chase price allocation recognized goodwill mil outpatient center occupational risk prevention lion intangible asset million center located economically important area spain goodwill million attributable acquisition company employee offer full fresenius medical care million fresenius kabis spectrum inpatient outpatient care acquisition acquisition million acquisition fresenius fresenius helios strengthens position europe largest helios private hospital operator goodwill asset representing future economic benefit arising asset acquired business com fresenius helios spent million acquisition bination individually identified separately mainly purchase minority interest recognized goodwill arises principally due fair value helios kreiskrankenhaus gotha ohrdruf gmbh sub placed established stream future cash flow versus sequent purchase price payment acquisition building similar business patient facility purchase share acquisition completed included lungenklinik diekholzen ggmbh germany consolidated statement first time full year con tributed following amount development sale fresenius vamed earnings fresenius vamed spent million acquisition mainly participation expansion thermal spa million austria sale ebitda ebit corporate net interest segment corporate includes con net income attributable solidation intercompany transaction amount shareholder fresenius se co kgaa million acquisition increased total asset fresenius group million financial statement special item primarily relating transaction consolidated financial statement note consolidated cost sale statement income cost sale comprised following special item million net income attributable shareholder fresenius se cost service manufacturing cost product co kgaa year amount million related good include special item cost longterm production contract net income attributable shareholder fresenius se cost sale co kgaa year amount million cost sale included special item relating fresenius kabis efficiency program integration acquired rhön hospital cost material divestment two helios hospital fiscal year cost material comprised cost raw material led additional disposal gain supply purchased component cost purchased special item following impact consol service idated statement income million net income cost raw material supply attributable purchased component shareholder fresenius cost purchased service million ebit se co kgaa cost material earnings adjusted cost fresenius kabis efficiency program personnel expense integration cost cost sale selling general administrative expense acquired rhön hospital disposal gain divestment research development expense included personnel two helios hospital expense million million earnings according u gaap respectively personnel expense comprised following sale sale activity follows million wage salary social security contribution cost retirement million pension social assistance sale service thereof retirement pension less patient service bad debt provision personnel expense sale product related good sale longterm production contract fresenius group annual average number employee sale function shown sale sale analysis business segment region shown production financial statement service segment information page administration sale marketing research development total employee per caput consolidated financial statement note consolidated statement income selling general administrative tax expense selling expense million million income tax mainly included expenditure sale personnel income income tax attributable following million million geographic region general administrative expense amounted million million related expendi million tures administrative function attributable research germany international development production selling total operating income million million operating expense million million included selling general income tax expense benefit consisted administrative expense following current deferred income net interest million tax tax tax net interest million included interest expense germany million interest income million main international portion interest expense resulted fresenius total group financial liability recognized fair value consolidated statement income see note financial instrument main portion interest income germany resulted valuation call option connection international total convertible bond fresenius se co kgaa valuation derivative embedded convertible bond fresenius medical care ag co kgaa see note reconciliation expected actual income tax convertible bond expense shown following table expected corpo rate income tax expense computed applying ger man corporation tax rate including solidarity surcharge effective trade tax rate income income tax respective combined tax rate fiscal year million computed expected income tax expense increase reduction income tax resulting item recognized tax purpose tax rate differential taxfree income financial statement tax prior year change valuation allowance deferred tax asset noncontrolling interest income tax effective tax rate consolidated financial statement deferred tax net operating loss tax effect temporary difference loss car expiration net operating loss follows ried forward prior year gave rise deferred tax asset liability december presented fiscal year million million deferred tax asset account receivable inventory current asset noncurrent asset accrued expense shortterm liability thereafter liability total benefit obligation loss carried forward prior year deferred tax asset valuation allowance total remaining operating loss million less valuation allowance mainly carried forward unlimited period deferred tax asset based upon level historical taxable income deferred tax liability projection future taxable income management account receivable fresenius group belief likely inventory fresenius group realize benefit deductible current asset difference net existing valuation allowance noncurrent asset december accrued expense shortterm liability liability unrecognized tax benefit deferred tax liability fresenius se co kgaa subsidiary subject net deferred tax tax audit germany united state regular basis ongoing tax audit jurisdiction consolidated statement financial position net germany fresenius se co kgaa subsid amount deferred tax asset liability included iaries tax year currently follows audit tax authority fresenius group recognized million recorded current proposed adjustment audit deferred tax asset period consolidated financial statement fiscal year deferred tax liability open audit net deferred tax fresenius kabi usa audit action fiscal year concluded regard federal tax december fresenius medical care currently tax audit progress two fresenius recognized deferred tax liability approximately bil kabi usa relevant federal state partly com financial statement lion undistributed earnings foreign subsidiary pleted proposed adjustment deemed immaterial earnings considered indefinitely reinvested fiscal year open audit regard federal tax consolidated financial statement note consolidated statement income united state fresenius medical care fiscal year noncontrolling interest open audit fresenius medical care december noncontrolling interest net income holding inc also subject audit various state jurisdic fresenius group follows tions number audit progress various year open audit various state jurisdiction million expected result federal state income tax audit noncontrolling interest fresenius medical care recognized consolidated financial statement noncontrolling interest subsidiary fresenius se co kgaa number fresenius vamed country outside germany united state also noncontrolling interest business segment subject tax audit fresenius group estimate fresenius medical care effect tax audit material consolidated fresenius kabi financial statement fresenius helios following table show change unrecognized fresenius vamed total noncontrolling interest tax benefit year million fiscal year fresenius medical care ag co kgaa balance january paid dividend noncontrolling interest amount increase unrecognized tax benefit prior period million million decrease unrecognized tax benefit prior period increase unrecognized tax benefit current period change related settlement tax authority earnings per share foreign currency translation following table show earnings per share including balance december excluding dilutive effect stock option issued included balance december mil numerator million net income attributable lion unrecognized tax benefit would affect shareholder effective tax rate recognized fresenius group cur fresenius se co kgaa less effect dilution due rently position forecast timing magnitude fresenius medical care share change unrecognized tax benefit income available fresenius group policy recognize interest ordinary share denominator number share penalty related tax position income tax expense weightedaverage number fiscal year fresenius group recognized ordinary share outstanding gain million interest penalty fresenius potentially dilutive ordinary share group total accrual million tax related inter weightedaverage number ordinary est penalty december share outstanding ssuming dilution basic earnings per share fully diluted earnings per share financial statement consolidated financial statement note consolidated trade account receivable statement financial position december trade account receivable follows cash cash equivalent million december cash cash equivalent follows trade account receivable less allowance doubtful account trade account receivable net million cash time deposit security trade account receivable due within one year maturity day total cash cash equivalent following table show development allow ance doubtful account fiscal year december december ear million marked fund million million respectively allowance doubtful account beginning year included cash cash equivalent change valuation allowance recorded fresenius group operates multicurrency notional consolidated statement income pooling cash management system fresenius group writeoffs recovery amount previously writtenoff met condition offset balance within cash pool foreign currency translation reporting purpose december million allowance doubtful account december million cash balance end year equivalent amount overdraft balance offset thereof million related fresenius medical care following table show aging analysis trade account receivable allowance doubtful account month month month month million overdue overdue overdue overdue overdue total trade account receivable less allowance doubtful account trade account receivable net inventory resenius group obliged purchase company f december inventory consisted following approximately million raw material pur chased component fixed term million million committed december term raw material purchased component agreement run one eight year advance payment work process customer million million financial statement finished good less reserve offset inventory exclusively related inventory net longterm construction contract consolidated financial statement note consolidated statement financial position current noncurrent asset december current noncurrent asset comprised following thereof thereof million shortterm shortterm equity investment tax receivables insurance recovery fresenius medical care prepaid expense advance made prepaid rent insurance asset nonfinancial asset net derivative financial instrument security longterm loan account receivable resulting german hospital law leasing receivables cost report receivable medicare medicaid investment deposit discount asset financial asset net asset net allowance asset gross equity investment mainly related joint venture approval evidenced letter written granting named vifor fresenius medical care renal pharma ltd authority fresenius helios already received fresenius medical care galenica ltd item insurance recovery fresenius medical care income million million resulting includes recognized amount relation naturalyte valuation included selling general adminis granuflo agreement principle partially offset trative expense consolidated statement income accrued settlement amount recorded accrued expense security longterm loan included million financial see note accrued expense information see asset available sale december note commitment contingent liability million mainly relating share fund fiscal year depreciation immaterial account receivable resulting german hospital amount depreciation recognized non law primarily contain approved yet received ear current asset marked subsidy fresenius helios operation financial statement consolidated financial statement property plant equipment december acquisition manufacturing cost well accumulated depreciation property plant equipment consisted following acquisition manufacturing cost foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec land land facility building improvement machinery equipment machinery equipment rental equipment capital lease construction progress property plant equipment depreciation foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec land land facility building improvement machinery equipment machinery equipment rental equipment capital lease construction progress property plant equipment acquisition manufacturing cost foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec land land facility building improvement machinery equipment machinery equipment rental equipment capital lease construction progress property plant equipment depreciation financial statement foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec land land facility building improvement machinery equipment machinery equipment rental equipment capital lease construction progress property plant equipment consolidated financial statement note consolidated statement financial position carrying amount million dec dec land land facility building improvement machinery equipment machinery equipment rental equipment capital lease construction progress property plant equipment depreciation property plant equipment year leasing million million respec machinery equipment december tively allocated within cost sale selling general included medical device fresenius medical care administrative expense research development fresenius kabi lease customer patient physician expense depending upon use asset operating lease amount million million respectively goodwill intangible asset december acquisition cost accumulated amortization intangible asset consisted following acquisition cost foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec goodwill patent product distribution right technology customer relationship tradenames software noncompete agreement management contract goodwill intangible asset financial statement consolidated financial statement amortization foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec goodwill patent product distribution right technology customer relationship tradenames software noncompete agreement management contract goodwill intangible asset acquisition cost foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec goodwill patent product distribution right technology customer relationship tradenames software noncompete agreement management contract goodwill intangible asset amortization foreign change currency entity reclassifi million jan translation consolidated addition cation disposal dec goodwill patent product distribution right technology customer relationship tradenames software noncompete agreement management contract goodwill intangible asset financial statement consolidated financial statement note consolidated statement financial position carrying amount million dec dec goodwill patent product distribution right technology customer relationship tradenames software noncompete agreement management contract goodwill intangible asset split intangible asset amortizable nonamortizable intangible asset shown following table amortizable intangible asset dec dec acquisition accumulated carrying acquisition accumulated carrying million cost amortization amount cost amortization amount patent product distribution right technology customer relationship software noncompete agreement total estimated regular amortization expense intangible asset next five year shown following table million estimated amortization expense financial statement consolidated financial statement nonamortizable intangible asset dec dec acquisition accumulated carrying acquisition accumulated carrying million cost amortization amount cost amortization amount tradenames management contract goodwill total amortization intangible asset amounted million administrative expense research development million year respectively expense depending upon use asset allocated within cost sale selling general carrying amount goodwill developed follows fresenius fresenius fresenius fresenius corporate fresenius million medical care kabi helios vamed group carrying amount january addition disposal reclassification foreign currency translation carrying amount december addition disposal reclassification foreign currency translation carrying amount december december december medical care well million million carrying amount nonamortizable intangible respectively fresenius kabi asset million million fresenius accrued expense december accrued expense consisted following thereof thereof million shortterm shortterm personnel expense selfinsurance program settlement fresenius medical care litigation risk financial statement warranty complaint accrued expense accrued expense consolidated financial statement note consolidated statement financial position following table show development accrued expense fiscal year foreign change currency entity reclassifi million jan translation consolidated addition cation utilized reversed dec personnel expense selfinsurance program settlement fresenius medical care litigation risk warranty complaint accrued expense total accrual personnel expense mainly refer bonus sev medical care recorded current noncurrent erance payment contribution partial retirement share asset see note current noncurrent asset based compensation plan holiday entitlement information see note commitment con item settlement fresenius medical care includes tingent liability accrual related naturalyte granuflo agreement detail regarding accrual selfinsurance pro principle partially offset insurance recovery fresenius gram please see note iii aa selfinsurance program liability december liability consisted following thereof thereof million shortterm shortterm tax liability account receivable credit balance advance payment customer liability nonfinancial liability personnel liability invoice outstanding derivative financial instrument debtor credit balance accrued variable payment outstanding acquisition account payable resulting german hospital law bonus discount interest liability leasing liability legal matter advisory audit fee commission liability financial statement financial liability liability consolidated financial statement account payable resulting german hospital law december total amount longterm primarily contain earmarked subsidy received yet liability million thereof million due spent appropriately fresenius helios amount yet one five year million due five spent appropriately classified liability year statement financial position line item long term accrued expense longterm liability million also included longterm accrued expense million december debt capital lease obligation shortterm debt december shortterm debt consisted following book value million fresenius se co kgaa commercial paper fresenius medical care ag co kgaa commercial paper shortterm debt shortterm debt shortterm debt mainly consists borrowing cer december tain entity fresenius group line credit respectively commercial bank average interest rate borrowing longterm debt capital lease bligations december longterm debt capital lease obligation net debt issuance cost consisted following million fresenius medical care credit agreement senior credit agreement schuldschein loan account receivable facility fresenius medical care capital lease obligation subtotal less current portion longterm debt capital lease obligation less current portion maturity longterm debt capital lease obligation shown following table financial statement million year year year year fresenius medical care credit agreement senior credit agreement schuldschein loan account receivable facility fresenius medical care capital lease obligation longterm debt capital lease obligation consolidated financial statement note consolidated statement financial position aggregate annual repayment applicable listed fresenius medical care credit agreement longterm debt capital lease obligation year fresenius medical care ag co kgaa fmcag co kgaa subsequent december originally entered syndicated credit facility fresenius medical care credit agreement us million fiscal year million year period large group bank institutional investor collectively lender october november fresenius medical care credit agreement amended increase total credit facility approximately us million extend term subsequent year additional two year october total following table show available outstanding resenius medical care credit agree amount f ment december maximum amount available balance outstanding million million revolving credit u u million u million revolving credit million million u term loan u million u million term loan million million total less financing cost total maximum amount available balance outstanding million million revolving credit u u million u million revolving credit million million u term loan u million u million term loan million million total less financing cost total december fresenius medical care term loan facility u million also scheduled credit agreement consisted mature october quarterly repayment u million began january remaining financial statement revolving credit facility approximately u mil balance outstanding due october lion comprising u million revolving facility term loan facility million scheduled mature million revolving facility due october quarterly repayment million payable october began january remaining balance standing due october consolidated financial statement interest credit facility fresenius medical december fmcag co kgaa sub care option rate equal either libor euribor sidiaries compliance covenant applicable plus applicable margin ii base fresenius medical care credit agreement rate defined fresenius medical care credit addition december december agreement plus applicable margin december fresenius medical care letter credit outstanding u dollar denominated tranche amount u million u dollar revolving standing fresenius medical care credit credit facility included part agreement weightedaverage interest rate balance outstanding date reduce available respectively december borrowing applicable revolving credit facility euro denominated tranche interest rate respectively senior credit agreement applicable margin variable depends december fresenius se co kgaa various fresenius medical care consolidated leverage ratio subsidiary entered delayed draw syndicated credit ratio consolidated funded debt less cash agreement senior credit agreement original cash equivalent consolidated ebitda term amount u million million since defined fresenius medical care credit initial funding senior credit agreement june agreement additional tranche added furthermore sched addition scheduled principal payment indebtedness uled amortization payment well voluntary repayment outstanding fresenius medical care credit made january term loan b facility agreement would reduced portion net cash pro million voluntarily prepaid february ceeds received certain sale asset revolving credit facility term loan obligation fresenius medical care tranche extended ahead time two year new credit agreement secured pledge capital stock maturity date june february certain material subsidiary favor lender term loan b u million voluntarily prepaid fresenius medical care credit agreement con october senior credit agreement tains affirmative negative covenant respect fmc increased incremental term loan mil ag co kgaa subsidiary certain circum lion incremental revolving facility million stance covenant limit indebtedness investment incremental facility used fund acquisition restrict creation lien fresenius medical resenius helios idc salud holding slu quirónsalud f care credit agreement fmcag co kgaa required incremental facility funded january comply maximum leverage ratio ratio net debt resenius medical care ebitda additionally f credit agreement provides limitation dividend share buyback similar payment dividend paid subject annual basket million increase subsequent year additional dividend restricted payment may made subject maintenance maximum leverage ratio default financial statement outstanding balance fresenius medical care credit agreement becomes immediately due payable option lender consolidated financial statement note consolidated statement financial position following table show available outstanding amount senior credit agreement december maximum amount available balance outstanding million million revolving credit facility million million revolving credit facility u u million u million term loan million million term loan u u million u million total less financing cost total include incremental facility amount billion funded january maximum amount available balance outstanding million million revolving credit facility million million revolving credit facility u u million u million term loan million million term loan u u million u million term loan b u u million u million total less financing cost total december senior credit agreement interest rate borrowing senior consisted credit agreement rate equal either libor euribor applicable plus applicable margin ii revolving credit facility aggregate principal base rate defined senior credit agreement amount u million million final plus applicable margin applicable margin variable repayment date june depends leverage ratio defined term loan facility u million million senior credit agreement together term loan term loan amortizes addition scheduled principal payment indebted repayable quarterly installment final maturity ness outstanding senior credit agreement june would reduced mandatory prepayment case certain sale asset incurrence certain addi tional indebtedness amount prepaid depending proceeds generated respective transaction financial statement consolidated financial statement senior credit agreement guaranteed condition covenant include limitation lien sale fresenius se co kgaa fresenius proserve gmbh fresenius asset incurrence debt among item kabi ag certain u subsidiary fresenius kabi ag senior credit agreement also includes financial covenant obligation senior credit agreement defined agreement require fresenius se secured pledge capital stock certain material sub co kgaa subsidiary fresenius medical sidiaries fresenius kabi ag since funding incre care subsidiary maintain maximum leverage mental facility february additionally secured ratio minimum interest coverage ratio pledge capital stock helios kliniken gmbh december fresenius group favor lender compliance covenant senior credit senior credit agreement contains number agreement customary affirmative negative covenant certain schuldschein loan december schuldschein loan fresenius group net debt issuance cost consisted following book value million notional amount maturity interest rate fresenius se co kgaa million april fresenius se co kgaa million aug fresenius se co kgaa million aug variable fresenius se co kgaa million april fresenius se co kgaa million april variable fresenius se co kgaa million april variable fresenius se co kgaa million april fresenius se co kgaa million october fresenius se co kgaa million october variable fresenius se co kgaa million april fresenius se co kgaa million april variable fresenius se co kgaa million april variable fresenius se co kgaa million april variable fresenius u finance ii inc u million march variable fresenius u finance ii inc u million march fresenius u finance ii inc u million march variable fresenius u finance ii inc u million march schuldschein loan financial statement consolidated financial statement note consolidated statement financial position december fresenius se co kgaa issued account receivable facility million schuldschein loan tranche fresenius medical care year fixed variable interest rate transaction december asset securitization facility closed january proceeds used account receivable facility fresenius medical care general corporate purpose finance acquisition refinanced term expiring december resenius helios idc salud holding slu quirónsalud f available borrowing u million schuldschein loan issued fresenius se co kgaa december outstanding borrowing amount million due april account receivable facility u million repaid scheduled million u million million march fresenius u finance ii inc issued amount shown debt issuance cost included schuldschein loan total amount u million fresenius medical care also letter credit outstanding consist fixed floating rate tranche term five account receivable facility amount seven year u million million december u schuldschein loan issued fresenius se co kgaa million million december letter total amount million due credit included part balance august shown current portion longterm standing december however reduce avail debt capital lease obligation consolidated able borrowing account receivable facility statement financial position account receivable facility certain receiv march fresenius se co kgaa voluntarily ter ables sold nmc funding corp nmc funding minated floating rate tranche schuldschein loan due wholly owned subsidiary fresenius medical care nmc amount million ahead time funding assigns percentage ownership interest furthermore company made termination offer account receivable certain bank investor investor fixed rate million schuldschein loan term account receivable facility nmc funding maturing april accepted million retains right time recall outstand respective repayment made april ing transferred interest account receivable con moreover april new schuldschein loan matur sequently receivables remain consolidated state ities issued total amount ment financial position proceeds million transfer percentage ownership interest recorded schuldschein loan fresenius se co kgaa longterm debt guaranteed fresenius kabi ag fresenius proserve nmc funding pay interest bank investor calcu gmbh schuldschein loan fresenius u finance ii lated based commercial paper rate particular inc guaranteed fresenius se co kgaa fresenius tranche selected december inter kabi ag fresenius proserve gmbh est rate respectively refinancing december fresenius group fee include legal cost bank fee amortized compliance covenant schuldschein term facility loan financial statement consolidated financial statement credit line source liquidity fresenius medical care also issue shortterm note addition financial liability described million commercial paper program fresenius group maintains additional credit facility december commercial paper program utilized utilized part fresenius medical care ag co kgaa utilized reporting date december additional amount million financial cushion resulting unutilized credit facility additional financing u million pro approximately billion vided using fresenius medical care account receivable syndicated credit facility accounted billion facility utilized amount u portion comprised fresenius medical care million december credit agreement amount u million million senior credit agreement amount bridge financing facility u million million furthermore bilateral december fresenius se co kgaa facility approximately million available loan facility million outstanding include credit facility certain entity fresenius entered bridge financing facility september group arranged commercial bank credit purpose acquisition idc salud holding slu facility used general corporate purpose usu quirónsalud original amount million ally unsecured reduced million december following addition fresenius se co kgaa commercial issuance longterm financial instrument form paper program million shortterm senior note convertible bond january note issued december commercial bridge financing facility cancelled prematurely without paper program fresenius se co kgaa utilized utilized amount million senior note december senior note fresenius group net debt issuance cost consisted following book value million notional amount maturity interest rate fresenius se co kgaa million feb fresenius se co kgaa million apr fresenius se co kgaa million july fresenius se co kgaa million feb fresenius se co kgaa million feb fresenius u finance ii inc u million feb fresenius u finance ii inc u million jan fmc finance vi sa million july fmc finance vii sa million feb fmc finance viii sa million oct variable fmc finance viii sa million sept financial statement fmc finance viii sa million july fresenius medical care u finance inc u million july fresenius medical care u finance inc u million feb fresenius medical care u finance ii inc u million sept fresenius medical care u finance ii inc u million july fresenius medical care u finance ii inc u million oct fresenius medical care u finance ii inc u million jan fresenius medical care u finance ii inc u million oct senior note senior note included table unsecured consolidated financial statement note consolidated statement financial position inance bv july original issuer fresenius f demand immediate repayment plus interest decem replaced issuer outstanding senior ber fresenius group compliance note successor issuer fresenius se co kgaa covenant resenius u finance ii inc senior note issued f january fresenius finance ireland plc due july repaid wholly owned subsidiary fresenius se co kgaa issued scheduled refinanced issuance commercial senior note aggregate volume billion paper consist four tranche maturity five seven ten september fresenius u finance ii inc fifteen year proceeds used fund acquisition issued u million senior note maturity idc salud holding slu quirónsalud general seven year senior note coupon corporate purpose issued par proceeds offering used senior note issued fmc finance vi sa refinance commercial paper due july senior note issued senior note fresenius u finance ii inc guar fmc finance viii sa due october anteed fresenius se co kgaa fresenius kabi ag repaid scheduled fresenius proserve gmbh senior note fresenius se senior note issued fresenius medical care u resenius kabi ag fresenius co kgaa guaranteed f finance inc due july proserve gmbh holder right request reclassified shortterm debt shown current por issuer repurchase senior note principal tion senior note consolidated statement finan plus accrued interest upon occurrence change con cial position trol followed decline rating respective senior senior note fresenius medical care u finance note senior note fresenius se co kgaa inc fresenius medical care u finance ii inc fmc finance fresenius u finance ii inc may redeemed prior vii sa fmc finance viii sa wholly owned subsidiary maturity option issuer price fmcag co kgaa guaranteed senior basis jointly plus accrued interest premium calculated pursuant severally fmcag co kgaa fresenius medical care term indenture observance certain holding inc fresenius medical care deutschland notice period gmbh holder right request respec fresenius se co kgaa agreed number cove tive issuer repurchase respective senior note nants provide protection bondholder partly principal plus accrued interest upon occurrence restrict scope action fresenius se co kgaa change control fmcag co kgaa followed subsidiary excluding fresenius medical care ag co decline rating respective senior note issu kgaa fmcag co kgaa subsidiary er may redeem senior note time covenant include restriction debt principal plus accrued interest premium calculated raised mortgaging sale asset entering pursuant term indenture sale leaseback transaction well merger consol fmcag co kgaa agreed number covenant idations company restriction provide protection holder certain lifted automatically rating respective senior circumstance limit ability fmcag co kgaa note reached investment grade event noncom subsidiary among thing incur debt incur lien pliance certain term senior note bondhold engage sale leaseback transaction merge con financial statement er owning aggregate outstanding solidate company sell asset decem senior note entitled call senior note ber fmcag co kgaa subsidiary compliance covenant senior note consolidated financial statement convertible bond december convertible bond fresenius group net debt issuance cost consisted following book value million current notional amount maturity coupon conversion price fresenius se co kgaa million sept fresenius medical care ag co kgaa million jan convertible bond fair value derivative embedded convertible fresenius group pension plan structured accor bond fresenius se co kgaa million dance differing legal economic fiscal circum december derivative embedded convert stance country fresenius group currently ible bond fresenius medical care ag co kgaa fmc two type plan defined benefit defined contribution ag co kgaa recognized fair value plan general plan benefit defined benefit plan million december fresenius se co kgaa based portion employee year service fmcag co kgaa purchased stock option call final salary plan benefit defined contribution plan option secure future fair value fluctuation determined amount contribution employee derivative call option also aggregate employer may limited legis fair value million million respectively lation return earned investment december contribution conversion cashsettled increase upon retirement defined benefit plan fresenius fresenius share price fresenius medical care share group required pay defined benefit former employ price conversion price would offset corre ee defined benefit become due defined benefit sponding value increase call option plan may funded unfunded fresenius group derivative embedded convertible bond funded defined benefit plan particular united state call option recognized noncurrent liability norway united kingdom netherlands austria asset consolidated statement financial position unfunded defined benefit plan located germany january fresenius se co kgaa issued france million equityneutral convertible bond due actuarial assumption generally determine benefit obli convertible bond bear interest issue gations defined benefit plan actuarial calculation price fixed nominal value corresponding require use estimate main factor used annual yield maturity initial con actuarial calculation affecting level benefit obliga version price represents premium tions assumption life expectancy discount rate reference share price fresenius share future salary benefit level fresenius group proceeds used fund acquisition funded plan asset set aside meet future payment idc salud holding slu quirónsalud general cor obligation estimated return plan asset recog porate purpose nized income respective period actuarial gain financial statement loss generated variation actu pension similar obligation arial assumption difference actual estimated projected benefit obligation return general fresenius group recognizes pension cost related pension liability current future benefit quali fied current former employee fresenius group consolidated financial statement note consolidated statement financial position plan asset year company pension liability major part pension liability relates germany impacted actuarial gain loss december pension liability related defined benefit plan fresenius group recognized germany predominantly rest exposed certain risk besides general actuarial risk e g europe north america beneficiary longevity risk interest rate risk fresenius located north america germany remainder group exposed market risk well investment risk throughout rest europe continent case fresenius group funded plan defined pension liability amount benefit obligation offset fair value plan asset million relate versorgungsordnung der fresenius funded status pension liability recognized con unternehmen established pension plan solidated statement financial position defined benefit applies german entity fresenius obligation exceeds fair value plan asset asset group except fresenius helios pension plan recognized reported asset consolidated updated version pension plan minor amend statement financial position fair value plan asset ments remaining pension liability relate individual exceeds defined benefit obligation fresenius plan fresenius helios entity germany non group right reimbursement fund right german group entity reduce future payment fund plan benefit generally based employee defined contribution plan fresenius group year service final salary consistent predominant pay defined contribution independent third party practice germany benefit obligation german directed employee employee service life entity fresenius group unfunded german pen satisfies obligation fresenius group sion plan separate pension fund employee employee retains right contribu fresenius medical care holding inc fmch subsid tions made employee vested portion iary fresenius medical care ag co kgaa defined fresenius group paid contribution upon leaving benefit pension plan employee united state fresenius group fresenius group main defined supplemental executive retirement plan first contribution plan united state quarter fmch curtailed pension plan curtailment amendment substantially employee defined benefit pension plan eligible participate plan benefit frozen december projected benefit obligation pbo curtailment date additional defined benefit fresenius group million future service earned fmch retained million included million million funded employee benefit obligation curtailment date plan asset million million year fmch contributes plan covering united state covered pension provision furthermore pension lia employee least minimum amount required bility contains benefit obligation offered sub employee retirement income security act amended sidiaries fresenius medical care amount mil fmchs minimum funding requirement u lion million current portion pension million million addition compulsory con liability amount million million tributions fmch voluntarily provided u million recognized consolidated statement financial position million defined benefit plan expected funding within shortterm accrued expense shortterm u million million financial statement liability noncurrent portion million million recorded pension liability consolidated financial statement benefit plan offered subsidiary fresenius pension liability developed follows medical care outside united state germany million france contain separate benefit obligation total pen benefit obligation beginning sion liability plan million year change entity consolidated million december respectively foreign currency translation consists pension asset thousand thou amendment sand recognized noncurrent asset current service cost pension liability million million rec prior service cost ognized current liability line item shortterm interest cost contribution plan participant accrued expense shortterm liability non transfer plan participant current pension liability million million curtailment settlement plan recorded pension liability consoli actuarial loss gain dated statement financial position benefit paid fresenius group benefit obligation relating fully plan amendment partly funded pension plan million benefit obliga benefit obligation end year thereof vested tions relating unfunded pension plan million following table show change benefit obliga fair value plan asset beginning tions change plan asset funded status year change entity consolidated pension plan pension liability benefit paid shown foreign currency translation change benefit obligation represent payment amendment made funded unfunded plan ben actual return cost plan asset efits paid shown change plan asset include contribution employer benefit payment fresenius group funded benefit contribution plan participant plan settlement transfer plan participant benefit paid fair value plan asset end year funded status december benefit plan offered subsidiary pension liability december financial statement consolidated financial statement note consolidated statement financial position december december fair sensitivity analysis value plan asset exceed benefit obligation increase decrease principal actuarial assumption pension plan percentage point would affect pension liability discount rate plan based upon yield december follows portfolio highly rated debt instrument maturity pp pp mirror plan benefit obligation fresenius group development pension liability million increase decrease discount rate weighted average plan based discount rate rate compensation increase upon benefit obligation rate pension increase following weightedaverage assumption utilized determining benefit obligation december sensitivity analysis calculated based average duration pension obligation determined decem discount rate rate compensation increase ber calculation performed isolated rate pension increase significant actuarial parameter order show effect fair value pension liability separately mainly change discount factor well inflation sensitivity analysis compensation increase pen mortality assumption used actuarial computation sion increase excludes u pension plan resulted actuarial gain decreased fair frozen therefore affected change value defined benefit obligation unrecognized actuarial two actuarial assumption loss million million explanatory note december accumulated benefit obligation defined benefit pension plan million million following table relates pension plan pro jected benefit obligation accumulated benefit obliga tions excess plan asset million projected benefit obligation pbo accumulated benefit obligation abo fair value plan asset financial statement consolidated financial statement pretax change comprehensive income loss relating pension liability year shown following table foreign currency million jan reclassification addition translation dec actuarial gain loss prior service cost transition obligation adjustment related pension liability effect recognized consolidated statement income foreign currency million jan reclassification addition translation dec actuarial gain loss prior service cost transition obligation adjustment related pension liability effect recognized consolidated statement income tax effect comprehensive income decem defined benefit pension plan net periodic benefit cost ber see note comprehensive income million million comprised loss following component fresenius group expects following amount amortized comprehensive income net million periodic pension cost year service cost interest cost expected return plan asset million amortization unrealized actuarial loss net actuarial gain loss amortization prior service cost prior service cost amortization transition obligation settlement loss net periodic benefit cost net periodic benefit cost allocated personnel expense within cost sale selling general administrative expense well research development expense allocation depends upon area beneficiary employed financial statement consolidated financial statement note consolidated statement financial position following weightedaverage assumption used following table show expected benefit payment determining net periodic benefit cost year ended next year december fiscal year million discount rate expected return plan asset rate compensation increase rate pension increase total expected benefit payment december december weightedaverage duration defined benefit obligation year fair value plan asset category follows december december quoted price active market significant quoted price significant identical observable active market observable asset input identical asset input million level level total level level total category plan asset equity investment index fund equity investment fixed income investment government security corporate bond fixed income investment total category mainly comprised lowcost equity index fund actively managed track p p russell msci emerging market index morgan stanley international eafe index category primarily comprised fixed income investment u government government sponsored entity category primarily represents investment grade bond u issuer diverse industry category mainly comprised private placement bond well collateralized mortgage obligation well cash fund invest treasury obligation directly treasury backed obligation category mainly represents cash money market fund well mutual fund comprised high grade corporate bond method input used measure fair value plan corporate bond bond valued based mar asset follows ket quote date statement financial position index fund valued based market quote cash stated nominal value equal fair value financial statement equity investment valued market price u treasury money market fund well money date statement financial position market mutual fund valued market price government bond valued based market price level market quote level consolidated financial statement plan investment policy strategy following schedule describes fresenius group alloca united state tion funded plan fresenius group periodically review assumption allocation allocation target longterm expected return pension plan asset part allocation assumption review range reasonable expected equity investment fixed income investment investment return pension plan whole deter incl real estate mined based analysis expected future return total asset class weighted allocation asset range return developed relies forecast include actuarial firm expected longterm rate overall expected longterm rate return asset return significant asset class economic indicator fresenius group amount compounded annually broadmarket historical benchmark expected contribution plan asset fiscal year expec return correlation volatility asset class ted amount million result expected rate return pension plan asset u pension plan year defined contribution plan overall investment strategy u pension plan fresenius group total expense defined contribution achieve mix approximately investment plan million million longterm growth income cash cash amount million related contribution fresenius equivalent investment income cash cash equivalent group several public supplementary pension fund used nearterm benefit payment investment employee fresenius helios million related governed investment policy include well diversified contribution u saving plan employee index fund fund targeting index performance fresenius medical care holding inc join target allocation plan asset united state following applicable collective bargaining agreement range around equity longterm fresenius group pay contribution given number u corporate bond investment policy considers employee fresenius helios rheinische zusatzversor time horizon invested fund gungskasse supplementary pension fund five year total portfolio measured public supplementary pension fund together referred custom index reflects asset class benchmark zvk öd complement statutory retirement pension target asset allocation plan policy allow invest given employee multiple participating entity ments security fresenius medical care ag co kgaa insured zvk öds plan multiemployer related party security performance bench plan employee entitled statutory benefit mark separate asset class include p regardless contributed amount index p mid cap index russell index msci eafe index msci emerging market index barclays capital longcorporate bond index financial statement consolidated financial statement note consolidated statement financial position plan operates payasyouearn system based noncontrolling interest subject put provision changed applying collection rate given part gross remuneration follows paid contribution accounted personnel expense within cost sale selling general admin million istrative expense amounted million noncontrolling interest subject put provision january million thereof million million noncontrolling interest subject payment rheinische zusatzversorgungskasse put provision profit versorgungsanstalt de bundes und der länder zusatz purchase noncontrolling interest subject put provision versorgungskasse wiesbaden supplementary pension dividend payment fund currency effect change disclosure either irrelevant immaterial noncontrolling interest subject put provision december plan supplementary pension fund necessary information cannot obtained zvk öds without undue cost effort noncontrolling interest subject put provision u saving plan employee deposit applied fresenius medical care december pay annual maximum u december put option year old u fresenius aggregate purchase obligation million medical care match employee deposit million respectively exercisable two put option maximum company contribution employee exercised total consideration million pay fresenius medical care total expense defined six put option total consideration million contribution plan year ended december million million respectively noncontrolling interest subject put provision noncontrolling interest december noncontrolling interest subject put provision fresenius group follows noncontrolling interest subject put provision million noncontrolling interest fresenius group potential obligation purchase subject put provision noncontrolling interest held third party certain fresenius medical care ag co kgaa consolidated subsidiary obligation noncontrolling interest subject put provision form put provision exercisable thirdparty vamed ag owner discretion within specified period outlined noncontrolling interest subject put provision specific put provision put provision exer business segment cised fresenius group would required purchase fresenius medical care part thirdparty owner noncontrolling interest fresenius kabi fresenius helios appraised fair value time exercise fresenius vamed total noncontrolling interest subject put provision financial statement financial information relating fresenius medical care see consolidated segment reporting page consolidated financial statement noncontrolling interest subject put provision changed eliminate fractional amount cash contribution follows authorization exercised issue price significantly stock exchange price already million listed share time issue price fixed final noncontrolling interest subject effect general partner furthermore case capi put provision january tal increase cash contribution proportionate noncontrolling interest subject put provision profit amount share issued exclusion subscription stock option right may exceed subscribed capital purchase noncontrolling interest exclusion subscription right context use subject put provision authorization concerning issuance sale dividend payment currency effect change share fresenius se co kgaa issuance right noncontrolling interest subject authorize bind subscription share put provision december fresenius se co kgaa taken consideration duration authorized capital utili fresenius se co kgaa zation case subscription kind subscription shareholder equity right excluded order acquire company part company participation company subscribed capital authorization granted concerning exclusion development subscribed capital subscription right used fresenius management se january subscribed capital fresenius se extent proportional amount total co kgaa consisted bearer ordinary share number share issued exclusion subscription fiscal year stock option right exceed subscribed capital exercised consequently december exclusion subscription right context use subscribed capital fresenius se co kgaa consisted authorization concerning issuance sale bearer ordinary share share issued share fresenius se co kgaa issuance nonpar value share proportionate amount right authorize bind subscription share subscribed capital per share fresenius se co kgaa taken consideration course acquisition quirónsalud janu duration authorized capital ary new share fresenius se co kgaa utilization issued authorized capital excluding subscription right new share full dividend entitlement conditional capital fiscal year following conditional capital exist order fulfill subscription right stock option plan authorized capital fresenius se co kgaa conditional capital stock option december general partner fresenius man plan conditional capital ii stock option plan agement se authorized approval super conditional capital iv stock option plan see visory board may increase fresenius se note sharebased compensation plan co kgaas subscribed capital total amount another conditional capital iii exists authorization financial statement single multiple issue new bearer issue option bearer bond convertible bond accord ordinary share cash contribution contribu ingly general partner authorized approval tions kind authorized capital thereof january supervisory board may issue option utilized issuance bearer bond convertible bearer bond share thereby reducing authorized capital several time total nominal amount billion fulfill granted subscription right subscribed subscription right must granted shareholder capital fresenius se co kgaa increased conditionally principle defined case general partner autho issuing rized consent supervisory board decide new bearer ordinary share conditional capital increase exclusion shareholder subscription right e g consolidated financial statement note consolidated statement financial position shall implemented extent holder long form settlement used cash issued convertible bond cash issued warrant new bearer ordinary share shall participate profit option bond exercise conversion option right start fiscal year issued following table show development conditional capital ordinary share conditional capital fresenius ag stock option plan conditional capital ii fresenius se stock option plan conditional capital iii option bearer bond convertible bond conditional capital iv fresenius se co kgaa stock option plan total conditional capital january fresenius ag stock option plan option exercised fresenius se stock option plan option exercised total conditional capital december december conditional capital composed follows ordinary share conditional capital fresenius ag stock option plan conditional capital ii fresenius se stock option plan conditional capital iii option bearer bond convertible bond conditional capital iv fresenius se co kgaa stock option plan total conditional capital december capital reserve dividend capital reserve comprised premium paid german stock corporation act aktg amount issue share exercise stock option additional dividend available distribution shareholder based paidin capital upon unconsolidated retained earnings fresenius se co kgaa reported statement financial position reserve determined accordance german commercial reserve comprised earnings generated code hgb group entity prior year extent may dividend per bearer ordinary distributed share approved fresenius se co kgaas sharehold er annual general meeting paid total divi dend payment million financial statement consolidated financial statement comprehensive income loss currency translation foreign subsidiary financial comprehensive income loss comprised statement effect measuring financial instrument amount recognized directly equity net tax resulting fair value well change benefit obligation change component comprehensive income loss follows total total non non controlling non controlling amount interest controlling interest million tax tax effect tax interest tax cash flow hedge change unrealized gain loss realized gain loss due reclassification change fair value available sale financial asset foreign currency translation actuarial loss defined benefit pension plan total change cash flow hedge change unrealized gain loss realized gain loss due reclassification change fair value available sale financial asset foreign currency translation actuarial gain loss defined benefit pension plan total change change accumulated comprehensive income loss net tax component follows actuarial change gain loss fair value defined total total available foreign benefit non non non cash flow sale financial currency pension controlling controlling controlling million hedge asset translation plan interest interest interest balance december comprehensive income loss reclassification amount reclassified accumulated comprehensive income loss comprehensive income loss net balance december comprehensive income loss reclassification amount reclassified accumulated comprehensive income loss comprehensive income loss net balance december financial statement consolidated financial statement note consolidated statement financial position reclassification accumulated comprehensive income loss net income follows amount gain loss r eclassified accumulated comprehensive income loss affected line item million consolidated statement income detail accumulated comprehensive income loss component cash flow hedge interest rate contract interest income expense foreign exchange contract cost sale selling general foreign exchange contract administrative expense foreign exchange contract interest income expense comprehensive income loss tax expense benefit comprehensive income loss net amortization defined benefit pension item prior service cost transition obligation actuarial gain loss defined benefit pension plan comprehensive income loss tax expense benefit comprehensive income loss net total reclassification period gain shown negative sign loss positive sign net periodic benefit cost allocated personnel expense within cost sale selling general administrative expense well research development expense financial statement consolidated financial statement note material noteworthy described mat ters described fresenius group belief commitment contingent loss reasonably possible estimable estimate liability loss range loss exposure provided matter described fresenius group belief operating lease rental payment loss probability remote loss range po fresenius group subsidiary lease hospital office sible loss cannot reasonably estimated time manufacturing building well machinery equipment outcome litigation legal matter always diffi various lease agreement expiring date cult predict accurately outcome consis rental expense recorded operating lease tent fresenius group view merit occur year ended december million fresenius group belief valid defense million respectively legal matter pending defending vigor future minimum rental payment noncancellable ously nevertheless possible resolution one operating lease year subsequent december legal matter currently pending threatened could material adverse effect business result operation financial condition fiscal year million commercial litigation product liability litigation april u judicial panel multidistrict litigation ordered numerous lawsuit pending var thereafter iou federal court alleging wrongful death personal total injury claim fresenius medical care holding inc fmch certain affiliate relating fmchs acid december future investment commitment concentrate product naturalyte granuflo trans existed year acquisition contract ferred consolidated pretrial management purpose hospital projected cost million thereof consolidated multidistrict litigation united state million relates year district court district massachusetts see besides mentioned contingent liability fresenius granuflo naturalyte dialysate product liability amount commitment immaterial litigation case md massachusetts state court st louis city missouri court subsequently legal regulatory matter established similar consolidated litigation case fresenius group routinely involved claim lawsuit filed massachusetts county court st louis city court regulatory tax audit investigation legal see consolidated fresenius case case micv matter arising part ordinary course massachusetts superior court middlesex business providing health care service product county lawsuit alleged generally inadequate legal matter fresenius group currently deems labeling warning product caused harm patient addition similar case filed state financial statement court february fmch reached com mittee plaintiff counsel reported court consolidated financial statement note agreement principle settlement potentially case applicable policy including reimbursement fmch liti agreement principle called fmch pay us gation defense cost incurred agreement principle million settlement fund exchange release reached affected carrier confirmed substantially plaintiff claim subject fmchs coverage litigation impact commitment fund right void settlement certain condition includ u million settlement plaintiff ing plaintiff rejected settlement certain complaint granuflo naturalyte distribution rejecters met certain criterion subse litigation named combination fresenius medical care ag quently agreed fmch plaintiff committee co kgaa fresenius medical care management ag ordered court plaintiff may enforce settlement fresenius se co kgaa fresenius management se compel payment fmch total case electing defendant addition fmch domestic united participate settlement dismissed court state affiliate agreement principle provides dis prejudice voluntarily involuntarily come comprise missal release claim encompassing european case court entering lone pine order defendant requiring plaintiff pain dismissal four institutional plaintiff filed complaint elected participate settlement submit specific justi fmch affiliate state deceptive practice statute fication satisfactory court complaint resting certain background allegation common including attorney verification certain material factual rep granuflo naturalyte personal injury litigation seek resentations expert medical opinion relating causation ing remedy repayment sum paid fmch attribut fmch may elect void settlement may able granuflo naturalyte product case threshold achieved plaintiff non implicate different legal standard theory liability participation fall suspect pattern incidental change form potential recovery personal injury date likely trial case participating set litigation claim extinguished tlement may resume scheduled discretion personal injury litigation settlement described respective court fmch expects combination four plaintiff attorney general state election participate notice dismissal already sub kentucky louisiana mississippi commercial insur mitted lone pine procedure result confirmation ance company blue cross blue shield louisiana settlement private capacity see state mississippi ex rel hood v fmchs affected insurer agreed fund u fresenius medical care holding inc cv million settlement fund settlement voided chancery court desoto county state louisiana ex reservation right regarding certain coverage issue caldwell louisiana health service indemnity company among fmch insurer fmch v fresenius medical care airline civ usdc accrued net expense us million consummation mass commonwealth kentucky ex rel beshear v settlement including legal fee anticipated fresenius medical care holding inc et al ci cost circuit court franklin county subsequent agreement principle fmchs insurer aig group initiated action declaratory judg ment new york state court advancing various argument reducing amount coverage obligation fmch financial statement filed action massachusetts state court seeking com pel aig group carrier honor obligation consolidated financial statement litigation potential exposure internal review fresenius medical care holding qui tam complaint fresenius medical care received communication alleging massachusetts conduct country outside united state may february whistleblower relator action violate u foreign corrupt practice act fcpa false claim act fresenius medical care hold antibribery law audit corporate governance ings inc fmch unsealed order united state committee fresenius medical care supervisory board district court district massachusetts served conducting investigation assistance indepen relator see united state ex rel chris drennen v dent counsel fresenius medical care voluntarily advised fresenius medical care holding inc civ u security exchange commission sec mass united state intervene initially u department justice doj fresenius medical care case relators complaint first filed seal investigation dialogue sec doj february alleged fmch sought received ongoing fresenius medical care cooperating reimbursement government payors serum ferritin government investigation multiple form hepatitis b laboratory test conduct identified may result monetary medically unnecessary properly ordered phy penalty sanction fcpa anti sician discovery relators complaint closed may bribery law addition fresenius medical care ability october united state attorney moved conduct business certain jurisdiction could negatively intervene relators complaint respect impacted fresenius medical care previously recorded certain hepatitis b surface antigen test performed prior nonmaterial accrual identified matter given cur medicare reimbursement rule test rent status investigation remediation activity changed fmch opposed government motion inter fresenius medical care cannot reasonably estimate range vene remains undecided possible loss may result identified matter final outcome investigation remediation subpoena fresenius vascular care activity october office inspector general fresenius medical care implementing enhancement united state department health human service anticorruption compliance program including internal oig issued subpoena fresenius medical care seeking control related compliance international antibribery information utilization invoicing fresenius law fresenius medical care continues fully committed vascular care facility whole period beginning fcpa antibribery law compliance fresenius medical care acquisition american access care llc aac october fresenius medical subpoena maryland care cooperating government inquiry august fresenius medical care holding inc fmch managed united state attorney eastern received subpoena united state attorney district new york allegation aac arising district maryland inquiring fmchs contractual arrange district connecticut florida rhode island relating ments hospital physician including contract utilization invoicing settled relating management inpatient acute dialysis ser vice fmch cooperating investigation financial statement civil complaint hawaii july attorney general hawaii issued civil complaint hawaii false claim act alleging conspiracy pursuant certain liberty subsidiary fresenius medical care holding inc fmch overbilled consolidated financial statement note hawaii medicaid liberty epogen administration subpoena new york hawaii medicaid patient period november fresenius medical care holding prior time fmchs acquisition inc fmch received subpoena united state liberty see hawaii v liberty dialysis hawaii llc et al attorney eastern district new york seeking docu case hawaii st circuit state ments information relating operation shiel alleges liberty acted unlawfully relying incorrect medical laboratory inc fmch acquired october unauthorized billing guidance provided liberty course cooperating investigation xerox state healthcare llc acted hawaii con preparing respond subpoena fmch identified tracted administrator medicaid program reimburse falsification misrepresentation document submitted ment operation relevant period amount shiel salesperson relate integrity certain overpayment claimed state approximately invoice submitted shiel laboratory testing patient us million state seek civil remedy interest fine longterm care facility february fresenius penalty liberty fmch hawaii medical care north america initiated termination false claim act substantially excess overpayment employee notification united state attorney fmch filed thirdparty claim contribution indemnifi termination circumstance fmch cannot time cation xerox state false claim act complaint determine scope conduct implicated filed liberty initiated administrative action chal employee termination whether related liability lenging state recoupment alleged overpayment payment penalty false claim act might sum currently owed liberty civil litigation material administrative action proceeding parallel subpoena american kidney fund cm litigation subpoena colorado new york january fresenius medical care holding august november respectively fresenius inc fmch received subpoena united state attor medical care holding inc fmch received subpoena ney district massachusetts inquiring fmchs united state attorney district colorado interaction relationship american kidney eastern district new york inquiring fmchs fund akf including fmchs charitable contribution participation management dialysis facility joint ven fund fund financial assistance patient tures physician partner fmch cooperating insurance premium fmch cooperating investigation investigation december center medicare medicaid service cm published interim final rule ifr subpoena texas dallas titled medicare program condition coverage end june fresenius medical care holding inc stage renal disease facilitiesthird party payment fmch received subpoena united state attorney would amend condition coverage dialysis provider northern district texas dallas seeking information like fresenius medical care north america fmcna use management pharmaceutical including ifr would effectively enabled insurer reject premium velphoro well fmchs interaction davita payment made patient received grant individual healthcare partner inc fmch understands subpoena market coverage akf therefore could isclosed davita relates investigation previously resulted patient losing individual market cov financial statement investigation encompasses davita amgen erage loss individual market coverage sanofi fmch cooperating investigation patient would material adverse impact operating result fmch consolidated financial statement january federal district court texas time time fresenius group party may responding litigation initiated patient advocacy threatened litigation arbitration claim group dialysis provider including fmcna preliminarily assessment arising ordinary course business enjoined cm implementing ifr dialysis patient management regularly analyzes current information includ citizen v burrwell ed texas sherman div prelimi ing applicable fresenius group defense insur nary injunction based cm failure follow appropriate ance coverage necessary provides accrual noticeandcomment procedure adopting ifr pre probable liability eventual disposition matter liminary injunction remain place absence fresenius group like health care provider contrary ruling district appellate court insurance plan supplier conduct operation time extent cm continue intense government regulation scrutiny must comply contest preliminary injunction unclear also unclear regulation relate govern safety effi whether cm elect pursue notice cacy medical product supply marketing comment another rule related topic operation distribution product operation manufacturing charitable assistance program also receiving increased facility laboratory clinic health care facility attention state regulator including state department environmental occupational health safety insurance result may regulatory framework respect development manufacture marketing dis differs state state even absence ifr tribution medical product compliance main similar administrative action insurer expected con tained fresenius group could subject significant tinue take step thwart premium assistance provided adverse regulatory action u food drug admin fresenius medical care patient individual market istration fda comparable regulatory authority outside plan well insurance coverage united state regulatory action could include warn ing letter enforcement notice fda subpoena nevada comparable foreign regulatory authority may require november fresenius kabi oncology limited fkol fresenius group expend significant time resource received subpoena u department justice order implement appropriate corrective action doj u attorney district nevada subpoena fresenius group address matter raised warning request document connection january letter enforcement notice satisfaction inspection u food drug administration fda fda comparable regulatory authority outside fkols plant active pharmaceutical ingredient kalyani united state regulatory authority could take additional india inspection resulted warning letter action including product recall injunction fda july subpoena mark doj criminal distribution product operation manufacturing plant civil investigation connection seek infor civil penalty seizure fresenius group product mation throughout fresenius kabi group criminal prosecution fmch currently engaged ancillary subpoena january doj requested remediation effort respect one pending fda warn additional historic information data ing letter fresenius kabi respect two pending fda ancilliary subpoena june november resenius group must also comply warning letter f doj requested information fresenius kabi law united state including federal antikick usa fresenius kabi ag without changing focus back statute federal false claim act federal stark financial statement investigation fresenius kabi fully cooperates law federal civil monetary penalty law federal governmental investigation foreign corrupt practice act well federal consolidated financial statement note state fraud abuse law applicable law regulation may accountability act health information technology amended enforcement agency court may make economic clinical health act foreign cor interpretation differ fresenius group interpreta rupt practice act among law comparable law tions manner conduct business country enforcement become high priority federal govern physician hospital participant health ment state addition provision care industry also subject large number lawsuit false claim act authorizing payment portion alleging professional negligence malpractice product recovery party bringing suit encourage private liability worker compensation related claim many plaintiff commence whistleblower action virtue involve large claim significant defense cost regulatory environment fresenius group business fresenius group currently subject activity practice subject extensive review suit due nature business expects regulatory authority private party continuing type lawsuit may continue although fresenius audit subpoena inquiry claim litigation relat group maintains insurance level belief ing fresenius group compliance applicable law prudent cannot assure coverage limit ade regulation fresenius group may always quate insurance cover asserted claim suc aware inquiry action begun particularly cessful claim fresenius group sub case whistleblower action initially filed sidiaries excess insurance coverage could material court seal adverse effect upon result operation fresenius group operates many facility handle claim regardless merit eventual outcome could personal health information patient beneficiary material adverse effect fresenius group reputa throughout united state part world tion business decentralized system often difficult maintain fresenius group also claim asserted desired level oversight control thousand lawsuit filed relating alleged patent individual employed many affiliated company infringement business acquired divested fresenius group relies upon management structure regu claim suit relate operation busi latory legal resource effective operation ness acquisition divestiture transaction compliance program direct manage monitor activ fresenius group appropriate asserted ities employee occasion fresenius group claim claim indemnification successful claim may identify instance employee agent delib fresenius group subsidiary could erately recklessly inadvertently contravene fresenius material adverse effect upon business financial group policy violate applicable law action condition result operation claim person may subject fresenius group subsid regardless merit eventual outcome could iaries liability antikickback statute stark material adverse effect fresenius group reputation law false claim act health insurance portability business financial statement consolidated financial statement financial instrument relationship class category well reconciliation statement financial position line item shown following table category financial liability asset financial liability measured fair value measured consolidated available sale loan receivables amortized cost statement income financial asset relating category cash cash ash cash c equivalent equivalent asset trade account receiv current non recognized able incl receivables current financial asset carrying amount loan related party ther current non current financial asset asset hare fund recognized fair value liability rade account payable ongterm capital l recognized hortterm account pay lease obligation carrying amount able related party hortterm debt incl shortterm loan related party ongterm debt l excluding capital lease class obligation enior note onvertible bond c shortterm longterm financial liability liability shortterm recognized longterm financial fair value liability noncontrolling oncontrolling n interest subject interest subject put provision put provision recognized fair value derivative ther current non ther current non hedging purpose current financial asset current financial asset ther shortterm ther shortterm longterm financial longterm financial liability liability financial statement consolidated financial statement note valuation financial instrument carrying amount financial instrument december classified category follows million loan receivables financial liability measured amortized cost asset measured fair value consolidated statement income liability measured fair value consolidated statement income available sale financial asset relating category financial instrument designated fair value profit loss upon initial recognition following table present carrying amount fair value well fair value hierarchy level fresenius group financial instrument december classified class fair value carrying fair value carrying fair value million hierarchy level amount amount cash cash equivalent asset recognized carrying amount asset recognized fair value liability recognized carrying amount liability recognized fair value noncontrolling interest subject put provision recognized fair value derivative hedging purpose significant method assumption used estimate class asset recognized fair value comprised fair value financial instrument well classification share fund fair value asset calcu fair value measurement according threetier fair lated basis market information fair value value hierarchy follows available sale financial asset quoted active market cash cash equivalent stated nominal value based price quotation periodend date level equal fair value therefore class classified level nominal value predominant part shortterm class liability recognized carrying amount clas financial instrument trade account receivable sified hierarchy level payable current financial asset shortterm finan derivative embedded convertible bond cial liability shortterm debt represents carrying included class liability recognized fair value amount reasonable estimate fair value due fair value embedded derivative calculated using relatively short period maturity instrument difference market value convertible fair value major longterm financial instrument bond market value adequate straight bond calculated basis market information financial discounted market interest rate reporting financial statement instrument market quote available mea date level furthermore class comprises variable pay sured market quote reporting date fair ments outstanding acquisition recognized value longterm financial liability calculated fair value estimation individual fair value present value respective future cash flow deter based key input arrangement determine mine present value prevailing interest rate future contingent payment well fresenius group credit spread fresenius group date expectation factor level fresenius group statement financial position used assesses likelihood timing achieving relevant class asset recognized carrying amount clas objective underlying assumption reviewed regu sified hierarchy level larly class classified level consolidated financial statement valuation class noncontrolling interest subject analysis credit risk derivative financial instru put provision recognized fair value determined using ments regular basis valuation derivative finan significant unobservable input therefore classified cial instrument credit risk considered fair level value every individual instrument basis default derivative mainly consisting interest rate swap probability credit default swap spread counter foreign exchange forward contract valued follows party appropriate duration calculation fair value interest rate swap calculated discount credit risk considered valuation done multiplying ing future cash flow basis market interest default probability appropriate duration rate applicable remaining term contract expected discounted cash flow derivative financial date statement financial position determine instrument fair value foreign exchange forward contract con class derivative hedging purpose includes tracted forward rate compared current forward rate call option purchased hedge convert remaining term contract date ible bond fair value call option derived statement financial position result discounted market quote fair value measurement class basis market interest rate prevailing derivative hedging purpose significant observ date statement financial position respective able input used therefore class classified level currency accordance defined fair value hierarchy level fresenius group credit risk incorporated currently indication decrease fair value estimation derivative liability counter value fresenius group financing receivables probable party credit risk adjustment factored valuation therefore allowance credit loss financing derivative asset fresenius group monitor receivables immaterial fair value derivative financial instrument dec dec million asset liability asset liability interest rate contract current interest rate contract noncurrent foreign exchange contract current foreign exchange contract noncurrent derivative designated hedging instrument interest rate contract current interest rate contract noncurrent foreign exchange contract current foreign exchange contract noncurrent derivative embedded convertible bond call option secure convertible bond derivative designated hedging instrument erivatives designated hedging instrument foreign exchange contract call option secure convertible bond designated hedging instrument classified derivative hedging purpose financial statement consolidated financial statement note derivative financial instrument marked market derivative embedded convertible bond reporting period resulting carrying amount equal fair call option secure convertible bond recognized value reporting date noncurrent liability asset consolidated state derivative designated hedging instrument ment financial position derivative qualify hedge accounting also solely entered hedge economic business transac effect financial instrument recorded tions speculative purpose consolidated statement income derivative hedging purpose well deriva net gain loss financial instrument consisted tives embedded convertible bond recognized allowance doubtful account amount gross value within asset amount mil million foreign currency transaction million interest lion liability amount million income million resulted mainly valuation current portion derivative indicated asset call option connection convertible bond preceding table recognized within current asset fresenius se co kgaa valuation derivative consolidated statement financial position embedded convertible bond fresenius medical current portion indicated liability included care ag co kgaa trade account receivable loan shortterm accrued expense shortterm liability related party interest expense million resulted noncurrent portion indicated asset liability mainly financial liability recognized recognized noncurrent asset longterm fair value consolidated statement income accrued expense longterm liability respectively effect derivative designated hedging instrument consolidated statement comprehensive income gain loss recognized gain loss reclassified gain loss comprehensive accumulated recognized income loss comprehensive income consolidated statement million effective portion loss effective portion income interest rate contract foreign exchange contract derivative cash flow hedging relationship amount gain loss recognized consolidated statement income solely relates ineffective portion gain loss recognized gain loss reclassified gain loss comprehensive accumulated recognized income loss comprehensive income consolidated statement million effective portion loss effective portion income interest rate contract foreign exchange contract derivative cash flow hedging relationship amount gain loss recognized consolidated statement financial statement income solely relates ineffective portion consolidated financial statement effect derivative designated hedging instrument consolidated statement comprehensive income gain loss recognized consolidated statement income million interest rate contract foreign exchange contract derivative embedded convertible bond call option secure convertible bond derivative designated hedging instrument loss foreign exchange contract designated course normal business next month hedging instrument recognized consolidated statement interest expense income faced gain underlying transac gain loss foreign exchange contract tions corresponding amount corresponding underlying transaction accounted fresenius group expects recognize net amount cost sale selling general administrative expense million existing loss foreign exchange con net interest gain loss resulting interest tract deferred accumulated comprehensive income rate contract recognized net interest consoli loss consolidated statement income within dated statement income next month interest rate contract fresenius gain thousand loss thou group expects recognize million loss sand available sale financial asset recognized comprehensive income loss following table show cash flow derivative financial instrument expected occur cash flow derivative financial instrument expected period million year year year year derivative designated hedging instrument derivative designated hedging instrument market risk order manage risk interest rate foreign general exchange rate fluctuation fresenius group enters fresenius group exposed effect related foreign certain hedging transaction highly rated financial exchange fluctuation connection international institution authorized management board deriva business activity denominated various currency tive financial instrument entered trading order finance business operation fresenius purpose group issue senior note commercial paper enters general fresenius group conduct derivative financial statement mainly longterm credit agreement schuldschein financial instrument activity control single loan bank due financing activity centralized department fresenius group established fresenius group exposed interest risk caused change guideline derived best practice standard bank variable interest rate risk change fair ing industry risk assessment procedure supervision value statement financial position item bearing fixed concerning use financial derivative guide interest rate line require amongst thing clear segregation duty consolidated financial statement note area execution administration accounting foreign exchange risk management controlling risk limit continuously monitored fresenius group determined euro financial appropriate use hedging instrument adjusted reporting currency therefore foreign exchange translation extent risk resulting fluctuation exchange rate fresenius group defines benchmark individual euro local currency financial state exposure order quantify interest foreign exchange ments foreign subsidiary prepared impact risk benchmark derived achievable sus result operation financial position reported tainable market rate depending individual bench consolidated financial statement mark hedging strategy determined generally imple besides translation risk foreign exchange transaction mented mean micro hedge risk exist mainly relate transaction denominated earnings fresenius group materially foreign currency purchase sale project affected hedge ineffectiveness reporting period since service well intragroup sale product critical term interest foreign exchange deriv fresenius group entity different currency area solely atives mainly matched critical term underlying purpose hedging existing foreseeable foreign exposure exchange transaction exposure fresenius group enters foreign exchange forward contract small scale derivative financial instrument foreign exchange option ensure foreign exchange classification risk result loan foreign currency fresenius reduce credit risk arising derivative group enters foreign exchange swap contract fresenius group concluded master netting agreement december notional amount bank agreement positive negative fair eign exchange contract totaled million foreign value derivative contract could offset one exchange contract entered hedge risk another partner becomes insolvent offsetting operational business connection loan valid transaction aggregate amount obliga eign currency foreign exchange forward contract hedge tions owed receivable equal insolvency risk operational business exclusively recognized occurs party owes larger amount obliged cash flow hedge fair value cash flow hedge pay party difference amount million owed form one net payment hedgeeffective portion change fair value fresenius elect offset fair value derivative foreign exchange forward contract designated financial instrument subject master netting agreement qualified cash flow hedge forecasted product purchase consolidated statement financial position sale reported accumulated comprehensive december december income loss amount subsequently reclassified fresenius group million million deriva earnings component cost sale selling tive financial asset subject netting arrangement general administrative expense period million million derivative financial liability hedged transaction affect earnings subject netting arrangement offsetting derivative december fresenius group party financial instrument would resulted net asset foreign exchange contract maximum maturity million well net liability million million month financial statement december december respectively consolidated financial statement resenius group u cashflowatrisk cfar model f rate swap notional volume million fair order estimate quantify transaction risk value million euro interest rate swap expire foreign currency basis analysis currency year bear average interest rate risk foreign currency cash flow reasonably furthermore fresenius group u dollar expected arise within following month less denominated interest rate swap amount u hedge cfar approach potential currency million million fair value u million fluctuation net exposure shown probability million expire bear average interest distribution based historical volatility correlation rate interest rate option outstanding preceding business day calculation made december notional volume million assuming confidence level holding period fair value thousand expire one year aggregation currency risk risk prehedges used hedge interest rate exposure mitigating effect due correlation transac regard interest rate relevant future tions concerned e overall portfolio risk exposure longterm debt issuance could rise respec generally less sum total underlying individual tive debt actually issued prehedges settled risk december fresenius group cash issuance date corresponding longterm debt flow risk amount million mean proba settlement amount recorded accumulated com bility potential loss relation forecasted prehensive income loss amortized interest expense eign exchange cash flow next month life debt december december higher million fresenius group million million following table show net position foreign respectively related settlement prehedges currency december significant deferred accumulated comprehensive income loss influence fresenius group foreign currency risk net tax interest payable interest receivables connection nominal million swap agreement accrued recorded chinese renminbi adjustment interest expense reporting date con korean cerning interest rate contract unscheduled repayment south african rand renegotiation hedged item may case lead russian ruble brazilian real dedesignation hedging instrument existed point date respective hedging transaction recognized consolidated statement interest rate risk management income fresenius group interest rate risk mainly arise money purpose analyzing impact change rel market capital market transaction group evant reference interest rate fresenius group result financing business activity operation group calculates portion financial debt fresenius group enters interest rate swap bear variable interest rate small scale interest rate option order protect hedged mean interest rate swap option ri risk rising interest rate interest rate ing interest rate particular part liability derivative mainly designated cash flow hedge fresenius group assumes increase reference rate financial statement entered order convert payment based compared actual rate date variable interest rate payment fixed interest rate statement financial position corresponding additional anticipation future longterm debt issuance pre annual interest expense compared net income hedge december euro denominated interest attributable shareholder fresenius se co kgaa consolidated financial statement note analysis show increase relevant performs aging analysis trade account receivable reference rate would effect less detail aging analysis allowance doubtful consolidated net income attributable shareholder account please see note trade account receivable fresenius se co kgaa fresenius se co kgaa share holder equity liquidity risk liquidity risk defined risk company credit risk potentially unable meet financial obligation man fresenius group exposed potential loss regarding agement fresenius group manages liquidity financial instrument event nonperformance group mean effective working capital cash counterparties respect derivative financial instrument management well anticipatory evaluation refi expected counterparty fails meet obli nancing alternative management fresenius group gations counterparties highly rated financial insti belief existing credit facility well cash tutions maximum credit exposure derivative rep generated operating activity additional shortterm resented fair value contract positive borrowing sufficient meet company foresee fair value amounting million foreign exchange able demand liquidity see note debt capital lease derivative maximum credit exposure interest rate obligation derivative million maximum credit risk result following table show future undiscounted con ing use nonderivative financial instrument tractual cash flow including interest resulting recog defined total amount receivables order con nized financial liability well fair value noncon trol credit risk management fresenius group trolling interest subject put provision fair value derivative financial instrument million year year year year longterm debt capital lease obligation including account receivable securitization program shortterm debt senior note convertible bond trade account payable financial liability noncontrolling interest subject put provision derivative financial instrument designated cash flow hedge derivative financial instrument designated hedging instrument total uture interest payment financial liability variable interest rate calculated f using latest interest rate fixed prior december supplementary information due company diversification within health care capital management sector strong market position business seg fresenius group solid financial profile capital ments global growing noncyclical market predict financial statement management includes equity debt principal objec able sustainable cash flow generated allow tive fresenius group capital management optimize reasonable proportion debt e employment weightedaverage cost capital sought extensive mix financial instrument moreover fresenius achieve balanced mix equity debt secure growth group customer generally high credit quality longterm basis capital increase may also con sidered exceptional case instance finance major acquisition consolidated financial statement shareholder equity debt developed follows fresenius group financing strategy reflected credit resenius group covered rating agen rating f shareholder equity cies moody standard poor fitch following table show company rating million dec dec fresenius se co kgaa shareholder equity total asset equity ratio rating fresenius se co kgaa dec dec fresenius se co kgaa subject capital require standard poor ments provided article association fresenius se corporate credit rating bbb bbb co kgaa obligation issue share condi outlook stable stable tional capital relating exercise stock option con moody corporate credit rating baa baa vertible bond basis existing outlook stable stable stock option plan see note sharebased compen fitch sation plan corporate credit rating bbb bb outlook stable stable debt july fitch upgraded credit rating million dec dec bb bbb stable outlook debt total asset debt ratio supplementary information consolidated statement cash flow assuring financial flexibility top priority group consolidated statement cash flow fresenius financing strategy flexibility achieved wide group fiscal year shown range financing instrument high degree diver page sification investor fresenius group maturity profile cash fund reported consolidated statement cash display broad spread maturity high proportion flow consolidated statement financial position medium longterm financing choice financ comprised cash hand check security cash ing instrument market capacity investor diversification bank readily convertible within three month flexibility credit condition existing maturity profile subject insignificant risk change value taken account following table provides additional information leverage ratio basis net debt ebitda key regard consolidated statement cash flow financial figure fresenius group december million leverage ratio received interest interest paid income tax paid fresenius helios used subsidy investment financial statement property plant equipment amount mil lion million offset purchase property plant equipment consolidated statement cash flow consolidated financial statement note cash paid acquisition without investment license resenius group follows business segment f consisted following fresenius medical care million fresenius kabi asset acquired fresenius helios liability assumed fresenius vamed noncontrolling interest corporate note assumed connection acquisition cash paid cash acquired segment corporate mainly comprised cash paid acquisition net holding function fresenius se co kgaa well cash paid investment fresenius netcare gmbh provides service field net cash acquired information technology addition segment corpo cash paid intangible asset net rate includes intersegment consolidation adjustment total cash paid acquisition investment net cash acquired well special item see note special item net purchase intangible asset detail business segment shown page note proceeds sale subsidiary million segment reporting region take account geographi million cal factor similarity market term opportu nities risk allocation particular region based note consolidated segment domicile customer reporting note business segment general key figure used management board assess consolidated segment reporting table shown page segment performance selected way annual report integral part include item income expense fall note area responsibility business segment fresenius group identified business segment management board convinced suitable per fresenius medical care fresenius kabi fresenius helios formance indicator operating income ebit man fresenius vamed corresponds internal orga agement board belief addition operating nizational reporting structure management approach income figure earnings interest tax december depreciation amortization ebitda also help investor key data disclosed conjunction consoli assess ability fresenius group generate cash dated segment reporting correspond key data flow meet financial obligation ebitda figure internal reporting system fresenius group internal also basis assessing fresenius group compliance external reporting accounting correspond term credit agreement e g fresenius key data definition used medical care credit agreement senior credit sale proceeds segment indicative agreement actual sale proceeds agreed third party financial statement administrative service billed accordance service level agreement business segment identified accordance fasb asc topic segment reporting defines segment reporting requirement annual financial statement interim report regard operating business product service business region consolidated financial statement depreciation amortization presented property plant addition key indicator depreciation amorti equipment intangible asset definite useful life zation sale operating cash flow sale respective business segment also disclosed net interest comprised interest expense interest income reconciliation key figure net income attributable shareholder fresenius se consolidated earnings co kgaa defined earnings income tax non controlling interest million operating cash flow cash provided used total ebit reporting segment special item operating activity general corporate expense cash flow acquisition dividend corporate ebit operating cash flow less net capital expenditure group ebit debt comprised bank loan senior note convertible interest expense interest income bond capital lease obligation liability relating outstand income income tax ing acquisition well intercompany liability capital expenditure mainly includes addition property plant equipment reconciliation net debt consolidated acquisition refer purchase share legally statement financial position independent company acquisition business divi million dec dec sion intangible asset e g license key figure shortterm debt shown regard acquisition present contractual pur shortterm debt related party chase price comprising amount paid cash less cash current portion longterm debt acquired debt assumed issuance share whereas capital lease obligation current portion senior note purpose statement cash flow cash longterm debt capital lease purchase price component less acquired cash cash equiv obligation less current portion alents reported senior note less current portion ebitda margin calculated ratio ebitda convertible bond debt sale less cash cash equivalent ebit margin calculated ratio ebit sale net debt return operating asset rooa defined ratio ebit average operating asset operating asset defined total asset less deferred tax asset trade following table show noncurrent asset geo account payable advance payment customer graphical region well guaranteed subsidy million dec dec germany europe excluding germany north america financial statement asiapacific latin america africa total noncurrent asset aggregate amount net noncurrent asset sum noncurrent asset less deferred tax asset less derivative financial instrument consolidated financial statement note fresenius group generated sale mil weightedaverage assumption calculation lion million germany sale united fair value grant fresenius se co kgaa stock state million actual rate option plan made follows million million constant currency july december july december sharebased compensation plan million grant grant grant grant expected dividend yield compensation cost connection riskfree interest rate sharebased compensation plan expected volatility f resenius group life option year year year year fresenius group recognized compensation cost exercise price per option amount million stock option granted since stock incentive plan performancebased fresenius group recognizes compensation cost expected volatility result historical volatility cal vesting period based market value underlying culated expected life option volatility stock grant date determined fair value stock option calculated expense related cashsettled sharebased pay first time since controlled every ment transaction determined based upon fair value year upon issuance new tranche measurement date number phantom stock performance share granted recognized sharebased compensation plan resenius group recognized vesting period f fresenius se co kgaa expense million connection cashsettled description fresenius se co kgaa sharebased payment transaction sharebased compensation plan place resenius se co kgaa three december f fair value stock option sharebased compensation plan place fresenius ag fresenius group u binomial option pricing model stock option plan plan based con determining fair value stock option granted vertible bond stock option based fresenius se stock resenius stock option plan fresenius se co kgaa f option plan plan f resenius se co kgaa medical care ag co kgaa option valuation model require long term incentive program ltip input highly subjective assumption including expec based stock option phantom stock stock ted stock price volatility fresenius group assumption option phantom stock solely granted based upon past experience market trend expe ltip riences entity size similar indus try incorporate effect expected early exercise model early exercise vested option assumed soon share price exceeds exercise price fresenius group stock option characteristic vary significantly traded option change financial statement subjective assumption materially affect fair value option consolidated financial statement ltip fresenius management se determines participant ltip comprised fresenius se co kgaa sop stock option granted stock option plan sop fresenius se exercise price option shall equal volume co kgaa phantom stock plan psp combine weighted average stock market price closing price granting stock option granting phantom nonpar value ordinary bearer share fresenius se stock award entitle holder receive cash payment co kgaa electronic xetra trading deutsche börse upon exercising phantom stock sop ag frankfurt main comparable successor system psp making ltip established last calendar day prior respective grant date standalone legal documentation option granted eightyear term exer cised fouryear vesting period exercise sop option subject condition precedent case sop approved annual gen annual success target within fouryear waiting eral meeting fresenius se co kgaa may period achieved success target achieved fresenius management se originally authorized issue case granting option respective million subscription right amount entitled person either consolidated net income attrib million nonpar value ordinary bearer share fresenius se utable shareholder fresenius se co kgaa according co kgaa may u gaap adjusted extraordinary effect con million option million option stant currency basis increased least per designated member management board annum comparison previous year case within fresenius management se million option waiting period ii case com designated member management directly indi pounded annual growth rate consolidated net income rectly affiliated company except fresenius medical attributable shareholder fresenius se co kgaa care million option designated exec according u gaap adjusted extraordinary effect utive employee fresenius se co kgaa affiliated constant currency basis four year company except fresenius medical care waiting period amount least event connection stock split total volume success target within fouryear waiting period yet granted subscription right increased achieved individual year compounded proportion subscribed capital factor far option annual growth rate option issued case yet granted sop feited proportion nonachievement success applies subset subscription right attrib target within waiting period e one quarter two utable individual group participant stock option quarter three quarter completely performance tar granted stock split came effect get met entitlement participant receive new share adjusted net income attributable shareholder exercise stock option increased fresenius se co kgaa according u gaap currency proportion subscribed capital factor partici adjusted change thereto compared adjusted pant entitled receive three bearer ordinary share net income according u gaap without currency adjust fresenius se co kgaa exercise price reduced ment relevant comparison year shall verified proportionally binding effect case auditor fresenius se financial statement granting option shall occur five annual co kgaa basis audited consolidated financial tranche last monday july first monday statement upon exercise vested option fresenius se december respect new option supervisory co kgaa right grant treasury share lieu board fresenius management se determines stock increasing capital issuance new share option granted member fresenius management expiration waiting period option management board whereas management board respect success target achieved may exercised time outside designated black period consolidated financial statement note psp success target within fouryear waiting period fresenius se co kgaas psp established may achieved individual year compounded together sop line ltip annual growth rate phantom stock award issued award phantom stock granted stock case forfeited proportion nonachievement option grant date phantom stock awarded success target within waitingperiod e one quarter psp may granted member fresenius manage two quarter three quarter completely performance ment management board member manage target met ment directly indirectly affiliated company except adjusted net income attributable shareholder fresenius medical care executive employee fresenius se co kgaa according u gaap currency fresenius se co kgaa affiliated company except adjusted change thereto compared adjusted net fresenius medical care income according u gaap without currency adjust holder phantom stock issued ment relevant comparison year shall verified stock split came effect granted eco binding effect case auditor fresenius se nomic compensation retroactively tripling num co kgaa basis audited consolidated financial ber phantom stock granted stock split statement came effect expiration waiting period exercisable sop supervisory board fresenius phantom stock deemed exercised cashed management se determines phantom stock granted march following end waiting period resenius management management board member f following banking day whereas management board fresenius management se determines participant psp stock option plan phantom stock granted fresenius se adopted plan grant phantom stock award psp entitle subscription right member management board holder receive cash payment phantom stock award executive employee company affiliated com shall entitle holder receive volumeweighted aver panies plan originally million age stock market price closing price nonpar value option could issued carried entitlement ordinary bearer share fresenius se co kgaa elec exclusively obtain million ordinary share tronic xetra trading deutsche börse ag frankfurt stock option granted stock split main comparable successor system last three came effect entitlement participant month prior date phantom stock exercised receive new share exercise stock option exercise phantom stock subject condition increased proportion subscribed capital precedent case annual success target within factor participant entitled receive three fouryear waiting period achieved success target bearer ordinary share fresenius se co kgaa achieved case granting subscription maximum number ordinary share issued increased right respective entitled person either consoli accordingly exercise price reduced proportionally dated net income attributable shareholder fresenius se option granted sevenyear term co kgaa according u gaap adjusted extraordinary exercised threeyear vesting period vesting effect constant currency basis increased option granted mandatorily subject condition financial statement least per annum comparison previous year case annual success target within three case within waiting period ii year vesting period achieved year case compounded annual growth rate consolidated success target achieved consolidated net income net income attributable shareholder fresenius se attributable shareholder fresenius se co kgaa co kgaa according u gaap adjusted extraordinary adjusted extraordinary effect increased least effect constant currency basis four compared respective adjusted net income attrib year waiting period amount least event utable shareholder fresenius se co kgaa pre vious fiscal year year success target consolidated financial statement met onethird option granted shall phantom stock ltip including feit adjusted net income attributable shareholder phantom stock granted member manage fresenius se co kgaa shall calculated basis ment board fresenius management se measure calculation method accounting principle ment date december fair value according u gaap purpose plan total fair value million revalued adjusted net income attributable shareholder fair value change amortized fouryear vesting fresenius se co kgaa determined verified period resenius se co kgaas auditor binding effect f resenius se co kgaa received fiscal year f audit consolidated financial statement cash million exercise stock performance target met year condition option average stock price ordinary share fulfilled stock option may exercised throughout exercise date intrinsic value convertible year exception certain predetermined black bond stock option exercised million period convertible bond outstanding exercisable stock incentive plan replaced sop plan december member last option granted fresenius management se management board held convertible bond december stock option plan outstanding exercisable stock option issued fresenius ag adopted plan mem plan held member fresenius bers management board executive employee management se management board stock option incentive plan based convertible bond issued ltip outstanding december replaced plan last convertible bond member fresenius management se man granted plan eligible employee agement board held stock option right acquire ordinary share fresenius se phantom stock issued ltip outstanding co kgaa bond expire year one third december member fresenius exercised beginning two three four year management se management board held phantom grant date respectively stock stock option transaction summarized follows transaction weighted resenius se co kgaa awarded stock f average number ordinary share number exercise price option option ltip including option dec option exercisable member management board fresenius manage balance ment se weightedaverage exercise price granted exercised weightedaverage fair value total fair forfeited value million amortized four balance year vesting period fresenius se co kgaa also awarded granted exercised forfeited balance financial statement consolidated financial statement note following table provides summary fully vested option outstanding exercisable ordinary share december option ordinary share option outstanding option exercisable range weightedaverage weightedaverage remaining weightedaverage remaining weightedaverage exercise price contractual life exercise price contractual life exercise price number option year number option year december aggregate intrinsic value exer ltip variable compensation program long cisable option ordinary share million term incentive effect pursuant ltip plan december total unrecognized compensation participant may granted socalled performance share cost related nonvested option granted annually semiannually performance plan ltip million cost expected share nonequity cashsettled virtual compensation recognized weightedaverage period year instrument may entitle plan participant receive cash payment depending achievement predefined fresenius medical care ag co kgaa performance target defined well fmc sharebased compensation plan ag co kgaas share price development december fresenius medical care ag co kgaa member management board supervisory fmcag co kgaa various sharebased compensation board due exercise discretion taking plan may either equity cashsettled account individual responsibility performance management board member determine initial value fresenius medical care ag co kgaa longterm grant award management board member incentive program plan participant member man may issuance stock option phan agement board determination made man tom stock fmcag co kgaa longterm incen agement board initial grant value determined tive program ltip longer possible order currency respective participant receives continue enable member management base salary time grant order determine board member management board affiliated number performance share plan participant receives company managerial staff member adequately par respective grant value divided value per ticipate longterm sustained success fresenius performance share time grant mainly financial statement medical care management board supervisory determined based average price fmcag co kgaas board fresenius medical care management ag share period calendar day prior respec approved adopted fmcag co kgaa longterm tive grant date incentive plan ltip successor program number granted performance share may change effective january performance period three year depending level achievement following revenue growth consolidated financial statement ii growth net income attributable shareholder fmc achievement level three performance target ag co kgaa net income growth iii return invested weighted annually onethird determine yearly capital roic improvement target achievement year threeyear performance revenue net income roic determined according period level overall target achievement ifrs euro based full year result revenue growth threeyear performance period determined net income growth purpose plan deter basis mean three average yearly target mined constant currency achievement overall target achievement annual target achievement level reached range revenue growth performance target revenue growth number performance share granted plan individual year threeyear performance participant beginning performance period period revenue growth lead target achieve multiplied level overall target achieve ment level maximum target achievement level ment order determine final number performance reached case revenue growth share least revenue growth range value final number performance share generally deemed degree target achievement linearly interpo earned four year day respective grant vest lated value ing period number vested performance share annual target achievement level net multiplied average fmcag co kgaa share income growth performance target reached net price period day prior lapse four income growth individual year three year vesting period respective resulting amount year performance period case net income growth paid plan participant cash compensation target achievement level also maxi mum target achievement reached fresenius medical care ag co kgaa long term case net income growth least incentive program value degree target achievement determined resenius medical care ag co kgaa may f mean linear interpolation stock option plan sop established reso regard roic improvement annual target lution fresenius medical care ag co kgaas fmcag achievement level reached target roic co kgaa annual general meeting agm sop defined respective year reached target together phantom stock plan estab roic increase percentage lished resolution fresenius medical care management point per year ag fmc management ag management supervisory target achievement level board form fmcag co kgaas long term incentive reached roic fall target roic program incentive program respective year percentage point whereas incentive program participant granted award maximum target achievement level consisted combination stock option phantom reached target roic respective year exceeded stock final grant incentive program percentage point degree target made december award incen achievement determined mean linear interpola tive program subject fouryear vesting period tion roic range value case vesting award granted subject achievement financial statement annual roic target achievement level third year predefined performance target sop estab performance period equal higher roic target lished conditional capital increase million achievement level two previous year subject issue million nonpar value bearer performance period roic target achievement level ordinary share nominal value third year deemed achieved year exercised obtain one ordinary share respective performance period consolidated financial statement note stock option granted incentive program option granted amended plan u eightyear term exercised first time participant nonqualified stock option united fouryear vesting period exercise price stock state internal revenue code amended option option granted incentive program shall amended plan transferable par average stock exchange price frankfurt stock exchange ticipant participant heir may pledged fmcag co kgaas share calendar day assigned otherwise disposed immediately prior grant date stock option granted incentive program u participant transaction nonqualified stock option united state internal first award ltip granted july revenue code amended stock option ltip fmcag co kgaa incentive program transferable participant awarded performance share including per participant heir may pledged assigned formance share awarded member manage disposed otherwise ment board fmc management ag measurement date phantom stock award incentive program weightedaverage fair value total fair entitle holder receive payment euro fmc value million revalued fair value ag co kgaa upon exercise phantom stock payment change total fair value amortized four per phantom share lieu issuance stock shall year vesting period based upon share price frankfurt stock exchange fmcag co kgaa received cash one fmcag co kgaas share exercise date million exercise stock option intrinsic value phantom stock award fiveyear term exer stock option exercised million fmc cised first time fouryear vesting period ag co kgaa recorded related tax benefit million participant u tax payer phantom stock connection cashsettled sharebased payment deemed exercised event month march transaction ltip ltip fmc following end vesting period ag co kgaa recognized expense million million year ending december stock option plan respectively resenius medical care ag co kgaa stock option plan f december management board member amended plan established condi fmc management ag held stock option tional capital increase million subject issue employee fmcag co kgaa held stock option million nonpar value bearer ordinary share various stockbased compensation plan nominal value exercised fresenius medical care obtain one ordinary share connection share split december management board member effected principal amount adjusted fmc management ag held phantom stock proportion share capital capital increase employee fmcag co kgaa held phantom million issue million new non stock incentive program par value bearer ordinary share december management board member december grant issued fmc management ag held performance share amended plan option granted employee fmcag co kgaa held perfor financial statement plan exercisable december mance share ltip consolidated financial statement table provides reconciliation option outstanding december compared december weightedaverage number option exercise price thousand balance december option ordinary share granted exercised forfeited balance december option ordinary share following table provides summary fully vested option ordinary share outstanding exercisable december weightedaverage number remaining weightedaverage aggregate option contractual life exercise price intrinsic value thousand year million option ordinary share december total unrecognized compensation cost related nonvested option granted plan million cost expected recognized weightedaverage period year financial statement consolidated financial statement note related party transaction million million paid fresenius prof dr h c roland berger partner roland berger management se compensation management board strategy consultant holding gmbh member supervisory board general partner fee supervisory board fresenius management se reimbursement outof pocket expense december fresenius se co kgaa may outstanding liability payable fresenius roland berger group provide consulting service management se amount million december fresenius group discussion million consisting mainly pension obligation approval supervisory board fresenius management management board compensation se fresenius se co kgaa fresenius group paid aforementioned payment net amount addi million affiliated company roland berger tion vat insurance tax paid group consulting service rendered fresenius medical care provided unsecured loan dr dieter schenk deputy chairman supervisory amount million associated company board fresenius management se partner customary condition fully repaid international law firm noerr llp provides legal ser june vice fresenius group discussion approval mandate supervisory board subsequent event fresenius management se fresenius group paid january fresenius helios closed acquisition million law firm legal service rendered share capital idc salud holding slu million amount paid includes also pay quirónsalud spain largest private hospital operator ments service already provided purchase price billion detail paid acquisition financing see note acquisition divestiture investment debt capital lease obli gations senior note convertible bond fresenius se co kgaa shareholder equity significant change fresenius group operating environment following end fiscal year february event material importance asset liability financial position result operation group occurred following end fiscal year financial statement consolidated financial statement note accordance cash compensation paid management board german commercial code hgb performance responsibility thousand thousand thereof thousand compensation management thousand performancebased thou board supervisory board sand thousand performancebased individualized information regarding compensation amount performancebased compensation depends member management board supervisory achievement target relating net income board disclosed audited compensation report see fresenius group business segment longterm incen page ff part management report tive component member management board compensation management board whole received stock option fresenius se performancebased composed three element co kgaa stock option plan sharebased compen fiscal year sation cash settlement amount thousand total compensation management board nonperformancebased compensation thousand thousand fixed compensation fringe benefit total compensation paid supervisory board shortterm performancebased compensation fresenius se co kgaa fresenius management se oneyear variable compensation committee thousand component longterm incentive effect thousand amount thousand fixed severalyear variable compensation comprising stock compensation thousand thousand option sharebased compensation cash compensation committee service thousand settlement phantom stock postponed payment thousand variable compensation oneyear variable compensation thousand based pension commitment former mem bers management board thousand thousand paid pension obligation person amounted thousand thousand fiscal year loan advance payment future compensation component made member management board fresenius manage ment se financial statement consolidated financial statement note accordance german commercial code hgb auditor fee fee auditor kpmg ag wirtschaftsprüfungsgesellschaft berlin affiliate expensed follows million total germany total germany audit fee auditrelated fee tax consulting fee fee total auditor fee leading auditor responsible audit proposal distribution consolidated financial statement since earnings general partner supervisory board corporate governance fresenius se co kgaa propose annual general consolidated stock exchange listed entity decla meeting earnings fresenius se ration pursuant section german stock corpo co kgaa distributed follows ration act aktiengesetz issued made available shareholder website fresenius se co kgaa wwwfreseniuscomcorporategovernance fresenius payment dividend per bearer ordinary share ordinary medical care ag co kgaa wwwfreseniusmedicalcarecom share entitled dividend balance carried forward retained earnings financial statement consolidated financial statement responsibility statement group management report includes fair review devel best knowledge accordance opment performance business position applicable reporting principle consolidated financial group together description principal oppor statement give true fair view asset liability tunities risk associated expected development financial position profit loss group group bad homburg v h february fresenius se co kgaa represented fresenius management se general partner management board sturm dr f de meo dr j götz henriksson r powell dr e wastler financial statement auditor report auditor report management report detected reasonable assurance knowledge business activity economic fresenius se co kgaa legal environment group expectation possi ble misstatement taken account determination audited consolidated financial statement prepared audit procedure effectiveness accounting fresenius se co kgaa bad homburg v höhe com related internal control system evidence supporting prising consolidated statement income consolidated disclosure consolidated financial statement statement comprehensive income consolidated state group management report examined primarily ment financial position consolidated statement cash test basis within framework audit audit flow consolidated statement change equity includes assessing annual financial statement note consolidated financial statement busi entity included consolidation determination ness year january december prepa entity included consolidation accounting ration consolidated financial statement accordance consolidation principle used significant estimate accounting principle generally accepted made legal representative well evaluating united state america u gaap responsibility overall presentation consolidated financial statement legal representative company responsibility believe audit provides reasonable basis express opinion consolidated financial statement opinion based audit addition engaged audit led reservation express opinion whether voluntarily prepared opinion based finding audit group management report agreement group consolidated financial statement comply u gaap management report fresenius se co kgaa bad homburg give true fair view net asset financial position v höhe prepared accordance result operation group accordance hgb handelsgesetzbuch german commercial code apart requirement voluntarily prepared group management appropriate incorporation u gaap financial data report consistent consolidated financial statement conducted audit consolidated financial prepared accordance u gaap apart statement accordance hgb german generally appropriate incorporation u gaap financial data agree accepted standard audit financial statement ment group management report fresenius se promulgated institut der wirtschaftsprüfer idw co kgaa prepared accordance hgb standard require plan perform audit issued unqualified statutory audit opinion misstatement materially affecting presentation based group management report complies net asset financial position result operation german statutory requirement whole provides consolidated financial statement accordance suitable view group position suitably present applicable financial reporting framework group opportunity risk future development frankfurt main february kpmg ag wirtschaftsprüfungsgesellschaft auditor report rohrbach walter german public auditor german public auditor report supervisory board report supervisory board supervisory board fresenius se co kgaa fulfilled obligation respective term accordance provision law article association rule procedure regularly advised management board general partner fresenius management se regarding manage ment company supervised management accordance supervisory board responsibility cooperation management supervisory board carrying monitoring advisory activity management board regularly kept supervisory board informed timely comprehensive oral written manner among thing supervisory board informed important matter relating business policy course business profitability position company group strategy planning risk situation risk management compliance well important business event report supervisory board report supervisory board based report submitted management board general partner supervisory board discussed business transaction important company committee meet ings management board general partner also discussed company strategic direction supervisory board supervisory board passed resolution within framework legal statutory authority supervisory board fresenius se co kgaa held four regular meeting march may october december addition extraordinary meeting september mem bers supervisory board informed acquisition spanish hospital group idc salud holding slu quirónsalud fresenius helios financing transaction meeting management board general partner sent detailed report comprehensive approval submission member supervisory board meeting supervisory board discussed general business development detail based report general partner management board addition dealt important business decision company matter requiring supervisory board approval submitted sufficient time proper scrutiny reviewing related approval document detailed consultation management board general partner supervisory board approved matter submitted supervisory board also kept informed meeting important business event addition chairman general partner management board regularly informed chairman supervisory board separate conversation current development business forthcoming decision discussed member supervisory board attended meeting march may following election employee representative european work council election shareholder representative annual general meeting supervisory board reconstituted member participated meeting supervisory board attendance supervisory board audit committee meeting shown member individually company website information found section supervisory board main focus supervisory board activity supervisory board mostly focused monitoring advisory activity business operation investment business segment furthermore supervisory board discussed detail significant business activity management board concerned acquisition especially report supervisory board report supervisory board acquisition quirónsalud fresenius helios investment planned expansion group headquarters supervisory board also dealt following topic budget midterm strategy fresenius group corporate strategy especially business outlook fresenius kabi fresenius helios digitalization initiative business sector also regularly informed risk analysis risk management compliance within group audit committee plenary session another focus discussion proposal election shareholder representative annual general meeting fresenius se co kgaa may meeting march supervisory board intensively dealt review approval financial statement consolidated financial statement ifrs u gaap well man agement report group management report fresenius se co kgaa based detailed report chairman audit committee presentation auditor result fiscal year discussed meeting vote taken proposal general partner fresenius management se distribution earnings addition business segment reported detail business performance first two month fiscal year included discussion competi tive situation fresenius kabi north america well innovation pharmaceutical division furthermore supervisory board informed plan extend group headquarters based document prepared nomination committee supervisory board also discussed length proposal election shareholder representative annual general meeting company may supervisory board considered international activity group potential conflict interest question independence candidate well diversity term qualification light requirement appoint woman member supervisory board finally supervisory board carried annual efficiency review meeting meeting may immediately following election shareholder representative annual general meeting supervisory board reconstituted supervisory board elected chairman two deputy chairman supervisory board well member chairman audit committee nomination committee furthermore rule procedure approved report supervisory board report supervisory board management board reported eu market abuse regulation consequence company director especially regarding reportable security transaction management board also reported business performance january april september extraordinary meeting held form conference call meet ing acquisition spanish hospital group quirónsalud fresenius helios intensively dealt member supervisory board provided comprehensive information spanish health care market well range medical service provided economic environment quirónsalud operates supervisory board meeting october took decision utilizing authorized capital finance acquisition quirónsalud well setting committee deal aspect equity financing transaction business performance january september pre sented member supervisory board detail particular focus business segment fresenius helios addition four business segment presented digitalization initiative inter company project focus supervisory board meeting december one hand business per formance hand budget planning year presented respect group well individually business segment chairman audit committee reported detail status preparation financial statement topic declaration conformity accordance german corporate governance code well informa tion supervisory board compliance regulatory issue legal risk addition supervisory board meeting october comprehensive onboarding event held meeting group four business segment presented newly constituted supervisory board also covering topic relating governance finance well else krönerfresenius foundation corporate governance supervisory board management board general partner jointly issued declaration conformity accordance german corporate governance code pursuant section german stock corporation act aktg december management board general partner supervisory board fresenius se co kgaa duty act best interest company performing activity pursue report supervisory board report supervisory board personal interest bestow unjustified benefit others sideline activity transaction company member corporate body must reported approved supervisory board prof dr med michael albrecht member supervisory board company medical director spokesman management board university hospital carl gustav carus dresden well member supervisory board university hospital aachen fresenius group maintains regular business relationship hospital ordinary course business market condition klauspeter müller member supervisory board chairman audit committee company member supervisory board fresenius management se also chairman supervisory board commerzbank ag fresenius group maintains business relationship market condition michael diekmann deputy chairman supervisory board well member supervisory board fresenius management se also nonexecutive director board director allianz australia ltd fresenius group paid insurance premium allianz market condition direct consultant service agreement company member supervisory board various company fresenius group advised company internation ally active law firm noerr dr dieter schenk deputy chairman supervisory board fresenius management se also partner law firm noerr llp reporting period fresenius group paid total million law firm noerr million corresponds less total amount paid fresenius group service legal advice payment also includes payment service provided actually paid total amount year less million attributable service group company related usiness business segment fresenius medical care service rendered group company b segment fresenius medical care require separate approval supervisory board fresenius medical care management ag fresenius medical care ag co kgaa supervisory board fresenius management se closely examined mandating approved dr schenk abstained voting supervisory board fresenius se co kgaa dr schenk member dealt volume legal fee paid law firm noerr relation fee volume paid law firm payment mentioned section net amount euro addition vat paid information corporate governance fresenius please refer corporate governance declaration report page annual report fresenius disclosed information related party quarterly report page annual report report supervisory board report supervisory board work committee reporting year audit committee held three meeting four conference call main focus monitoring activity preliminary audit annual financial statement fresenius se co kgaa group discussion auditor report term reference audit another matter dealt audit committee recommendation super visory board regarding auditing firm propose annual general meeting election auditor annual financial statement fresenius se co kgaa group supervisory board proposal annual general meeting elect kpmg ag wirtschaftsprüfungsgesellschaft berlin auditor based recommendation audit committee finally audit committee also reviewed detail quarterly report controlling report development acquisition compliance risk management system internal control system internal auditing system approval nonaudit service kpmg ag wirtschaftsprüfungsgesellschaft berlin chairman audit committee reported regularly supervisory board work audit committee respective subsequent meeting company nomination committee met march preparation supervisory board election may joint committee whose approval necessary certain important transaction fresenius se co kgaa certain legal activity company else krönerfresenius foundation meet transaction effected required joint committee approval mediation committee supervisory board fresenius se co kgaa appoint management board member fresenius management se information committee composition work method please refer corporate governance declaration report page annual report personnel term office member supervisory board company ended annual general meeting fresenius se co kgaa may would like thank retiring member supervisory board valuable cooperation contribution successful development company report supervisory board report supervisory board regular election six shareholder representative carried annual general meeting may prof dr iris löwfriedrich hauke star elected first time twelveperson panel prof dr michael albrecht mr michael diekmann dr gerd krick mr klauspeter müller reelected european work council elected mr konrad kölbl mr rainer stein mr niko stumpfögger employee representative already member supervisory board also elected stefanie lang frauke lehmann mr oscar romero de paco first meeting may supervisory board elected dr gerd krick chairman supervisory board fresenius se co kgaa upon proposal shareholder representative mr michael diekmann upon proposal employee representative mr niko stumpfögger elected deputy meeting hauke star mr konrad kölbl dr gerd krick mr klauspeter müller mr rainer stein elected member audit committee mr klaus peter müller elected chairman audit committee furthermore may meeting mr michael diekmann dr gerd krick mr klauspeter müller elected member nomina tion committee dr gerd krick elected chairman composition management board supervisory board general partner fresenius management se also changed annual general meeting fresenius management se may supervisory board member elected regularly dr kurt bock newly joined board mr michael diekmann dr gerd krick mr klauspeter müller dr dieter schenk dr karl schneider reelected effective july mr stephan sturm appointed chairman management board previ ously served year chief financial officer company time mr stephan sturm proved outstanding finance expert entrepreneur contributing significantly design execution business strategy delivered continued growth appointment chair man management board demonstrates continuity company leadership mr stephan sturm succeeded dr ulf schneider left company request june take new professional challenge supervisory board would like thank dr ulf schneider tremendously successful effort behalf fresenius previous year played central role company rapid sustained growth time chairman management board fresenius quadrupled sale increased earnings fold dr ulf schneiders distinguished achievement helped make fresenius today report supervisory board report supervisory board financial statement consolidated financial statement accounting record financial statement prepared according german commercial code hgb management report company audited kpmg ag wirtschaftsprüfungsgesell schaft berlin done accordance resolution passed annual general meeting fresenius se co kgaa may subsequent appointment supervisory board auditor kpmg issued unqualified audit opinion company financial statement manage ment report applies company consolidated financial statement prepared accordance ifrs accounting principle regulation govern statement pursuant section german commercial code hgb also applies company consolidated financial statement prepared voluntarily according u gaap financial statement consolidated financial statement management report auditor report submitted member company supervisory board timely manner meeting march first audit committee supervisory board discussed document detail auditor delivered detailed report result audit meeting found weakness risk management system internal control system regard accounting process auditor attended meeting supervisory board meeting conference call audit committee audit committee supervisory board approved auditor result also audit committee supervisory board review found objection company financial statement management report consolidated financial statement group management report meeting march supervisory board approved financial statement manage ment report presented general partner statement contained therein respect future development company supervisory board concurs general partner proposal allocation distrib utable profit supervisory board would like thank member management board general partner employee outstanding achievement bad homburg v h march supervisory board report supervisory board dr gerd krick chairman board board supervisory board fresenius se co kgaa dr gerd krick dario anselmo ilossi prof dr med iris löwfriedrich former chairman fresenius ag may since may chairman trade union collaborator femca cisl chief medical officer und executive office energy fashion chemical vice president head development supervisory board fresenius management se chairman medical patient value practice fresenius medical care ag co kgaa chairman fresenius medical care management ag konrad kölbl ucb sa vamed ag austria chairman fulltime work council member office supersivory board evotec ag prof dr med michael albrecht member manual worker work medical director spokesman council vamedkmb krankenhaus klauspeter müller management board universitäts management und betriebsführungs chairman supervisory board klinikum carl gustav carus dresden ge mbh commerzbank ag office supervisory board chairman group work council office gök consulting ag supervisory board universitätsklinikum aachen vamed ag commerzbank ag chairman fresenius management se deputy chairman european work board director prof dr h c roland berger parker hannifin corporation usa council fresenius se co kgaa may corporate office supervisory board dieter reuß management consultant vamedkmb krankenhausmanagement und betriebsführungsges mbh austria may office supervisory board fresenius management se may fulltime work council member rocket internet se stefanie lang schuler ag wmp eurocom ag july deputy chairman since may chairman joint work council board director fresenius se co kgaa banzai spa italy since april fulltime work council member geox spa italy may bad homburg site chairman work council deputy chairman general work michael diekmann fresenius medical care deutschland council fresenius se co kgaa former chairman management gmbh board allianz se gerhard roggemann frauke lehmann deputy chairman may since may office supervisory board management consultant basf se deputy chairman fulltime work council member fresenius management se office linde ag deputy chairman supervisory board siemens ag chairman work council bremer ag since august deutsche beteiligungs ag deputy chairman board director helios kliniken schwerin gmbh deutsche börse ag may allianz australia ltd australia december gp günter papenburg ag chairman nonexecutive director wave management ag deputy chairman member european work council board fresenius se co kgaa corporate office supervisory board helios kliniken schwerin gmbh deputy chairman board supervisory board fresenius se co kgaa oscar romero de paco hauke star niko stumpfögger since may since may secretary trade union verdi head company industry politics staff member production member executive board health care social affair deutsche börse ag member european work council office deputy chairman fresenius se co kgaa supervisory board eurex frankfurt ag deutsche börse ag group mandate gfk se may klöckner co se may stefan schubert administrative board may eurex zürich ag deutsche börse ag group mandate kühne nagel international ag since may hospital nurse fulltime work council member rainer stein fulltime work council member chairman work council helios klinik bad schwalbach chairman group work council helios klinik idstein helios kliniken gmbh chairman group work council chairman european work wittgensteiner kliniken gmbh council fresenius se co kgaa september member european work council fresenius se co kgaa committee supervisory board audit committee nomination committee joint committee prof dr h c roland berger dr gerd krick chairman dr dieter schenk chairman may chairman prof dr h c roland berger michael diekmann klauspeter müller may dr gerd krick since may chairman michael diekmann dr karl schneider konrad kölbl klauspeter müller since may dr gerd krick gerhard roggemann may board hauke star since may rainer stein committee consists equally two member supervisory board fresenius se co kgaa fresenius management se board management board fresenius management se general partner fresenius se co kgaa dr ulf schneider dr francesco de meo rice powell june business segment fresenius helios business segment corporate office fresenius medical care chairman supervisory board helios beteiligungs ag chairman corporate office corporate office helios kliniken schwerin gmbh chairman administrative board supervisory board vifor fresenius medical care renal pharma ltd fresenius kabi ag june chairman switzerland vice chairman medical care management ag june chairman dr jürgen götz board director fresenius medical care holding inc usa board director chief legal compliance officer chairman fresenius kabi usa inc usa june labor relation director office board director dr ernst wastler e du pont de nemours company usa mat henriksson business segment fresenius vamed business segment fresenius kabi corporate office stephan sturm supervisory board corporate office charité cfm facility management gmbh chairman since july supervisory board deputy chairman fresenius kabi austria gmbh austria vamedkmb krankenhausmanagement und chief financial officer chairman betriebsführungsges mbh austria chairman fresenius kabi españa sau spain corporate office labesfal laboratórios almiro sa portugal supervisory board fresenius kabi ag deputy chairman august administrative board chairman since august fresenius kabi italia spa italy chairman fresenius medical care management ag since may chairman since june board director vamed ag austria deputy chairman fenwal inc usa fhc holding ltd great britain office fresenius kabi pharmaceutical holding inc usa supervisory board fresenius kabi singapore pte ltd singapore deutsche lufthansa ag fresenius kabi usa inc usa sinoswed pharmaceutical corp ltd china board board supervisory board fresenius management se general partner fresenius se co kgaa dr gerd krick michael diekmann dr karl schneider chairman former spokesman südzucker ag klauspeter müller office foundation board prof dr h c roland berger else krönerfreseniusstiftung deputy chairman may dr dieter schenk lawyer tax consultant dr kurt bock deputy chairman since may office supervisory board chief executive officer basf se bank schilling co ag chairman fresenius medical care ag co kgaa deputy chairman fresenius medical care management ag deputy chairman gabor shoe ag chairman greiffenberger ag deputy chairman toptica photonics ag chairman foundation board else krönerfreseniusstiftung chairman board glossary glossary health care term product service administrative data dialysis machine epo erythropoietin data transmitted sickness fund part hemodialysis process controlled dial hormone stimulates red blood cell produc billing process federal agency like ysis machine pump blood add anti tion recombinant ie artificially produced german federal statistical office due coagulant regulates cleansing process human epo commonly prescribed patient legal requirement germany includes control mixture dialysate flow dialysis suffer anemia information coded diagnosis pro rate system cedures fda u food drug administration dialysis solution dialysate official authority food observation drug albumin fluid used process dialysis order registration united state protein indicative patient general remove filtered substance excess nutritional status water blood hd hemodialysis treatment method dialysis patient blood volume substitute dialyzer blood patient cleansed dia used temporary stabilization special filter used hemodialysis removing lyzer solute exchange blood maintenance blood volume exam toxic substance waste product metabolic dialysate dominated diffusive process ple event major blood loss process excess water blood dialyzer sometimes referred artifi hemoglobin dialysis cial kidney component red blood cell transport form renal replacement therapy oxygen around body insufficient level semipermeable membrane peritoneal dial enteral nutrition hemoglobin indicative anemia ysis peritoneum patient hemo application liquid nutrition tube sip typically occurs patient chronic kidney dialysis membrane dialyzer used feed via gastrointestinal tract failure besides dialysis anemia treated clean patient blood iron supplement hormone compound erythropoietin epo glossary glossary health care term product service kt v value parenteral nutrition prevalence provides information urea content application nutrient directly blood number patient suffer specific blood urea mostly excreted healthy kid stream patient intravenously disease within defined period prevalence ney dialysis patient must filtered necessary condition patient rate indicates number people blood renal replacement ther allow absorb metabolize essential nutri specific disease eg terminal kidney failure apy kt v value show whether patient ents orally sip tube feed suffi treated per million population detoxified effectively dialysis cient quantity ppp publicprivate partnership model medicare medicaid pd peritoneal dialysis publicprivate partnership describes govern program developed federal u social dialysis treatment method using patient ment service private business venture security administration reimburses health peritoneum filter cleanse blood funded operated partnership insurance company provider medi government one privatesector cal service medical care individual phosphate company case ppp accompanies people chronic kidney failure phosphate concentration show whether treat partprivatization governmental service disabled ing patient dialysis medication sufficient body absorb phosphate threechamber bag outpatient clinic ingested food healthy people excrete threechamber bag contains macro interdisciplinary facility outpatient care excess phosphate via kidney diseased nutrient like amino acid glucose lipid managed physician responsible body kidney unable phosphate well electrolyte three separate cham medical care center includes service concentration blood high bers immediately infusion nutrient provider physician pharmacist lead severe condition mixed thoroughly within bag simply health care facility authorized opening individual chamber reduces treat patient statutory health insurance risk contamination save time preparing infusion glossary glossary financial term special item cash flow acquisition dividend ebitda earnings interest tax order measure operating performance fresenius u cash flow acquisi depreciation amortization extending several period key perfor tions dividend financial measure ebitda calculated ebit adding mance measure adjusted special item free cash flow cash flow acquisition depreciation recognized income applicable adjusted measure dividend calculated operating cash deducting writeups recognized income labelled special item reconcil flow less investment net net investment intangible asset well property iation table available within respective calculated payment purchase plant equipment quarterly annual report present property plant equipment less proceeds composition special item sale property plant equipment ebitda margin ebitda margin calculated ratio cash flow constant currency ebitda sale financial key figure show net balance constant currency income expense incoming outgoing payment calculated using prior year average rate net debt ebitda reporting period constant currency asset liability net debt ebitda financial measure reflect calculated using midclosing rate ing ability fresenius fulfill pay operating cash flow date respective statement financial ment obligation net debt ebitda cal operating cash flow financial measure position culated ltm last twelve month average showing cash inflow operating activity exchange rate respectively period operating cash flow calcu day sale outstanding dso lated subtracting noncash income add indicates average number day take calculation net debt ing noncash expense net income receivable paid shortterm debt shortterm debt related party cash flow investing activity ebit earnings interest tax current portion longterm debt capital cash flow investing activity financial ebit include depreciation writeups lease obligation measure opposing payment acquisition property plant equipment current portion senior note purchase property plant equipment longterm debt capital lease obligation investment versus proceeds sale ebit calculated subtracting cost sale less current portion property plant equipment invest selling general administrative expense senior note less current portion ments research development expense convertible bond sale debt cash flow financing activity less cash cash equivalent cash flow financing activity financial ebit margin net debt measure showing investment ebit margin calculated ratio ebit reporting period financed sale nopat net operating profit tax nopat cash flow financing activity calculated calculated operating income ebit addition equity plus proceeds stated profit loss statement less exercise stock option less dividend paid income tax plus proceeds debt increase loan bond senior note etc less repayment debt plus organic growth change noncontrolling interest plus pro growth generated company ceeds hedge exchange rate effect existing business acquisition due corporate financing divestiture foreign exchange impact glossary integral part management report glossary financial term reconciliation average invested capital roic december december december million except roic total asset plus cumulative goodwill amortization minus cash cash equivalent minus loan related party minus deferred tax asset minus account payable minus account payable related party minus provision current liability minus income tax payable invested capital average invested capital december operating income income tax expense nopat roic includes noncurrent provision payment outstanding acquisition include pension liability noncontrolling interest subject put provision includes adjustment acquisition respective reporting period purchase price certain level million includes adjustment acquisition respective reporting period purchase price certain level million special item reconciliation average operating asset rooa december december december million except rooa total asset minus payment received account minus cash held trust minus loan related party minus deferred tax asset minus account payable minus account payable related party minus approved subsidy due hospital funding act krankenhausfinanzierungsgesetz khg operating asset average operating asset december operating income rooa includes adjustment acquisition respective reporting period purchase price certain level million glossary includes adjustment acquisition respective reporting period purchase price certain level million special item integral part management report glossary financial term roe return equity rooa return operating asset soi scope inventory measure corporation profitability reveal calculated ratio ebit operating indicates average number day ing much profit company generates asset average receiving good inventory sale money shareholder invested finished product roe calculated fiscal year net income operating asset total asset deferred tax total equity x asset trade account payable cash held calculated inventory cost good trust payment received account approved sold x day roic return invested capital subsidy calculated ebit tax invested capital working capital current asset including deferred asset invested capital total asset accumulated accrual trade account payable liabili amortization goodwill deferred tax asset tie deferred charge cash cash equivalent trade account pay able accrual without pension accrual liability bearing interest glossary integral part management report imprint imprint commercial register bad homburg v h hrb chairman supervisory board dr gerd krick general partner fresenius management se registered office commercial register bad homburg v h hrb management board stephan sturm president ceo dr francesco de meo dr jürgen götz mat henriksson rice powell dr ernst wastler chairman supervisory board dr gerd krick german version annual report legally binding editorial closing date annual report march published march annual report financial statement fresenius se co kgaa consolidated statement accordance ifrs accounting principle available website may obtained upon request investor relation find information current news company website wwwfreseniuscom forwardlooking statement annual report contains forwardlooking statement statement represent assessment made basis information available u time assumption statement based occur risk arise mentioned risk report sec filing fresenius medical care ag co kgaa actual result could differ materially result currently expected design concept realization hilger boie design wiesbaden print ziegler gmbh co kg neckarbischofsheim germany imprint financial calendar report st quarter conference call live webcast may annual general meeting frankfurt main germany may payment dividend may report nd quarter conference call live webcast august report rd quarter conference call live webcast november subject prior approval annual general meeting schedule update information live webcasts event wwwfreseniuscomeventsandpresentations fresenius share adr ordinary share adr security identification cusip ticker symbol fre ticker symbol fsnuy isin de isin usm bloomberg symbol fre gr structure sponsored level adr reuters symbol fregde ratio adr share main trading location frankfurt xetra trading platform otcqx contact corporate headquarters postal address contact shareholder contact journalist elsekrönerstraße fresenius se co kgaa investor relation corporate communication bad homburg v h bad homburg v h telephone telephone germany germany telefax telefax email irfrefreseniuscom email prfrefreseniuscom